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Abstract 
Homo sapiens DnaJ 1 (HSJ1) is a neuronal DnaJ protein that functions to target misfolded 
and aggregated proteins for degradation. The accumulation of misfolded and aggregated 
protein can be toxic to cells, causing neurodegeneration; therefore, proteins that function in 
protein quality control, such as HSJ1, play a critical role in maintaining protein homeostasis 
and promoting cell survival. 
The protective nature of HSJ1 is highlighted by the ability of the HSJ1a isoform to combat 
protein aggregation in cell and mouse models of neurodegenerative diseases, such as 
amyotrophic lateral sclerosis (ALS), a disease caused by the progressive loss of motor 
neurons. Based on the anti-aggregation function of HSJ1a towards ALS-associated proteins, 
I sought to determine whether HSJ1a could also protect against mutant ubiquilin-2 
aggregation, a protein recently implicated in X-linked ALS. I identified wild-type ubiquilin-2 
as a binding partner of HSJ1a and demonstrated that HSJ1a retained the ability to bind to 
ubiquilin-2 mutants, suggesting HSJ1a could potentially modulate mutant ubiquilin-2 
aggregation in cells. 
Recently, three mutations in HSJ1 have been identified in autosomal recessive cases of 
hereditary motor neuropathies, diseases caused by the degeneration of lower motor neurons. 
I sought to determine the pathogenicity of the most recently identified variant, HSJ1-Y5C. 
Using a combination of the heterologous expression of HSJ1-Y5C in SK-N-SH 
neuroblastoma cells and the examination of endogenous HSJ1-Y5C in patient fibroblasts, I 
characterised the Y5C substitution as a disease-causing, loss of function mutation that 
reduces the half-life of HSJ1, leading to a loss of protein. To investigate how the loss of 
HSJ1 function causes motor neuron degeneration, I examined the cellular phenotype of 
motor neurons in Hsj1 knockout mice. I demonstrated that a significant 12% of motor 
neurons degenerate between P15 and P20. Prior to motor neuron loss, motor neurons appear 
chromatolytic and signs of impaired protein homeostasis are observed, with an increase in 
protein ubiquitylation, a possible increase in autophagosome formation and activation of the 
IRE1 and PERK branches of the unfolded protein response. The activation of these cellular 
stress responses suggests that HSJ1 is a critical component of the protein quality control 
network in motor neurons.  
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Chapter 1 – Introduction 
1.1 The nervous system 
The nervous system is the main control centre of the body, functioning to detect, interpret 
and respond to internal and external stimuli. The nervous system can be divided into the 
central nervous system (CNS) and the peripheral nervous system (PNS). The CNS consists 
of the brain, brainstem, spinal cord and the retina, whilst the PNS encompasses the motor 
and sensory neurons that extended from the CNS and connect to the muscles and organs of 
the body. 
1.1.1 Motor neurons  
Motor neurons are large polarised cells that function to convey electrical impulses (action 
potentials) from the CNS to muscle fibres, stimulating muscle contraction. Structurally, they 
can be divided into four distinct regions; the dendrites, the cell body, the axon and the 
synaptic terminal (Lodish et al. 2000). The dendrites branch outwards from the cell body 
and are specialised to receive chemical signals from the synaptic terminals of other neurons. 
Dendrites then convert the chemical signal into an action potential, which is propagated 
along the axon, away from the cell body and towards the synaptic terminal. In humans, 
motor neuron axons can reach up to one metre in length. To ensure the efficient propagation 
of action potentials over long distances, axons are insulated with a myelin sheath. 
Motor neurons are divided into upper motor neurons or lower motor neurons depending 
upon their location in the CNS (Figure 1.1). Upper motor neurons originate from the 
cerebral cortex region of the brain. Their axons descend via the corticobulbar and 
corticospinal tracts to the brainstem and the spinal cord, respectively, where they innervate 
lower motor neurons. The axons of lower motor neurons project outwards from the 
brainstem and spinal cord and innervate skeletal muscle fibres (Figure 1.2) (Purves et al. 
2001).  
Lower motor neurons can be divided into three subtypes (α, β or γ) according to the type of 
muscle fibre they innervate (Kuffler et al. 1951). α-motor neurons innervate extrafusal 
muscle fibres. Extrafusal muscle fibres are the most numerous muscle fibres and are 
responsible for muscle contraction. γ-motor neurons innervate intrafusal muscle fibres, 
which are located in the muscle spindle, a specialised sensory receptor embedded in 
extrafusal muscle fibres. The muscle spindle senses position and movement and contributes 
to fine motor control. In contrast to α- and γ-motor neurons, β-motor neurons are able to 
innervate both extrafusal and intrafusal muscle fibres.  
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An α-motor neuron and the muscle fibres it innervates form a motor unit. Motor units can be 
further divided into fast-fatigable (FF), fast-fatigue resistant (FR) or slow (S) (Burke et al. 
1973). FF motor units stimulate large muscles and achieve the greatest force of the three 
types, however, the muscle fibres fatigue quickly. FR motor units stimulate moderately sized 
muscle groups. They do not react as fast as FF motor units but they can be sustained for 
much longer. S motor units exert low force and are required for sustained muscle 
contraction, such as the maintenance of posture. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 The location of upper motor neurons and lower motor neurons in the CNS. 
Upper motor neurons are located in the cerebral cortex of the brain. Lower motor neurons 
are located in the brainstem and spinal cord. Lower motor neurons project outward from the 
brainstem and spinal cord to directly innervate skeletal muscle fibres. Figure from 
http://mdna.org/disease. 
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Figure 1.2 Lower motor neurons project from the spinal cord and directly innervate 
skeletal muscle fibres. A single motor neuron can branch to innervate multiple muscle 
fibres. Figure from Pearson Education Inc. 2011.  
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1.1.2 The neuromuscular junction 
The neuromuscular junction mediates synaptic transmission between a motor neuron and a 
muscle fibre. The arrival of an action potential at the pre-synaptic terminal of a motor 
neuron triggers the opening of voltage-dependent calcium channels, resulting in an influx of 
calcium. The influx of calcium causes synaptic vesicles to dock and fuse with the pre-
synaptic membrane, resulting in the release of the neurotransmitter acetylcholine into the 
synaptic cleft. Acetylcholine binds to acetylcholine receptors on the plasma membrane of the 
muscle fibre, which serve as ligand-gated ion channels. Acetylcholine binding triggers the 
opening of the channel and the influx of sodium ions, inducing depolarisation and 
subsequent muscle contraction (Takamori 2012). 
1.2 Motor neuron disorders 
Motor neuron disorders are a heterogeneous group of neurological diseases caused by the 
progressive degeneration of upper and/or lower motor neurons. Examples of motor neuron 
disorders are discussed briefly below. 
1.2.1 Amyotrophic lateral sclerosis 
Amyotrophic lateral sclerosis (ALS) is caused by the progressive loss of upper and lower 
motor neurons. Clinically, the disease is characterised by muscle weakness and atrophy, with 
muscles in the hands, arms and legs typically the first to be affected (Talbot 2009). ALS is a 
fatal disease, with death usually occurring 2-5 years after symptom onset due to respiratory 
failure. The disease affects around 2 in every 100,000 individuals, with the majority of cases 
being sporadic (Al-Chalabi et al. 2014). Of the familial cases, 40% are caused by the 
intronic hexanucleotide repeat expansion of the C9orf72 gene (Renton et al. 2014). 
Mutations in the enzyme superoxide dismutase 1 (SOD1) are the second most common 
cause of familial ALS, accounting for 12% of cases, followed by mutations in the RNA-
binding proteins TAR DNA binding protein (TDP-43) and fused in sarcoma (FUS), each 
accounting for 4% of cases (Renton et al. 2014). Mutations are most commonly inherited in 
an autosomal dominant manner, although autosomal recessive and X-linked inheritance have 
also been reported. 
1.2.2 Hereditary spastic paraplegia 
Hereditary spastic paraplegia (HSP) is an inherited disorder caused by the degeneration of 
upper motor neuron axons in the corticospinal tract, causing progressive spasticity and 
weakness of the lower limbs. The disease affects around 3 in every 100,000 individuals, with 
symptom onset varying from early childhood to late adulthood (Lo Giudice et al. 2014). 
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HSP can be divided into uncomplicated or complicated, depending on the presence of 
additional clinical features. The disease can be inherited in an autosomal dominant, 
autosomal recessive or X-linked manner. Autosomal dominant uncomplicated HSP is the 
most prevalent subtype and over 20 causative genes for this subtype have been identified to 
date (Fink 2014). The causative genes encode proteins with a diverse range of function, 
including axonal transport, mitochondrial function and myelin formation (Fink 2014). 
1.2.3 Spinal muscular atrophy 
Spinal muscular atrophy (SMA) is an inherited disorder caused by the degeneration of lower 
motor neurons in the spinal cord. The disease affects around 1 in 100,000 individuals and 
patients typically present with weakness and atrophy of the proximal limb muscles. SMA is 
classified according to the age of onset and the severity of symptoms (Crawford et al. 1996, 
Hamilton et al. 2013). Type I is the most severe form of the disease and has the earliest age 
of onset, with symptoms usually presenting at birth. Type II typically presents in early 
childhood and is less severe, although still disabling. Type III and type IV present in 
adolescence and adulthood, respectively, and are the least severe forms of the disease. The 
majority of cases display autosomal recessive inheritance, although autosomal dominant and 
X-linked inheritance has also been reported. 95% of patients have a loss of function 
mutation in the survival motor neuron gene (SMN1) (Lefebvre et al. 1995), which encodes a 
protein with a key role in RNA splicing (Li et al. 2014). 
1.3 Inherited peripheral neuropathies 
Inherited peripheral neuropathies are a clinically heterogeneous group of disorders caused by 
the degeneration of the motor and/or sensory neurons of the peripheral nervous system. 
Inherited peripheral neuropathies can be divided into three main subtypes; hereditary motor 
and sensory neuropathy (HMSN), distal hereditary motor neuropathy (dHMN) and 
hereditary sensory neuropathy (HSN). 
1.3.1 Charcot Marie Tooth disease 
HMSN, also known as Charcot Marie Tooth disease (CMT), is the one of the most 
commonly inherited neurological disorders, affecting around 1 in 2500 individuals (Vallat et 
al. 2013, El-Abassi et al. 2014). Symptom onset typically occurs in the second decade of 
life, although onset in the third decade is not uncommon. Although both motor and sensory 
neurons are affected, motor symptoms predominate. The clinical phenotype of CMT is 
characterised by progressive muscle weakness and wasting of the distal lower limbs.  The 
muscles in the feet are typically the first to be affected, leading to foot deformities and foot 
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drop. Gradually the muscles of the lower legs become affected, causing gait disturbances, 
with frequent stumbling and falling. Tendon reflexes are reduced or absent. As with the 
motor deficits, sensory deficits are more pronounced distally, with decreased sensation to 
touch, vibration and pain (Vallat et al. 2013, El-Abassi et al. 2014). 
CMT can be divided into a demyelinating form (CMT1) and an axonal form (CMT2). CMT1 
is the more prevalent subtype, accounting for around 80% of cases (Murphy et al. 2012). 
CMT1 and CMT2 are clinically indistinguishable and nerve conduction studies (NCS) are 
required to differentiate between the two forms (Harding and Thomas 1980). NCS are 
performed on the upper limbs, usually on the median motor nerve and the sural sensory 
nerve. A reduction in nerve conduction velocity (NCV) indicates demyelination, with a 
velocity less than 38 m/s characteristic of CMT1. Patients with CMT2 display a normal 
NCV, with speeds above 45 m/s. 
The majority of CMT1 and CMT2 cases have an autosomal dominant pattern of inheritance, 
although autosomal recessive and X-linked inheritance has also been reported. To date, over 
30 causative genes for CMT1 and CMT2 have been identified (Table 1.1). A molecular 
diagnosis can be established in 50-70% of patients; with 90% of such patients having 
mutations in one of four genes; PMP22, MFN2, GJB1 or MPZ (Saporta et al. 2011). Most 
types of CMT1 map to genes that encode proteins associated with myelin proteins and 
Schwann cell function, whereas CMT2 causative genes encode proteins that are typically 
associated with axonal structure and function (Rossor et al. 2013, Jerath et al. 2015). 
1.3.2 CMT2 and dHMN 
Patients that lack the sensory component of CMT are classified as having dHMN. Clinically, 
it is difficult to differentiate between dHMN and CMT2, as it is not uncommon for CMT2 
patients to present without significant sensory symptoms. NCS are therefore required to 
determine whether sub-clinical sensory deficits are present and distinguish between the two 
diseases. As with CMT2, dHMN is usually associated with an autosomal dominant pattern 
of inheritance. Ten causative genes for dHMN have been identified to date (Table 1.2), 
however a large proportion of patients remain without a genetic diagnosis (Rossor et al. 
2012). Interestingly, mutations in the same gene have been identified to cause both dHMN 
and CMT2. dHMN and CMT2 causative genes encode proteins with a range of cellular 
functions, including protein folding and degradation (HSPB1, HSPB8, LRSAM1, TRIM2, 
DNAJB2), axonal transport (DCTN1, DYNC1H1, NEFL, RAB7, KIF1B), mitochondrial 
dynamics (MFN2, GDAP1) protein translation (IGHMBP2, AARS, GARS) and ion channel 
function (ATP7A, TRPV4) (Figure 1.3). Potential pathogenic mechanisms are discussed 
below, with impairments in protein folding and degradation discussed in section 1.8. 
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Table 1.1 Identified causative genes in CMT1 and CMT2. AD – autosomal dominant, AR 
– autosomal recessive (Reilly et al. 2011, Rossor et al. 2013, Baets et al. 2014, Tazir et al. 
2014, Brennan et al. 2015, Jerath et al. 2015). 
AD CMT1 Gene Protein 
CMT1A PMP22 Peripheral myelin protein 22 
CMT1B MPZ Myelin protein zero 
CMT1C LITAF Lipopolysaccharide-induced tumor necrosis factor 
CMT1D EGR2 Early growth response 2 
CMT1E PMP22 Peripheral myelin protein 22 
CMT1F NEFL Neurofilament light chain 
AR CMT1   
AR CMT1A GDAP1 Ganglioside-induced differentiation-associated protein 1  
AR CMT1B1 MTMR2 Myotubularin-related protein 2 
AR CMT1B2 MTMR13 Myotubularin-related protein 13 
AR CMT1B3 SBF1 SET binding factor 1 
AR CMT1C SH3TC2 SH3 domain and tetratricopeptides repeats 2 
AR CMT1D NDRG1 N-myc downstream-regulated gene 1 protein 
AR CMT1E EGR2 Early growth response 2 
AR CMT1F PRX Periaxin 
AR CMT1G HK1 Hexokinase 1 
AR CMT1H FGD4 Frabrin 
AR CMT1J FIG4 FIG4 homolog, SCA domain containing lipid phosphatase 
AD CMT2   
CMT2A1 KIF1B Kinesin family member 1B 
CMT2A2 MFN2 Mitofusin 2 
CMT2B RAB7 RAS-associated protein 7 
CMT2C TRPV4 
Transient receptor potential cation channel subfamily V 
member 4 
CMT2D GARS Glycyl-tRNA synthetase 
CMT2E NEFL Neurofilament light chain 
CMT2F HSPB1 Heat shock protein B1 
CMT2I MPZ Myelin protein zero 
CMT2J MPZ Myelin protein zero 
CMT2K GDAP1 Ganglioside-induced differentiation-associated protein 1 
CMT2L HSPB8 Heat shock protein B8 
CMT2M DNM2 Dynamin 2 
CMT2N AARS Alanyl-tRNA synthetase 
CMT2O DYNC1H1 Dynein cytoplasmic 1 heavy chain 1 
CMT2P LRSAM1 Leucine-rich repeats and sterile alpha motif-containing 1 
CMT2Q DHTKD1 Dehydrogenase E1 and transketolase domain-containing 1 
AR CMT2   
AR CMT2 HINT1 Histidine triad nucleotide-binding protein 1 
AR CMT2 TRIM2 Tripartite motif containing 2 
AR CMT2 DNAJB2 DnaJ homolog subfamily B member 2 
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Table 1.2 Identified causative genes in dHMN. AD – autosomal dominant, AR – 
autosomal recessive (Rossor et al. 2012, Drew et al. 2011). 
  
AD dHMN 
Gene Protein 
BSCL2 Berardinelli-seip congential lipodystrophy 2 (seipin) 
DCTN1 Dynactin 1 
DYNC1H1 Dynein cytoplasmic 1 heavy chain 1 
GARS Glycyl-tRNA synthetase 
HSPB1 Heat shock protein B1 
HSPB8 Heat shock protein B8 
TRPV4 
Transient receptor potential cation channel subfamily 
V member 4 
AR dHMN 
IGHMBP2 Immunoglobulin µ-binding protein 2 
DNAJB2 DnaJ homolog subfamily B member 2 
X-linked dHMN ATP7A ATPase copper transporting alpha polypeptide 
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1.3.3 Mechanisms of disease pathogenesis in CMT2 and dHMN 
1.3.3.1 Impaired axonal transport 
Axonal transport is responsible for the movement of organelles, proteins and lipids between 
the cell body and the synaptic terminal of a neuron. The process is bi-directional, with 
anterograde transport moving cargo from the cell body to the synaptic terminal and 
retrograde transport moving cargo from the synaptic terminal back to the cell body (Gentil et 
al. 2012, Jerath et al. 2015). The platform for transportation is provided by the cytoskeleton, 
which runs along the entire length of the axon. The neuronal cytoskeleton consists of three 
components; microtubules, actin filaments and neurofilaments. Cargo is attached to the 
microtubules via the kinesin and dynein motor proteins, which function in anterograde and 
retrograde transport, respectively (Gentil et al. 2012, Jerath et al. 2015). 
Motor neurons place a substantial demand on the axonal transport system due to their long 
axons and high synaptic activity. The system is, therefore, under considerable pressure to 
supply the synaptic terminal with the proteins, lipids and organelles required for synaptic 
function, whilst returning elements that require degradation back to the cell body. Such a 
high dependence on an efficient transport system makes motor neurons particularly 
vulnerable to impairments in the trafficking process. Five of the dHMN/CMT2 causative 
genes identified to date encode proteins that function in axonal transport, with four of the 
genes encoding motor proteins or motor protein adaptors (KIF1B, DYNC1H1, DCTN1 and 
RAB7). Although the mechanisms of pathogenesis remain to be fully characterised, 
accumulating evidence suggests that the mutations result in a loss of function phenotype. 
Mutations in KIF1B, a member of the kinesin family, were reported to cause a decrease in 
ATPase activity and motility (Zhao et al. 2001). Kif1b
+/-
 mice show defects in synaptic 
vesicle trafficking, supporting the hypothesis that a loss of KIF1B function reduces the 
anterograde transport of cargo (Zhao et al. 2001). Mutations in DYNC1H1, DCTN1 and 
RAB7 were reported to impair the retrograde transport system. DYNC1H1 encodes a 
component of dynein, whereas both DCTN1 and RAB7 encode dynein adaptor proteins. In 
transfected cells, mutant DCTN1 exhibited a reduced binding affinity for microtubules, 
whilst mutant RAB7 showed impaired GTPase activity (Puls et al. 2003, McCray et al. 
2010). Whilst the consequences of the impaired activity remain to be determined, it is likely 
that the mutant proteins impair the attachment of specific cargo to microtubules, preventing 
their retrograde transport.  
In addition to the identification of mutations in motor proteins and motor protein adaptors, 
mutations have also been identified in NEFL, encoding neurofilament light chain (NFL), a 
component of neurofilaments. Mutations in NFL were found to promote the aggregation of 
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the protein, reducing the incorporation of NFL into neurofilaments and destabilising the 
cytoskeletal network (Brownlees et al. 2002, Zhai et al. 2007). The destabilisation of the 
cytoskeleton was found to impair the trafficking of mitochondria in motor neurons 
(d’Ydewalle et al. 2012). Collectively, the identification of KIF1B, DYNC1H1, DCTN1, 
RAB7 and NEFL as dHMN/CMT2 causative genes highlights defective axonal transport as a 
common mechanism of motor neuron degeneration. 
1.3.3.2 Mitochondrial dysfunction 
Mitochondria are fundamental for neuronal function and survival. They primarily function to 
produce adenosine triphosphate (ATP), the energy currency of the cell; however, they also 
play important roles in calcium storage, cell signalling and apoptosis (Sheng 2014). Motor 
neurons have a high rate of ATP consumption; the exocytosis of synaptic vesicles and the 
restoration of ion gradients following the propagation of an action potential are both ATP-
dependent processes. To meet this demand, motor neurons have a large number of 
mitochondria that are strategically localised to regions where demand for ATP and calcium 
buffering are high, such as the synaptic terminals (Sheng 2014).  
Mitochondria are dynamic organelles that undergo fission and fusion events (Scorrano 
2013). Mitochondrial fission is important for the trafficking of the organelle and the removal 
of damaged parts of the network, whereas the fusion of mitochondria is proposed to enable 
the mixing of mitochondrial content, a process that is postulated to be crucial for 
maintaining mitochondrial homeostasis. Interestingly, 20% of autosomal dominant cases of 
CMT2 are caused by mutations in mitofusin 2 (MFN2), an outer mitochondrial membrane 
GTPase that functions in mitochondrial fusion (Verhoeven et al. 2006).  In addition to 
mediating fusion, MFN2 is also important in the formation of endoplasmic reticulum (ER) -
mitochondria contact sites, enabling the movement of calcium between the two organelles 
(de Brito et al. 2008). The protein is also proposed to function in the axonal transport of 
mitochondria, interacting with Miro/Milton, a complex that serves as an adaptor to dock 
mitochondria to motor proteins (Misko et al. 2010). Over 50 patient mutations in MFN2 
have been identified to date, with the majority of mutations missense mutations (Cartoni et 
al. 2009). In patient nerve biopsies, mitochondria appear small and fragmented, suggesting 
an impairment in the fusion process (Baloh et al. 2007). Furthermore, the mitochondria were 
observed to accumulate in the distal regions of the motor neuron axon, which may also 
suggest an impairment in the retrograde transport of mitochondria (Baloh et al. 2007). 
Indeed, mitochondrial trafficking was markedly reduced in cells expressing mutant MFN2 
constructs (Misko et al. 2010). Cytosolic calcium levels were also increased (de Brito et al. 
2010). MFN2 mutations therefore appear to cause a variety of mitochondrial defects. 
Chapter 1 
28 
 
Mutations in ganglioside-induced differentiation-associated protein 1 (GDAP1) have also 
been identified to cause autosomal dominant cases of CMT2. GDAP1 is an outer 
mitochondrial membrane protein and is proposed to have a role in mitochondrial fission and 
fusion (Pareyson et al. 2015). Interestingly, the expression of GDAP1 mutants resulted in 
mitochondria appearing fragmented, indicative of either a reduced rate of fusion or an 
increased rate of fission. The fragmented mitochondria showed an increase in toxic reactive 
oxygen species (ROS) production (Niemann et al. 2009). Impairments in either the fusion or 
fission of mitochondria therefore appear to have deleterious effects on motor neuron 
survival. 
1.3.3.3 Ion channel dysfunction 
Copper is an essential element, acting as a cofactor for numerous enzymes. Its intracellular 
levels, however, are tightly regulated due to its ability to act as a potential generator of toxic 
free radicals. Copper-transporting ATPase 1 (ATP7A) forms part of a network to regulate 
copper metabolism (La Fontaine et al. 2007). ATP7A resides in the trans-Golgi network 
where it functions to transport copper into the Golgi compartment for incorporation into 
copper-dependent enzymes. The protein translocates to the plasma membrane in response to 
an increase in intracellular copper levels, where it mediates the removal of copper from the 
cell (Kim et al. 2008). Missense mutations in ATP7A have been identified in two families 
with X-linked dHMN (Kennerson et al. 2010). The expression of mutant ATP7A in HeLa 
and N2a cells led to a greater accumulation of the transporter at the plasma membrane 
compared to the wild-type protein, suggesting an impairment in the endocytic recycling of 
ATP7A back to the trans-Golgi compartment (Kennerson et al. 2010). The prolonged 
retention of ATP7A at the plasma membrane has been proposed to lead to a chronic 
deficiency of copper-dependent enzymes.  
Mutations in transient receptor vallanoid 4 (TRPV4), encoding a cation channel, have also 
been identified in autosomal dominant cases of CMT2 (Auer-Grumbach et al. 2010, Deng et 
al. 2010, Landoure et al. 2010). Mutant TRPV4 expressed in N2a cells displayed increased 
calcium channel activity, leading to an increase in the levels of intracellular calcium (Fecto 
et al. 2011). Interestingly, elevated levels of intracellular calcium retard the mobility of 
mitochondria and it has been suggested that mutant TRPV4 may indirectly interfere with 
axonal transport of mitochondria, although this hypothesis remains to be confirmed 
experimentally (Gentil et al. 2012). 
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1.3.3.4 Impaired protein translation 
Aminoacyl tRNA synthetases are ubiquitous enzymes that function in protein translation, 
catalysing the attachment of an amino acid to its cognate tRNA molecule. Once tRNA is 
charged, the ribosome transfers the amino acid from the tRNA into the growing polypeptide 
chain, in accordance to the mRNA codon sequence. Interestingly, mutations in glycyl-tRNA 
synthetase (GARS) and alanyl-tRNA synthetase (AARS) have been identified in autosomal 
dominant cases of dHMN and CMT2, respectively (Antonellis et al. 2003, Latour et al. 
2010, Wallen et al. 2013). Investigations into the mechanism of pathogenesis suggest that 
the mutations result in a loss of function phenotype. In yeast complementation studies, the 
majority of AARS and GARS mutants resulted in a loss of complementation, suggesting an 
impairment in tRNA charging (Antonellis et al. 2006). However, a proportion of AARS and 
GARS mutants were able to rescue yeast viability, implying that impaired tRNA charging 
does not underlie the pathogenesis of all disease-associated mutations (Antonellis et al. 
2006). In human spinal cord tissue, wild-type GARS localises to puncta in the axons of 
motor neurons (Antonellis et al. 2006). In transfected motor neuron cell lines, mutant GARS 
failed to localise to axons (Antonellis et al. 2006, Jordanova et al. 2006). The lack of axonal 
localisation of the protein has been proposed to deplete tRNA charging in the axon, 
impairing local axonal translation and potentially decreasing the levels of axonal proteins 
that are critical for axonal function (Wallen et al. 2013). 
Mutations in immunoglobulin µ-binding protein 2 (IGHMBP2) have been identified to 
underlie autosomal recessive cases of dHMN. Although the precise function of IGHMBP2 
remains unknown, the protein has been identified as an ATP-dependent helicase, unwinding 
both DNA and RNA (Guenther et al. 2009). The protein has been reported to interact with 
the ribosome, suggesting a possible function in protein translation (Guenther et al. 2009). 
The majority of mutations in IGHMBP2 are missense mutations that lie in close proximity to 
the helicase domain (Grohmann et al. 2001, Guenther et al. 2007). The characterisation of 
patient mutations using in vitro assays revealed that mutant IGHMBP2 has reduced ATPase 
and helicase activity (Guenther et al. 2009), suggesting that mutations in IGHMBP2 could 
potentially impair protein translation. 
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Figure 1.3 Examples of CMT2 and dHMN causative genes. Schematic of a motor neuron 
highlighting the cellular processes that may be impaired in CMT2 and dHMN; axonal 
transport (DCTN1, DYNC1H1, KIF1B, NEFL, RAB7), mitochondrial function (GDAP1, 
MFN2), ion channel activity (ATP7A, TRPV4), protein translation, (AARS, GARS, 
IGHMBP2), protein folding and protein degradation (DNAJB2, HSPB1, HSPB8, LRSAM1, 
TRIM2) and ER homeostasis (BSCL2). Figure adapted from Rossor et al. 2013. 
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1.4 Protein folding 
Proteins are central players in the majority of cellular processes. They are synthesised as 
linear polypeptide chains, yet they must fold to their native three-dimensional structure in 
order to achieve functionality. In 1973, Anfinsen demonstrated that the three-dimensional 
structure of a protein is encoded in its amino acid sequence. Each amino acid residue can 
adopt a number of different conformations, generating a large number of possible three-
dimensional structures. Taking this into consideration, Levinthal argued that protein folding 
simply cannot occur through the random sampling of all possible conformations until the 
native structure is reached. Instead, he postulated the existence of a protein folding pathway 
(Levinthal 1969). The current model of protein folding is highly complex and the principles 
that guide the folding process remain to be fully characterised. However, the model is based 
on the principle that folding occurs through a free energy funnel (Figure 1.4), with proteins 
seeking the most thermodynamically favourable conformation with the lowest free energy 
(Hartl et al. 2011, Kim et al. 2013). Folding is proposed to be initiated by the spontaneous 
collapse of the polypeptide chain into a compact state, referred to as a molten globule, a 
process mediated by hydrophobic interactions among non-polar residues. The burial of non-
polar residues in the interior of the protein is thermodynamically favourable and decreases 
the free energy of the protein. Following hydrophobic collapse, folding to the native state 
relies on the formation of native hydrogen bonds and van der Waals forces. Such 
interactions further decrease the free energy of the protein and subsequently the free energy 
funnel narrows, representing the restricted conformational space that needs to be searched en 
route to the native state (Hartl et al. 2011, Kim et al. 2013).  
1.5 Protein quality control 
In the crowded cellular environment, partially folded proteins with exposed hydrophobic 
amino acid residues are susceptible to the formation of non-native interactions that can lead 
to protein misfolding and aggregation. If allowed to accumulate, misfolded and aggregated 
proteins can cause toxicity (cytotoxicity), leading to numerous diseases such as diabetes, 
cardiovascular disease and neurodegenerative diseases (Mukherjee et al. 2015, Del Monte et 
al. 2014, Hipp et al. 2014). Cells have therefore adopted an intrinsic network of protein 
quality control that promotes efficient folding and either the re-folding or degradation of 
misfolded and aggregated protein. The protein quality control machinery includes molecular 
chaperones, the ubiquitin proteasome system (UPS) and autophagy. The mechanisms by 
which these three systems function to maintain protein homeostasis (proteostasis) are 
discussed in the following section. 
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Figure 1.4 Protein folding free-energy funnel. Hydrophobic collapse of the polypeptide 
chain into a molten globule is thermodynamically favourable. The formation of native 
interactions further decreases the free energy of the protein and limits the free-energy 
landscape that needs to be searched en route to the native state. The free-energy landscape is 
often rugged; proteins must cross kinetic barriers during folding. Failure to do so can result 
in partially folded intermediates becoming kinetically trapped. Figure adapted from 
www.learner.org/proteinfoldingfunnel and Hartl et al. 2011. 
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1.5.1 Molecular chaperones 
Molecular chaperones are defined as proteins that interact with, stabilise or assist another 
protein to gain its native and functionally active conformation, without being present in the 
final structure (Ellis 1987). Members of the molecular chaperone family are often referred to 
as heat-shock proteins (Hsp) due to their upregulation under stress conditions that typically 
destabilise proteins, such as elevated temperature and oxidative stress. Molecular chaperones 
are often classified according to their molecular weight and families include Hsp90, Hsp70, 
Hsp60, Hsp40 (DnaJ) and the small Hsp (Figure 1.5). Molecular chaperones display large 
functional diversity and in addition to their fundamental roles in de novo folding, and the 
refolding of misfolded proteins, chaperones also regulate critical cellular processes such as 
protein trafficking, protein degradation and macromolecular complex assembly and 
disassembly (Hartl et al. 2011). 
1.5.1.1 Hsp90 (HSPC) 
Hsp90 (HSPC) is an ATP-dependent chaperone that functions in the activation and 
stabilisation of client proteins. Client proteins include protein kinases, cell cycle regulators, 
cell surface receptors and transcription factors; therefore, Hsp90 plays a critical role in 
cellular processes such as signal transduction, cell cycle progression, apoptosis and protein 
degradation (Kim et al. 2013). The activation of Hsp90 clients is driven by a cycle of 
substrate binding and release, mediated by a series of conformational changes and an ATP-
induced transition between an open and a closed conformation. Hsp90 exists as a 
homodimer (Figure 1.5), with each subunit consisting of three domains; an N-terminal ATP-
binding domain (N-domain), a middle domain that binds the substrate (M-domain) and a C-
terminal dimerisation domain (C-domain). In the absence of nucleotide Hsp90 adopts a V-
shaped open conformation. The binding of ATP to the N-domain induces a conformational 
change that closes a lid over the nucleotide binding pocket. Following lid closure, the N-
domains dimerise, forming a compact structure with a closed conformation. The formation 
of the closed dimer induces ATP hydrolysis, subsequently promoting the N-domains to 
dissociate and the return of Hsp90 to the open conformation, with the release of the substrate 
(Pearl et al. 2006). 
The reaction cycle of Hsp90 is regulated by various co-chaperones. The co-chaperones 
exhibit specific binding preferences for different Hsp90 conformations and affect different 
stages of the cycle, such as client binding and ATP hydrolysis (Li et al. 2014). Co-
chaperones therefore usually co-operate in a sequential cycle to facilitating the maturation of 
Hsp90 clients. Many co-chaperones contain a tetratricopeptide repeat (TPR) domain that 
recognises a docking site at the C-terminal of Hsp90 formed by a conserved EEVD motif 
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(Scheufler et al. 2000). Such TPR domain-containing co-chaperones include Hop, which 
stabilises the open conformation of Hsp90 and facilitates substrate binding by acting as an 
adaptor protein between Hsp70 and Hsp90, enabling client transfer (Chen et al. 1998). 
Alternatively, CHIP, an E3 ubiquitin ligase, is a TPR domain-containing co-chaperone that 
mediates the attachment of ubiquitin chains to the client and thereby signals for its 
degradation (Bozaykut et al. 2014). 
1.5.1.2 Hsp70 (HSPA) 
Hsp70 (HSPA) functions in a wide array of cellular processes including the folding of newly 
synthesised protein, the refolding of misfolded and aggregated protein, transport of proteins 
across membranes, and protein degradation (Kim et al. 2013). These functions rely on the 
ability of Hsp70 to interact with hydrophobic stretches exposed in client proteins and 
subsequently undergo an ATP-dependent cycle of substrate binding and release (Figure 1.6). 
Hsp70 is composed of a 44 kDa N-terminal ATPase domain (NBD) and a C-terminal 
substrate binding domain (SBD), divided into an 18 kDa β-sandwich subdomain that forms a 
hydrophobic binding pocket and a 10 kDa α-helical subdomain that acts as a lid (Figure 1.6) 
(Hartl et al. 2011). The NBD and SBD are connected by a flexible linker that enables the 
NBD to allosterically control the conformation of the SBD. In the ATP-bound state the 
binding pocket and lid are in an open conformation. The SBD has a low substrate affinity 
and fast substrate exchange rates. The hydrolysis of ATP to ADP drives the SBD into a high 
affinity state for substrate binding through the closing of the lid, enabling stable binding of 
the client protein. The release of ADP and the rebinding of ATP triggers the opening of the 
lid and the subsequent unloading of the bound substrate (Mayer et al. 2010).  
The Hsp70 reaction cycle contains two rate limiting steps; ATP hydrolysis, due to low basal 
ATPase activity, and the dissociation of ADP. Hsp70 therefore requires the action of 
cofactors to facilitate the reaction cycle between ATP and ADP bound states. The ATPase 
activity of Hsp70 is stimulated by members of the DnaJ family via their conserved J domain 
(Liberek et al. 1991). The dissociation of ADP requires the opening of the nucleotide 
binding cleft, a process catalysed by nucleotide exchange factors (NEFs) (Gassler et al. 
2001).  
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Figure 1.5 Ribbon diagrams showing the structure of representatives from the major 
molecular chaperone families. A: Yeast Hsp90 with its co-chaperone p23 (PDB 2CG9). B: 
Amino acids 1-554 of bovine Hsc70 (PDB 1YUW). C: Bacterial GroEL viewed from above 
(PDB 1GR1). D: J domain of human DnaJ protein HDJ-1 (PDB 1HDJ). E: Small Hsp 
family member Hsp16.3 from Mycobacterium tuberculosis. Figure adapted from 
Kosmaoglou et al. 2008.   
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Figure 1.6 Hsp70 reaction cycle and structure. Hsp40 (DnaJ) delivers unfolded or 
misfolded clients to the SBD of Hsp70. The conserved J domain of DnaJ stimulates the 
ATPase activity of Hsp70, promoting lid closure and the tight binding of the substrate. NEFs 
induce the dissociation of ADP leading to the opening of the lid and the release of the 
substrate. A cycle of binding and release promotes protein folding. Figure from Kim et al. 
2013.  
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1.5.1.3 DnaJ (Hsp40/DNAJ) 
As mentioned above, members of the DnaJ family are important regulators of Hsp70 
activity. All DnaJ proteins contain a J domain, a conserved region of 70 amino acids that 
folds into four α-helices. Helix II and helix III form an antiparallel two-helix bundle, with a 
loop connecting the two helices containing a histidine-proline-aspartate (HPD) motif (Figure 
1.7) (Kampinga et al. 2010). The HPD motif is critical for lowering the activation energy of 
ATP hydrolysis by Hsp70, although the exact mechanism by which this occurs remains 
elusive. It has been established that interactions between the J domain and both the NBD and 
the flexible linker of Hsp70 are crucial for stimulating ATPase activity. However, the C-
terminal lid of Hsp70 has also been shown to be critical for modulating DnaJ binding, 
suggesting that a complex interaction between the J domain and Hsp70 is required to 
efficiently stimulate ATPase activity (Gao et al. 2012). 
The human genome encodes 49 DnaJ proteins, which can be divided into three classes 
according to their domain composition (Cheetham et al. 1998, Kampinga et al. 2009). Class 
I proteins share all domains present in Escherichia coli DnaJ, with an N-terminal J domain, a 
glycine-phenylalanine (GF) rich region, a zinc binding domain and a C-terminal domain. 
Class II proteins contain an N-terminal J domain and a GF rich region, whereas class III 
proteins share only the J domain. The diversification of domains outside the J domain has 
enabled DnaJ proteins to adopt specialised functions. For example, domains that target DnaJ 
proteins to precise intracellular locations promote the interaction of Hsp70 with specific 
clients. Furthermore, client binding domains enable DnaJ proteins to deliver clients directly 
to the SBD of Hsp70 (Kampinga et al. 2010). 
 
 
 
 
 
 
Figure 1.7 Structure of the J domain from E. coli DnaJ. The J domain contains four 
helices, with a loop between helix II and helix III containing a HPD motif. The HPD motif is 
critical for lowering the activation energy of Hsp70 ATPase activity. PDB 1XBL. Figure 
from Kampinga et al. 2010. 
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1.5.1.4 Hsp60 (HSPD/HSPE) 
Hsp60, also called chaperonins, are large double ring complexes that enclose a central cavity 
(Figure 1.5). Substrate proteins, typically folding intermediates, are encapsulated in the 
central cavity, thereby shielding exposed hydrophobic residues from aggregation and 
allowing the substrate to fold in a protected environment (Kusmierczyk et al. 2001, Yébenes 
et al. 2011). Chaperonins can be divided to two subgroups. Group I chaperonins (HSPD) are 
present in bacteria (GroEL) and the mitochondrial matrix (Hsp60). They contain 7 subunits 
per ring and require co-chaperones that act as lids over the complexes (GroES in bacteria 
and Hsp10 in mitochondria). Group II chaperonins (HSPE) are found in archaea 
(thermosome) and in the cytosol of eukaryotes (TRiC) and they typically have 8 subunits per 
ring (Yébenes et al. 2011). 
The GroEL chaperonin in E. coli has been the most extensively studied (Hartl et al. 2009). 
Each subunit consists of an equatorial ATP binding domain, a hinge domain and an apical 
substrate binding domain. The apical domain forms the entrance to the GroEL cavity and 
exposes hydrophobic residues to mediate substrate binding. Following substrate binding to 
one of the rings, ATP binds to each of the 7 subunits, inducing conformational changes, 
enabling the association of GroES and the subsequent encapsulation of the substrate. Upon 
GroES binding, the GroEL cavity enlarges, creating an environment for productive protein 
folding. The hydrolysis of ATP to ADP triggers the dissociation of the GroES lid and the 
release of the substrate (Horwich et al. 2007, Hartl et al. 2011, Yébenes et al. 2011). 
Multiple folding cycles may be required before the substrate reaches its native state.  
1.5.1.5 Small Hsp (HSPB) 
Small heat shock proteins differ from the other members of the molecular chaperone family 
in that they are ATP independent. The human genome encodes 10 small Hsps (termed 
HSPB1-10) and they range in size from 12-42 kDa. They share a conserved 100 amino acid 
α-crystallin domain that is flanked by variable N-terminal and C-terminal extensions. These 
extensions mediate substrate recognition as well as enabling the formation of oligomers. 
Small Hsps are able to bind to unfolded or misfolded protein and prevent their aggregation 
until the protein can be transferred to Hsp70 (Carra et al. 2012). 
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1.5.2 The ubiquitin proteasome system 
The ubiquitin proteasome system (UPS) mediates the degradation of short-lived, damaged 
and misfolded proteins. Such proteins are targeted for degradation through the covalent 
attachment of ubiquitin, a modification that enables substrates to be recognised by the 
proteasome, a proteolytic machine localised in the cytosol and nucleus of eukaryotic cells 
(Inobe et al. 2014).  
The conjugation of ubiquitin to protein substrates requires the co-ordinated action of three 
enzymes (Komander 2009). First, an ubiquitin-activating enzyme (E1) activates ubiquitin in 
an ATP-dependent manner. The E1 enzyme catalyses the formation of a high-energy 
thioester bond between an active site cysteine residue and the C-terminal glycine residue of 
ubiquitin (Gly76). Following activation, ubiquitin is transferred from E1 to an active site 
cysteine residue of an ubiquitin-conjugating enzyme (E2). The final step in the cascade is 
mediated by an ubiquitin ligase enzyme (E3) that binds to both the E2 and the substrate and 
promotes the transfer of ubiquitin, catalysing the formation of an isopeptide bond between 
the glycine residue of ubiquitin and a lysine residue of the substrate. E3 ubiquitin ligases 
contain one of two domains; a HECT (homologous to E6-AP C-terminus) domain or a 
RING (really interesting new gene) domain (Bernassola et al. 2008, Deshaies et al. 2009). 
HECT domain E3 ubiquitin ligases bind ubiquitin during the transfer process whereas RING 
domain E3 ubiquitin ligases catalyse the direct transfer of ubiquitin from the E2 to the 
substrate. The human genome encodes over 600 E3 ubiquitin ligases. Their abundance and 
selectivity suggests that E3 ubiquitin ligases are responsible for the substrate specificity of 
the UPS (Metzger et al. 2012).  
Ubiquitin has seven lysine residues that can be used in the formation of polyubiquitin chains 
(K6, K11, K27, K29, K33, K48 and K63). The different linkages generate distinct topologies 
that can be recognised by specific ubiquitin-binding proteins (Komander 2012). K48-linked 
ubiquitin chains are the primary signal for proteasomal degradation, with at least four 
ubiquitin molecules required for recognition by the proteasome (Thrower et al. 2000) The 
functional significance of K6, K11, K27, K29 and K33-linked ubiquitin chains remains to be 
fully characterised, however there is evidence to suggest that K6, K11, K27, K29 and K63-
linked chains can also target a protein for proteasomal degradation (Komander 2012). 
The 26S proteasome is a 2.5 mDa protein complex that consists of a 20S core particle and a 
19S regulatory particle (Figure 1.8). The 20S core particle is composed of four stacked 
heptameric rings that form a central chamber, with two outer α-rings and two inner β-rings 
(Inobe et al. 2014, Gu et al. 2014). Subunits β1, β2 and β5 of each β-ring have proteolytic 
activity, displaying caspase-like, trypsin-like and chymotrypsin-like peptidase activity, 
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respectively. Access to the proteolytic sites is restricted by the two outer α-rings, which gate 
the central chamber. Gate opening and the translocation of the substrate into the proteolytic 
chamber is regulated by the 19S particle. The 19S regulatory particle can be divided into a 
base and a lid complex (Lander et al. 2012). The base structure consists of a ring of six AAA 
ATPase subunits (Rpt1-6) (Tomko et al. 2010). Three of the ATPase subunits contain C-
terminal tails with a specific HbYX motif. These C-terminal tails bind to pockets in the 20S 
α-ring, tethering the two particles and subsequently promoting gate opening (Smith et al. 
2007, Gillette et al. 2008). Both the base and the lid structures contain subunits that bind to 
polyubiquitin chains. Once the ubiquitylated substrate is bound to the 19S regulatory 
particle, the ubiquitin chain is cleaved by Rpn11, a subunit of the lid complex (Verma et al. 
2002). The ATPase subunits of the base subsequently unfold the polypeptide chain through 
cycles of ATP hydrolysis. Only once the chain is unfolded can it proceed into the proteolytic 
chamber, where the substrate is cleaved into small peptides. Upon their exit from the 
proteasome, the small peptides are digested by cytosolic endopeptidases and 
aminopeptidases. 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 Schematic representation of the 26S proteasome. The 26S proteasome is 
composed of a 20S core particle and a 19S regulatory particle. The 20S particle is composed 
of four stacked heptameric rings. Subunits of the β-rings have proteolytic activity. The α-
rings act as a gate to the proteolytic chamber. Gate opening is regulated by the 19S particle, 
which is composed of a lid and a base sub-complex. Figure from Lee et al. 2013. 
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1.5.3 Autophagy 
Autophagy mediates the lysosomal degradation of cellular components. Unlike the UPS, 
which degrades short-lived proteins, autophagy typically degrades long-lived proteins and is 
capable of degrading large structures such as protein aggregates and damaged organelles. 
There are three types of autophagy; macroautophagy, microautophagy and chaperone-
mediated autophagy (CMA) (Lee et al. 2013). In CMA, cytosolic proteins containing a 
pentapeptide KFERQ motif are recognised by Hsc70 and targeted to the lysosome through 
an interaction with the integral lysosomal membrane protein, LAMP2A. In microautophagy, 
cytosolic material is directly engulfed into the lysosome through the invagination of the 
membrane. In macroautophagy, cytosolic components are engulfed by vesicles, which 
subsequently fuse with the lysosome. The molecular machinery of macroautophagy (herein 
referred to as autophagy) has been extensively characterised in yeast, with the identification 
of approximately 30 autophagy-related genes (ATG), many of which have mammalian 
orthologues (Mizushima 2011).  
Autophagy requires the formation of a double membrane vesicle called an autophagosome 
(Rubinsztein et al. 2012). Autophagosome formation is initiated by the extension of an 
enveloping membrane (isolation membrane), a process dependent on the activation of the 
ULK1 complex, composed of ULK1, ATG13, ATG101 and FIP200. The activity of the 
induction complex is regulated by two kinases; mammalian target of rapamycin complex 
(mTORC1) and adenosine monophosphate-activated protein kinase (AMPK) (Kim et al. 
2011). Under nutrient-rich conditions, mTORC1 phosphorylates ULK1 and ATG13, 
maintaining the complex in an inactive state. Under starvation conditions, mTORC1 is 
inhibited, resulting in the dephosphorylation of the ULK1 complex, which in turn facilitates 
the binding of AMPK. AMPK then activates the complex via a series of phosphorylation 
events. In addition to requiring the activation of the ULK1 complex, isolation membrane 
formation also requires the activation of the phosphoinositide 3-kinase (PI3K) complex, 
whose components include Beclin1 and the P13K Vps34. Vsp34 is responsible for the 
formation of phosphatidylinositol 3-phosphate, which is essential for the nucleation, 
expansion and curvature of the isolation membrane.  
The elongation of the isolation membrane into an autophagosome is mediated by two 
ubiquitin-like conjugation reactions (Rubinsztein et al. 2012). ATG12 is conjugated to 
ATG5 via the concerted action of ATG7 and ATG10, E1-like and E2-like enzymes, 
respectively. The conjugate then interacts with ATG16L. The ATG12-ATG5-ATG16L 
complex is proposed to serve as a platform for protein-protein interactions at the 
autophagosome membrane. The second ubiquitin-like conjugation reaction involves the 
Chapter 1 
42 
 
conversion of LC3-I to LC3-II. LC3 is synthesised as pro-LC3; the protein is subsequently 
cleaved at its C-terminus by ATG4, exposing a conserved glycine residue (LC3-I). ATG7 
and ATG3 facilitate the binding of phosphatidylethanolamine to the exposed glycine 
residue, forming LC3-II. The lipidated form is recruited into the autophagosome membrane 
and promotes the maturation of the vesicle, with the subsequent engulfment of cytosolic 
cargo. Upon maturation, the autophagosome fuses with lysosomes, allowing the degradation 
of the cargo by lysosomal hydrolytic enzymes. 
Autophagy adaptor proteins, such as p62, NBR1 and NIX, mediate the selective recruitment 
of cargo into the autophagosome (Johansen et al. 2011). The adaptor proteins contain two 
critical domains, an LC3-interacting region (LIR) and an ubiquitin binding domain (UBA). 
The UBA domain binds to ubiquitylated substrates, typically with K63-linked ubiquitin 
chains. Once bound to the cargo, the adaptor can then bind to LC3-II via the LIR, thereby 
targeting the ubiquitylated substrate for engulfment by the autophagosome. 
 
Figure 1.9 The autophagy pathway. Autophagosome formation requires the activation of 
the ULK1 complex and the Vps34 PI3K complex. These complexes function to initiate the 
formation of an isolation membrane. The isolation membrane is extended into an 
autophagosome through two ubiquitylation-like (UBL) reactions. ATG7 and ATG10 
conjugate ATG12 to ATG5. The conjugate then associates with ATG16L. The second 
ubiquitylation-like reaction requires the conversion of pro-LC3 to LC3-I by ATG4. ATG7 
and ATG3 then catalyse the attachment of phosphatidylethanolamine (PE) to LC3-I, forming 
LC3-II. As the autophagosome forms, cargo becomes engulfed in the vesicle. Upon 
formation, the autophagosome fuses with the lysosome, enabling the cargo to be degraded 
by acidic hydrolases. Figure from Mariño et al. 2014. 
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1.5.4 ER-associated degradation 
The ER is responsible for the folding and post-translational modification of newly 
synthesised membrane and secretory proteins. The high rate of protein folding in the ER 
places a burden on the organelle and a significant fraction of proteins fail to reach their 
native conformation (Matus et al. 2011). Misfolded proteins in the ER are targeted to the 
proteasome for degradation in a process termed ER-associated degradation (ERAD). The 
process can be divided into four stages; the recognition of misfolded substrates, their 
retrotranslocation to the cytosol, protein ubiquitylation, and finally targeting to the 
proteasome (Ruggiano et al. 2014).  
The ERAD pathway is co-ordinated by a membrane complex consisting of multiple 
components (Olzmann et al. 2013). Components of the complex can interact with misfolded 
proteins directly or alternatively, misfolded proteins can be recruited to the complex by 
molecular chaperones, such as the ER luminal Hsp70 protein BiP, or EDEM1, a lectin that 
exhibits chaperone-like activity. Once recruited to the ERAD machinery, the misfolded 
protein must be retrotranslocated across the lipid bilayer to the cytosol. The identity of the 
retrotranslocation channel remains unknown, however, a series of candidates have been 
proposed. One possible candidate is the Sec61 translocon, which facilitates the import of 
newly synthesised polypeptide chains into the ER (Schäfer et al. 2009). It is possible that the 
translocon may function in a bidirectional manner, enabling both the import and export of 
polypeptide chains. Members of the Derlin family have also been proposed to function as 
retrotranslocation channels, along with Hrd1 and gp78, integral membrane E3 ubiquitin 
ligases (Carvalho et al. 2010). The function of Hrd1 and gp78 as retrotranslocation channels 
could couple protein export with protein ubiquitylation. Protein ubiquitylation is a pre-
requisite for the binding of p97/VCP, a cytosolic AAA ATPase that drives the extraction of 
the polypeptide chains from the ER membrane in an ATP-dependent manner (Stolz et al. 
2011). Upon the extraction from the membrane, the ubiquitylated ERAD substrate is 
recognised by molecular chaperones and ubiquitin-binding proteins and is targeted to the 
proteasome for degradation. 
1.6 Cell stress responses 
1.6.1 The unfolded protein response 
The accumulation of misfolded proteins in the ER can activate an unfolded protein response 
(UPR), a dynamic signalling pathway that aims to restore proteostasis by increasing the 
folding and degradative capacity of the organelle (Walters and Ron 2011). The UPR is 
orchestrated by three transmembrane proteins; inositol-requiring enzyme 1 (IRE1), protein 
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kinase RNA-like ER kinase (PERK) and activating transcription factor 6 (ATF6). Under 
resting conditions, the three transmembrane proteins are maintained in an inactive state 
through their association with BiP. Upon the accumulation of misfolded proteins, BiP 
dissociates and the UPR is activated (Figure 1.10).  
IRE1 is a type I transmembrane protein that contains a cytosolic serine/threonine kinase 
domain and an endoribonuclease domain. The dissociation of BiP leads to the dimerisation 
and autophosphorylation of IRE1, activating the endoribonuclease activity of the protein. 
The endoribonuclease activity of IRE1 catalyses the unconventional splicing of X-box 
binding protein 1 (XBP1) mRNA, with the excision of a 26-nucleotide intron that 
subsequently shifts the coding reading-frame. Spliced XBP1 is stable and is translated to 
XBP1s, an active transcription factor that upregulates ER chaperones and ERAD machinery, 
thus increasing the folding and degradative capacity of the ER (Walters and Ron 2011, 
Deegan et al. 2013).  
PERK is a type I transmembrane protein with a cytosolic serine/threonine kinase domain. 
Upon its activation, the kinase domain catalyses the phosphorylation of eukaryotic initiation 
factor 2 (eIF2α), leading to the inhibition of general translation and thereby reducing the 
entry of newly synthesised proteins into the ER. Phosphorylated eIF2α results in the 
selective translation of activating transcription factor 4 (ATF4), a transcription factor that 
upregulates ER chaperones as well as proteins involved in autophagy, amino acid 
metabolism and oxidative stress (Walters and Ron 2011, Deegan et al. 2013).  
ATF6 is a type II transmembrane protein and a member of the leucine zipper protein family. 
The dissociation of BiP unmasks two Golgi localisation signals, promoting the translocation 
of ATF6 to the cis-Golgi compartment. At the Golgi, the 90 kDa protein is cleaved by a site 
1 protease and a site 2 protease, generating a 50 kDa N-terminal fragment that contains the 
leucine zipper DNA-binding domain. Following cleavage, the active fragment translocates 
to the nucleus where it acts as a transcription factor, upregulating ER chaperones, ERAD 
machinery and XBP1 (Walters and Ron 2011, Deegan et al. 2013).  
If the adaptive responses of the UPR are unable to restore proteostasis, the UPR activates an 
apoptotic signalling pathway, leading to programmed cell death (Szegezdi et al. 2006). One 
mechanism by which apoptosis is induced is though the PERK branch. ATF4 upregulates 
the pro-apoptotic transcription factor CHOP. CHOP downregulates the anti-apoptotic 
protein BCL2 whilst upregulating the transcription of pro-apoptotic BH3-only proteins such 
as BIM and PUMA (Puthalakath et al. 2007). BH3-only proteins translocate to the outer 
mitochondrial membrane (OMM) where they activate BAK/BAX, the regulators of 
apoptosis. Once activated, BAK/BAX form homo-oligomers in the OMM, initiating 
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membrane permeabilisation, the release of cytochrome c and the subsequent activation of 
caspases, cysteine proteases that play an essential role in apoptosis. 
 
Figure 1.10 The three branches of the unfolded protein response. The accumulation of 
misfolded protein in the ER results in the dissociation of BiP from the three transmembrane 
proteins, leading to their activation. PERK phosphorylates eIF2α causing an inhibition of 
general translation. Phosphorylated eIF2α results in the selective translation of the 
transcription factor ATF4, which upregulates UPR target genes. IRE1 activation leads to the 
unconventional splicing of XBP1 mRNA. Spliced XBP1 is stable and is translated to 
XBP1s, an active transcription factor. The dissociation of BiP from ATF6 exposes Golgi 
localisation signals. Upon translocation, ATF6 is cleaved by site 1 and site 2 proteases, 
producing an active transcription factor. The active 50 kDa fragment translocates to the 
nucleus and upregulates target genes. If the UPR fails to restore homeostasis, an apoptotic 
signalling cascade is induced. Figure from Wang et al. 2014. 
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1.6.2 The heat shock response 
The heat shock response (HSR) is a highly conserved stress pathway that functions to up-
regulate heat shock proteins upon exposure to cell stressors, such as elevated temperature, 
oxidative stress and altered pH (Morimoto 2011). In mammals, the HSR is co-ordinated by 
heat shock transcription factor 1 (HSF1), a transcription factor with an N-terminal DNA 
binding domain and a C-terminal oligomerisation domain (McMillan et al. 1998). Under 
normal conditions, HSF1 is retained in a complex with Hsp90 or Hsp70, maintaining the 
transcription factor in a monomeric repressed state (Zou et al. 1998, Shi et al. 1998). Upon 
cell stress, Hsp90 and Hsp70 preferentially bind to non-native proteins, thereby releasing 
HSF1, enabling its trimerisation and subsequent activation. Activated HSF1 translocates to 
the nucleus and binds to heat shock elements in the promoter region of genes encoding heat 
shock proteins, leading to their elevated transcription (Vihervaara et al. 2014). The rapid 
expression of molecular chaperones promotes the recovery from stress-induced damage to 
proteins. 
1.7 Impaired protein quality control in neurodegenerative diseases 
Whilst the degeneration of upper and/or lower motor neurons defines motor neuron 
disorders, the selective degeneration of other neuronal populations in the brain, brainstem 
and spinal cord defines other neurological diseases. Collectively, these diseases are referred 
to as neurodegenerative diseases. ALS, Alzheimer’s disease (AD), Huntington’s disease 
(HD) and Parkinson’s disease (PD) are four of the most widely studied neurodegenerative 
diseases, with particular focus on dissecting the molecular mechanisms that underlie 
neuronal degeneration in each disease (Bettens et al. 2013, Walker et al. 2007, Kailia and 
Lang 2015, Kiernan et al. 2011).  
HD is a hereditary disease, whereas AD, ALS and PD are predominantly sporadic. Clinically 
and pathologically, sporadic cases of AD, ALS and PD are often indistinguishable from the 
hereditary forms of the disease (representing 5-10% of cases), suggesting common 
mechanisms of disease pathogenesis. The identification and characterisation of causative 
genes for hereditary cases can therefore advance our understanding of the molecular 
mechanism that underlie neuronal degeneration in both forms of the disease. 
1.7.1 Protein aggregates are a hallmark of neurodegenerative diseases 
Ubiquitylated protein aggregates are a pathological hallmark of many neurodegenerative 
diseases. Impairments in proteostasis may therefore be a common underlying mechanism of 
disease pathogenesis. Indeed, many of the causative mutations identified in hereditary cases 
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lead to the misfolding and aggregation of the disease-related protein, for example, amyloid-β 
(Aβ) in AD, SOD1 in ALS, huntingtin in HD and α-synuclein in PD (Hardy et al. 1992, 
Goedert et al. 1989, Rosen et al. 1993, DiFiglia et al. 1997, Spillantini et al. 1998, Ross et 
al. 2004, Soto et al. 2008). The chronic production of misfolded protein can overwhelm the 
protective capabilities of the protein quality control network, with the over-burdening of 
available chaperones and degradation machineries (Hartl et al. 2011). The functional 
depletion of protein quality control components leads to further protein misfolding and 
aggregation, promoting the collapse of proteostasis and driving disease progression.  
The large aggregates observed pathologically are thought to represent the end point of the 
aggregation process, which begins with the formation of small soluble oligomers, followed 
by the formation of protofibrils then mature fibrils (Lim and Yue 2015). Soluble oligomers 
and protofibrils are suggested to pose the most toxic potential to the cell; these toxic species 
expose hydrophobic surfaces that can mediate aberrant interactions with other proteins and 
cellular membranes (Walsh et al. 2002, Winner et al. 2011). The aggregation of soluble 
oligomers into larger insoluble deposits is suggested to be a protective response, reducing 
the exposed surface area that can form aberrant interactions (Arrasate et al. 2004). Although 
larger aggregates may not be considered the most toxic species, it is unlikely that they are 
completely harmless. Large aggregates may contribute to cytotoxicity through their ability to 
physically obstruct axonal transport (Goldstein 2012). Neurons rely heavily on axonal 
transport in order to efficiently sustain their function. Neurons are therefore vulnerable to 
aggregate formation and thus place a high demand on the protein quality control machinery 
to maintain proteostasis. 
1.7.2 Molecular chaperones are protective in neurodegenerative disease 
Molecular chaperones are important therapeutic targets in neurodegenerative diseases. Their 
manipulation could re-balance the protein quality control network, restoring proteostasis and 
potentially slowing disease progression. The first demonstration that molecular chaperones 
could act as potent modulators of protein aggregation and neurodegeneration was provided 
by Cummings et al. (1998) using a cellular model of polyglutamine (polyQ) disease. They 
showed that the overexpression of DnaJA1 was able to reduce the aggregation of 
polyglutamine expanded ataxin-1. Since this first report, the effect of other DnaJ proteins on 
polyQ aggregation has been studied. DnaJB2a was identified as a particularly effective 
suppressor of polyQ aggregation in cells and will be discussed in more detail is section 1.8.4 
(Westhoff et al. 2005). A comparative study by Hageman et al. (2010) revealed that 
members of the DnaJB subfamily were more effective than members of the DnaJA 
subfamily at reducing the formation of high molecular weight species and insoluble 
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aggregates in cells expressing mutant polyQ. Interestingly, within the DnaJB subfamily, 
members were found to exhibit differential anti-aggregation properties; DnaJB6b and 
DnaJB8 were found to suppress polyQ aggregation to a greater extent than DnaJB1 and 
DnaJB2b (Hageman et al. 2010). All four DnaJB proteins were found to reduce polyQ 
aggregation by facilitating its degradation via the proteasome (Bailey et al. 2002, Westhoff 
et al. 2005, Hageman et al. 2010); however, unlike DnaJB1 and DnaJB2b, the ability of 
DnaJB6b and DnaJB8 to reduce polyQ aggregation was almost completely independent of J 
domain activity. Instead, the anti-aggregation properties were found to be dependent on the 
C-terminal serine-rich region (Hageman et al. 2010), a region unique to DnaJB6 and 
DnaJB8 that functions in substrate recognition and the formation of oligomers. Small Hsps 
have also been shown to suppress polyQ aggregation. As with members of the DnaJB 
family, members of the small Hsp family also exhibited different anti-aggregation 
properties; the overexpression of HSPB6, HSPB7, HSPB8 or HSPB9 reduced polyQ 
aggregation in cells, whereas the overexpression of HSPB1, HSPB2, HSPB3, HSPB4, 
HSPB5 or HSPB10 had little or no effect (Vos et al. 2010). HSPB7 was identified as the 
strongest suppressor of polyQ inclusion formation, acting to target polyQ for autophagy-
mediated degradation. This corresponded with a reduction in polyQ-mediated cytotoxicity 
(Vos et al. 2010).  
The anti-aggregation properties of molecular chaperones have also been examined in other 
models of neurodegenerative disease. Hsp70 has been particular well studied in models of 
PD. The overexpression of Hsp70 has been shown to suppress α-synuclein aggregation both 
in vitro and in vivo. In a cell model, the overexpression of Hsp70 reduced the levels of high 
molecular weight and detergent insoluble α-synuclein, as well as reducing total α-synuclein 
levels. This corresponded with a reduction in α-synuclein-mediated cytotoxicity (Klucken et 
al. 2004). Consistent with the in vitro observations, the overexpression of Hsp70 in a 
transgenic mouse model reduced α-synuclein aggregation (Klucken et al. 2004). Further 
studies in mice and Drosophila melanogaster revealed that the Hsp70-mediated reduction in 
α-synuclein aggregation corresponded with an increase in dopaminergic neuron survival, 
enabling the preservation of striatal dopamine levels (Auluck et al. 2002, Cleren et al. 2005). 
The mechanism by which Hsp70 suppresses α-synuclein aggregation was proposed to rely 
on the inhibition of fibril formation, with Hsp70 binding to protofibrils and preventing their 
elongation and further nucleation (Huang et al. 2006). 
Hsp70 is also protective in cell models of ALS, ameliorating mutant SOD1 aggregation and 
toxicity in primary motor neuron cultures (Takeuchi et al. 2002, Patel et al. 2004). Members 
of the small Hsp family are also protective in vitro, with HSPB1 protecting against mutant 
SOD1-induced cell death and HSPB8 reducing mutant SOD1 aggregation by stimulating the 
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autophagy-mediated degradation of the protein (Patel et al. 2004, Crippa et al. 2010). 
Although Hsp70 and HSPB1 showed promising effects in vitro, their upregulation in vivo 
has proved less successful. The overexpression of Hsp70 was unable to delay disease 
progression or improve survival in mutant SOD1 mice (Liu et al. 2005). The overexpression 
of HSPB1 in mutant SOD1 mice only proved beneficial at an early stage of the disease, 
increasing motor neuron survival (Patel et al. 2008). However, the protective effect was not 
sustained; the overexpression of HSPB1 had no effect on late-stage disease progression. In 
contrast to the upregulation of individual chaperones, the upregulation of multiple 
chaperones has proved more successful in combating mutant SOD1 aggregation and toxicity 
in vivo (Kieran et al. 2004). The treatment of SOD1 G93A mice with arimoclomal, a drug 
that upregulates chaperones such as Hsp90, Hsp70 and DnaJ proteins by stabilising the 
binding of HSF1 to heat shock elements, delayed disease progression, with a decrease in 
ubiquitin positive aggregates in the spinal cord and an improvement in motor neuron 
survival at late stages of the disease. This was accompanied by a 22% increase in life-span 
(Kieran et al. 2004). 
1.7.3 Mutations in molecular chaperones cause neurodegenerative diseases 
Mutations in molecular chaperones cause inherited neurodegenerative diseases, highlighting 
their critical role in neuronal survival (Table 1.3). Interestingly, mutations in five members 
of the molecular chaperone family (Hsp60, DnaJC29, HSPB1, HSPB8 and DnaJB2) have 
been identified to cause motor neuron degeneration.  
1.7.3.1 Hsp60 
As discussed in section 1.2.2, hereditary spastic paraplegia is caused by the degeneration of 
upper motor neuron axons in the corticospinal tract, leading to progressive spasticity and 
weakness of the lower limbs. Two missense mutations in the mitochondrial chaperonin 
Hsp60 (V98I and Q461E) have been reported in autosomal dominant cases of the disease 
(Hansen et al. 2002, Bross et al. 2007). Hsp60 Q461E, complemented the deletion of GroEL 
in E. coli, however, the resultant colonies were consistently smaller than wild-type colonies 
and grew at a significantly slower rate at higher and lower temperatures (Hansen et al. 
2002). These observations suggest that the substitution may compromise the activity of 
Hsp60. The V98I patient mutation was found to have a more severe effect on Hsp60 
function. Hsp60 V98I was unable to support the growth of E. coli lacking GroEL (Bross et 
al. 2007). Furthermore, purified Hsp60 V98I displayed decreased ATPase activity and 
exhibited a reduced capacity to fold denatured malate dehydrogenase (Bross et al. 2007). 
The cellular consequences of impaired Hsp60 function have been investigated in vivo, using 
a heterozygous Hsp60 knockout mouse (Magnoni et al. 2013). The heterozygous mice 
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developed progressive, late onset deficits in motor function. Morphological changes in 
mitochondria were observed, with a reduction in ATP synthesis. The reduction in ATP 
synthesis was attributed to lower levels of complex III, suggesting that Hsp60 plays an 
important role in respiratory chain complex assembly. Overall, this research suggests that 
the neurodegeneration process could be driven by Hsp60 haploinsufficiency rather than a 
dominant or dominant-negative effect of the mutant protein. 
1.7.3.2 DnaJC29 
Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is an early onset 
neurodegenerative disease caused by the progressive loss of Purkinje cells in the cerebellum, 
followed by motor neurons in the spinal cord (Bouchard 1978). The disease is caused by 
mutations in DnaJC29 (sacsin), with over 170 mutations identified throughout the 520 kDa 
protein. Sacsin contains an N-terminal ubiquitin-like domain (UBL) followed by three large 
sacsin repeat regions, an XPCB domain, a C-terminal J domain and a HEPN domain. A full 
understanding of sacsin function is currently lacking, however, the identification of sacsin-
interacting proteins suggests a role in protein quality control, with the ubiquitin-like domain 
and the XPCB domain binding to the proteasome and ubiquitin ligases, respectively (Parfitt 
et al. 2009, Greer et al. 2010). Sacsin is predominantly localised in the cytosol but also 
localises to mitochondria (Girard et al. 2012). Sacsin was shown to interact with dynamin-
related protein 1 (DRP1), a GTPase that mediates mitochondrial fission (Girard et al. 2012). 
Interestingly, in patient fibroblasts, mitochondria appear overly fused, suggesting a role for 
sascin in mitochondrial fission (Girard et al. 2012). Impairments in mitochondrial fission are 
likely to lead to mitochondrial dysfunction, a common mechanism underlying motor neuron 
degeneration. 
1.7.3.3 DNAJB2, HSPB1 and HSPB8 
Mutations in DNAJB2, HSPB1 and HSPB8 are associated with dHMN and CMT2. The 
mechanisms by which mutations in these chaperones cause motor neuron degeneration are 
discussed in the following section. 
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Family Chaperone Inheritance Disease Reference 
Hsp70 
HSPA9 
(Mortalin) 
Dominant Parkinson’s disease 
De Mena et al. 2009, 
Freimann et al. 2013 
Hsp60 
HSP60 
(HSPD) 
Dominant Spastic paraplegia 
Hansen et al. 2002, 
Bross et al. 2007 
Recessive 
Hypomyelinating 
leukodystrophy  
Magen et al. 2008 
CCT4 Recessive 
Hereditary sensory 
neuropathy 
Lee et al. 2003 
CCT5 Recessive 
Sensory neuropathy 
with spastic paraplegia 
Bouhouche et al. 
2006, Lee et al. 2003 
Hsp40 
(DnaJ) 
DNAJB2 
(HSJ1) 
Recessive 
Distal hereditary motor 
neuropathy, 
Charcot Marie Tooth 2 
Blumen et al. 2012, 
Gess et al. 2014 
DNAJB6 
(MRJ) 
Dominant 
Limb-girdle muscular 
dystrophy 
Harms et al. 2012, 
Sarparanta et al. 
2012, Sato et al. 2013 
DNAJC3 
(ERdj6) 
Recessive 
Diabetes and 
multisystemic 
neurodegeneration 
Vilariño-Güell et al. 
2014 
DNAJC5 
(CSPα) 
Dominant 
Neuronal ceroid 
lipofusinosis 
Benitez et al. 2011, 
Noskova et al. 2011 
DNAJC6 
(Auxilin) 
Recessive Juvenile Parkinsonism 
Edvardson et al. 
2012, Köroğlu et al. 
2013 
DNAJC13 
(RME-8) 
Dominant Parkinson’s disease 
Vilariño-Güell et al. 
2014 
DNAJC19 
(TIM14) 
Recessive 
Dilated 
cardiomyopathy and 
cerebellar ataxia 
Davey et al. 2006, 
Ojala et al. 2012 
DNAJC29 
(Sacsin) 
Recessive 
Spastic ataxia of 
Charlevoix-Saguenay 
Engert et al. 2000, 
Thiffault et al. 2013 
Small Hsp 
HSPB1 
(Hsp27) 
Dominant 
and recessive 
Distal hereditary motor 
neuropathy, 
Charcot Marie Tooth 2 
Evgrafov et al. 2004, 
Houlden et al. 2008, 
Ikeda et al. 2009 
HSPB3 
(HspL27) 
Dominant 
Hereditary motor 
neuropathy 
Kolb et al. 2010 
HSPB5 
(αβ-
crystallin) 
Recessive 
Infantile muscular 
dystrophy 
Del Bigio et al. 2011 
HSPB8 
(Hsp22) 
Dominant 
Distal hereditary motor 
neuropathy, 
Charcot Marie Tooth 2 
Irobi et al. 2004 
Chaperone 
co-factors 
SIL1 Recessive Cerebellar ataxia Senderek et al. 2005 
VCP Dominant 
Amyotrophic lateral 
sclerosis 
Johnson et al. 2010, 
Gonzalez-Perez et al. 
2012 
BAG3 Dominant 
Muscular dystrophy 
Giant axonal 
neuropathy 
Selcen et al. 2009, 
Jaffer et al. 2012 
 
Table 1.3 Molecular chaperones as causative genes in inherited neurodegenerative 
diseases  
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1.8 Impaired proteostasis in dHMN and CMT2 
The identification of causative genes in dHMN and CMT2 has provided the foundations to 
explore the cellular mechanisms underlying motor neuron degeneration. The characterisation 
of mutations in HSPB1, HSBP8, LRSAM1, BSCL2 and DNAJB2 has implicated impaired 
proteostasis as a critical driving force in the pathogenesis of the disease. 
1.8.1 HSPB1 and HSPB8 
Mutations in HSPB1 (Hsp27) and HSPB8 (Hsp22) are typically associated with autosomal 
dominant forms of dHMN and CMT2 (Irobi et al. 2004, Evgrafov et al. 2004, James et al. 
2008, Ikeda et al. 2009, Luigetti et al. 2010). The majority of mutations identified are 
missense mutations that lie in the α-crystallin domain (Carra et al. 2012). The mutations 
trigger Hsp27 or Hsp22 aggregate formation, thereby disrupting proteostasis. Proteostasis is 
further impaired through the co-aggregation of the wild-type counterpart, resulting in a loss 
of wild-type Hsp27 or Hsp22 chaperone activity (Carra et al. 2012). Accumulating evidence 
suggests that a loss of Hsp22 chaperone activity plays a central role in disease pathogenesis 
through a loss of protein quality control. Mutant Hsp22 exhibited a reduced ability to block 
mutant huntingtin and SOD1 aggregation in cells compared to the wild-type protein (Carra 
et al. 2005, Crippa et al. 2010). Mutant Hsp22 was also less effective at reducing the levels 
of high molecular weight aggregated protein in a cell model expressing mutant ataxin-3 
(SCA3) (Carra et al. 2010). The loss of anti-aggregation function was confirmed in 
Drosophila; mutant Hsp22 was unable to protect against SCA3-mediated eye degeneration 
(Carra et al. 2010). Mutant Hsp22 showed a reduced binding affinity for its interacting 
partner Bag3 (Carra et al. 2010, Shemetov et al. 2011). Hsp22 interacts with Bag3 to target 
misfolded proteins for autophagy-mediated degradation (Carra et al. 2008). Whether the 
decreased binding affinity for Bag3 accounts for the impaired anti-aggregation function of 
the protein remains to be determined. However, an inability to target misfolded proteins for 
degradation, in addition to Hsp22 aggregate formation, is likely to overwhelm the protective 
capabilities of the protein quality control network, driving the collapse of proteostasis and 
motor neuron degeneration. 
1.8.2 LRSAM1 
The inability to target specific client proteins for degradation has also been identified as an 
underlying cause of CMT2 in patients with a mutation in LRSAM1. A 2bp insertion in 
LRSAM1, which encodes an E3 ubiquitin ligase, was identified in a family with autosomal 
dominant CMT2 (Weterman et al. 2012). The insertion resulted in a frameshift, with a 
L708R substitution and the introduction of a stop codon 28 bp downstream. Mutant 
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LRSAM1 expression levels were unaffected, however the E3 ubiquitin ligase activity of the 
protein was found to be impaired. In cells, the expression of mutant LRSAM1 led to the 
accumulation of TSG101, the only identified client of LRSAM1 to date (Weterman et al. 
2012). Whether motor neuron degeneration is mediated by the accumulation of TG101 or 
another unidentified client remains to be determined, however the identification of LRSAM1 
as a causative gene highlights the importance of maintaining proteostasis for motor neuron 
survival. 
1.8.3 BSCL2 
Missense mutations in BSCL2 have been reported to cause autosomal dominant cases of 
dHMN and CMT2. BSCL2 encodes the ER transmembrane protein seipin. The mutations 
disrupt N-glycosylation motifs, preventing its correct folding and maturation 
(Windpassinger et al. 2004). The overexpression of mutant seipin in cells resulted in the 
accumulation of misfolded seipin in the ER and induced the upregulation of the UPR 
markers BiP and CHOP (Ito et al. 2008). The activation of the UPR in response to the 
accumulation of misfolded protein resulted in an increase in apoptotic cell death (Ito et al. 
2008). The characterisation of BSCL2 mutants potentially links protein misfolding to motor 
neuron degeneration. 
1.8.4 DnaJB2 
Recently, mutations in DNAJB2 have been identified in autosomal recessive cases of dHMN 
and CMT2 (Blumen et al. 2012, Gess et al. 2014), further supporting the important role of 
molecular chaperones and protein quality control in motor neuron survival. The identified 
mutations are discussed in more detail in Chapter 4. 
DnaJB2 (HSJ1) is a type II DnaJ protein that is alternatively spliced to produce two isoforms 
with alternative C-termini (Cheetham et al. 1998). The two isoforms, HSJ1a and HSJ1b, are 
preferentially expressed in neurons and show distinct intracellular localisations (Cheetham et 
al. 1992, Chapple and Cheetham 2003). The shorter isoform, HSJ1a, is a 36 kDa protein that 
localises to the nucleus and the cytoplasm, whereas the longer HSJ1b isoform is a 42 kDa 
protein that localises to the cytoplasmic face of the ER by C-terminal geranylgeranylation 
(Chapple and Cheetham 2003). Both isoforms contain an N-terminal J domain, a client 
binding domain and two ubiquitin interacting motifs (UIMs) (Figure 1.11) (Chapple et al. 
2004, Westhoff et al. 2005). 
Both HSJ1 isoforms function to target misfolded proteins for proteasomal degradation 
(Westhoff et al. 2005, Howarth et al. 2007, Meimaridou et al. 2011, Novoselov et al. 2013). 
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The combination of a J domain, a client binding domain and UIMs enables HSJ1 to 
recognise misfolded, ubiquitylated client proteins and load them onto Hsp70, with 
subsequent delivery to the proteasome for degradation. Alternatively, HSJ1 can load non-
ubiquitylated misfolded clients onto Hsp70 and subsequently promote their ubiquitylation by 
co-operating with E3 ubiquitin ligases. The binding of the UIMs to the generated ubiquitin 
chains enables HSJ1 to protect the client from de-ubiquitylation by ubiquitin hydrolases, 
ensuring that the signal for proteasomal degradation remains intact (Westhoff et al. 2005). 
The cytoplasmic localisation of HSJ1a enables the isoform to act as an escort factor, 
accompanying the client-bound Hsp70-E3 ubiquitin ligase complex to the proteasome. 
Interestingly, HSJ1a has been found to bind to the proteasome, suggesting a possible role in 
proteasomal docking (Westhoff et al. 2005). 
HSJ1 has been demonstrated to be a potent modulator of protein aggregation in cell and 
mouse models of neurodegenerative diseases. The overexpression of HSJ1a was able to 
significantly reduce polyQ inclusion incidence in a cell model of HD (Westhoff et al. 2005). 
The anti-aggregation properties were specific to HSJ1a; HSJ1b was only able to reduce 
polyQ aggregation when it was released from the cytoplasmic face of the ER through the 
introduction of a mutation that prevented its C-terminal prenylation. The localisation of 
HSJ1a is therefore critical for its protective function against polyQ. The ability of HSJ1a to 
modulate polyQ aggregation was found to be both J domain and UIM dependent (Westhoff 
et al. 2005). PolyQ levels were increased upon proteasome inhibition, indicating that HSJ1a 
reduces polyQ inclusion formation in vitro by targeting the protein for proteasomal 
degradation. The overexpression of HSJ1a also reduced aggregate formation in vivo, in a 
R6/2 mouse model of HD (Labbadia et al. 2012). HSJ1a expression significantly reduced the 
level of aggregated mutant huntingtin in the brain, whilst increasing the levels of soluble 
protein. In contrast to the observations made in vitro, the mechanism of action did not rely 
on proteasomal degradation, instead relying on the association of HSJ1a with K63-linked 
ubiquitylated, higher order, detergent insoluble species, preventing their further nucleation. 
The reduction in aggregation was neuroprotective and led to an improvement in neurological 
performance of the R6/2 mice at a late stage of the disease (Labbadia et al. 2012). 
The overexpression of HSJ1a was also shown to reduce the aggregation of SOD1 G93A in a 
cell model of ALS. HSJ1a stimulated the ubiquitylation and proteasomal degradation of 
SOD1 G93A, leading to a reduction in inclusion formation. The process was dependent on 
the J domain and functional UIMs (Novoselov et al. 2013). In vivo, the overexpression of 
HSJ1a was able to ameliorate late stage disease in a SOD1 G93A mouse model of ALS 
(Novoselov et al. 2013). HSJ1a reduced the levels of insoluble SOD1 G93A, leading to a 
significant improvement in neuromuscular function, with a preservation of muscle force, an 
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increase in motor unit number and enhanced motor neuron survival. Altered ubiquitin 
immunoreactivity was observed in the double transgenic mice, suggesting that ubiquitin 
modifications may be important for the observed improvements (Novoselov et al. 2013). 
The ability of HSJ1a to protect against mutant SOD1-mediated toxicity highlights the 
potential importance of HSJ1 for normal motor neuron function. 
In contrast to cells models of HD and ALS, the overexpression of HSJ1a in a cell model of 
PD reduced mutant parkin aggregation in a manner solely dependent on the J domain (Rose 
et al. 2011). HSJ1a was therefore proposed to reduce mutant parkin aggregation by targeting 
the protein for refolding rather than for proteasomal degradation. HSJ1a was able to partially 
rescue the re-location of mutant parkin to damaged mitochondria, suggesting HSJ1a 
promoted a proportion of misfolded parkin to be refolded to a functionally active 
conformation (Rose et al. 2011). 
The localisation of HSJ1b to the cytoplasmic face of the ER enables the isoform to function 
in ERAD, targeting misfolded ER membrane proteins with exposed cytoplasmic domains for 
ubiquitylation and subsequent proteasomal degradation (Chapple and Cheetham 2003, 
Westhoff et al. 2005). The overexpression of HSJ1b in cells reduced the levels of cystic 
fibrosis transmembrane conductance regulator (CFTR), a large membrane protein processed 
in the ER that this particularly prone to misfolding (Westhoff et al. 2005). The decline in 
CFTR levels was abolished upon proteasome inhibition, confirming that HSJ1b targets 
CFTR for ERAD (Westhoff et al. 2005). HSJ1b was also able to target the G-protein 
coupled receptor melanocortin-4 receptor (MC4R) for ERAD (Meimaridou et al. 2011). The 
two HSJ1 isoforms therefore both act to target misfolded proteins for degradation. 
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Figure 1.11 Domain composition of HSJ1a and HSJ1b. HSJ1 is alternatively spliced at 
the C-terminal to produce two isoforms, HSJ1a and HSJ1b. Both isoforms contain an N-
terminal J domain, a GF region and two UIMs. Residues 160-207 are predicted to form a 
client binding domain. Figure from Chapple et al. 2004. 
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1.9 Aims 
This Thesis describes investigations into the function of HSJ1 in motor neurons and probes 
the mechanisms by which loss of function mutations in HSJ1 cause motor neuron 
degeneration. Specifically, I aimed to; 
 Examine whether UIM1 of HSJ1a functions to bind to the UBL-containing protein 
ubiquilin-2, a protein recently implicated in ALS. 
 Investigate the pathogenicity of a recently identified amino acid substitution in HSJ1 
in a family with CMT2. 
 Characterise motor neuron survival in a Hsj1 knockout mouse model and investigate 
the potential cellular mechanisms by which loss of function mutations in HSJ1 cause 
dHMN and CMT2. 
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Chapter 2 – Materials and Methods 
2.1 In vitro techniques 
2.1.1 Molecular techniques 
2.1.1.1 Plasmid transformation 
10 ng of plasmid was added to a pre-chilled 1.5 mL eppendorf tube containing 25 µL of 
thawed JM109 competent cells (Promega). The tube was placed in a water bath at 42°C for 
45 seconds before being chilled on ice for 1 minute. 500 µL of Luria-Bertani (LB) broth 
(Sigma) was then added to the eppendorf and the tube was placed in a shaker and incubated 
for 1 hour at 37°C. 100 µL of bacterial culture was then spread onto an ampicillin or 
kanamycin agar plate. Plates were incubated at 37°C overnight. The following day, 2-4 
colonies were picked and used to inoculate either 5 mL (for miniprep) or 50 mL (for 
midiprep) of LB media with appropriate antibiotic selection (ampicillin (50 µg/mL) or 
kanamycin (10 µg/mL)). Cultures were grown overnight at 37°C with shaking. 
2.1.1.2 Plasmid purification (Miniprep) 
The miniprep was performed using a GenElute Plasmid Miniprep Kit (Sigma) according to 
the manufacturer’s protocol. Briefly, 5 mL of bacterial culture was centrifuged at 13,000 x g 
for 2 minutes. The supernatant was removed and the pellet was resuspended in 200 µL of 
Resuspension solution. 200 µL of Lysis solution was added and the solution was mixed by 
inverting the tube 5 times before being centrifuged at 13,000 x g for 2 minutes. 350 µL of 
Neutralisation solution was added, the solution was mixed 5 times, then centrifuged for 10 
minutes at 13,000 x g. Following centrifugation, the lysate was transferred to a binding 
column that had been equilibrated with 500 µL of Column Wash solution. The column was 
spun for 1 minute and the flow-through was discarded. 750 µL of Wash solution was added 
to the column; the column was centrifuged and the flow-through discarded. The column was 
spun for a further minute to dry the column and the column was subsequently transferred to 
a 1.5 mL eppendorf tube. 100 µL of ultra pure Milli-Q water was added to the column and 
was spun for 1 minute to elute the DNA. Plasmid concentration was measured on a 
NanoDrop ND-1000 spectrophotometer (Lab Tech). 
2.1.1.3 Plasmid purification (Midiprep) 
Midipreps were performed using a HighLink HiPure Midi Prep kit (Invitrogen) according to 
the manufacturer’s protocol. Briefly, 50 mL of bacterial culture was centrifuged at 4,000 x g 
for 10 minutes. The supernatant was removed and the pellet was resuspended in 10 mL of 
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Resuspension solution (50 mM Tris-HCl, pH 8.0, 10 mM EDTA). 10 mL of Lysis solution 
(0.2 M NaOH, 1% SDS) was added and the solution was mixed by gently inverting the tube 
5 times. After 5 minutes, 10 mL of Precipitation solution (3.1 M Potassium acetate, pH 5.5) 
was added; the solution was mixed and transferred to a filter column that had been 
equilibrated with 15 mL of Equilibration solution (0.1 M Sodium acetate, pH 5.0, 0.6 M 
NaCl, 0.15% Triton X-100). The lysate was allowed to pass through the filter by 
gravitational flow. The filter cartridge was then removed from the column, the column was 
washed with 20 mL of Wash solution (0.1 M Sodium acetate, pH 5.0, 825 mM NaCl) and 
the flow-through was discarded. 5 mL of Elution buffer (100 mM Tris-HCl, pH 8.5, 1.25 M 
NaCl) was added to the column and the eluted DNA was collected in a 15 mL falcon tube. 
The eluted DNA was incubated with 3.5 mL isopropanol for 2 minutes before being 
centrifuged at 4,000 x g for 30 minutes. The supernatant was removed and the pellet was 
resuspended in 3 mL 70% ethanol. Following a 10 minute centrifugation, the supernatant 
was removed and the pellet was air-dried for 10 minutes. The pellet was then resuspended in 
100 µL of Milli-Q water. Plasmid concentration was measured on a NanoDrop ND-1000 
spectrophotometer (Lab Tech). 
2.1.1.4 Site directed mutagenesis 
Site directed mutagenesis was performed using a QuikChange II kit (Stratagene). 5 µL of 
10x Reaction buffer (100 mM KCl, 100 mM (NH4)2SO4, 200 mM Tris-HCl, 20 mM MgSO4, 
1% Triton X-100, 1 mg/mL bovine serum albumin (BSA)), 125 ng of forward and reverse 
primers, 25 ng of DNA template, 1 µL dNTPs and 1 µL of PfuUltra HF DNA polymerase 
(2.5 U) was added to a 0.5 mL eppendorf tube and the reaction mixture was made up to 50 
µL with Milli-Q water. The polymerase chain reaction (PCR) cycle was as follows; initial 
denaturation of 95°C for 3 minutes, followed by 18 cycles of 95°C for 30 seconds, 60°C for 
1 minute and 68°C for 5 minutes. The PCR product was then incubated was 1.5 µL of DpnI 
(15 U) restriction enzyme for 1 hour at 37°C. 2.5 µL of the DpnI-treated DNA was added to 
a pre-chilled 1.5 mL eppendorf containing 50 µL of the XL1 Blue supercompetent cells. The 
mixture was then incubated on ice for 30 minutes then placed in a water bath set to 42°C for 
45 seconds. The mixture was placed on ice for 1 minute, 500 µL of LB was added and the 
tubes were incubated at 37°C with shaking for 2 hours. Cells were then plated on the 
appropriate antibiotic plate and were left to grow overnight at 37°C. The following day 2-4 
colonies were picked and used to inoculate a culture of LB containing the appropriate 
antibiotic. After a 16 hour incubation period, the DNA was isolated and purified before 
being sequenced. 
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Table 2.1 Primer sequences 
 
 
 
 
  
Primer Sequence 5’-3’ 
Untagged HSJ1 Y5C F cggatccgatggcatcctactgcgagatcctaga 
Untagged HSJ1 Y5C R tctaggatctcgcagtaggatgccatcggatccg 
Ubiquilin-2 P497H F ggcccagtcacccacataggccccata 
Ubiquilin-2 P497H R tatggggcctatgtgggtgactgggcc 
Ubiquilin-2 P497S F ggcccagtcacctccataggccccata 
Ubiquilin-2 P497S R tatggggcctatggaggtgactgggcc 
Ubiquilin-2 P506T F ccataggccctatagtcacttttacccccataggc 
Ubiquilin-2 P506T R gcctatgggggtaaaagtgactatagggcctatgg 
Ubiquilin-2 P509S F cctatagtcccttttacctccataggccccattgggc 
Ubiquilin-2 P509S R gcccaatggggcctatggaggtaaaagggactatagg 
Ubiquilin-2 P525S F ctggccctgcagccccctctggctccaccggctctgg 
Ubiquilin-2 P525S R ccagagccggtggagccagagggggctgcagggccag 
oIM0872 aagttcatctgcaccaccg 
oIM1416 tccttgaagaagatggtgcg 
DloxR gcactctactgacaaagttacagcctc 
Int2F cctttttactcatatccctggcacacc 
Gx2478 cctgtgtttgagagactgctgcatagc 
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Table 2.2 Plasmid constructs 
  
Vector Insert Tag Resistance Source 
pCMV Tag 3A 
 
HSJ1a WT 
HSJ1b WT 
HSJ1a H31Q 
HSJ1a ∆UIM 
HSJ1a ∆UIM1 
HSJ1a ∆UIM2 
 
N-terminal 
myc 
Kanamycin 
Professor 
Cheetham 
pBSTR1 
 
HSJ1a WT 
HSJ1b WT 
 
Untagged Ampicillin 
 
Professor 
Cheetham 
 
pBSTR1 
HSJ1a Y5C 
HSJ1b Y5C 
Untagged Ampicillin 
 
H.Smith 
This study 
 
pCMV4 
 
Ubiquilin-2 WT 
 
N-terminal 
FLAG 
Ampicillin 
Addgene 
 (8661) 
pCMV4 
 
Ubiquilin-2 P497H 
Ubiquilin-2 P497S 
Ubiquilin-2 P506T 
Ubiquilin-2 P509S 
Ubiquilin-2 P525S 
 
N-terminal 
FLAG 
Ampicillin 
H.Smith 
This study 
pEGFP-C3 LC3 
N-terminal 
GFP 
Kanamycin 
Addgene 
(11546) 
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2.1.1.5 DNA sequencing 
4 µL of sequencing buffer (200 mM TrisHCl pH 9.0, 5 mM MgCl2), 4 µL Big Dye v3.1 
(Life Technologies), 1 µL of 10 µM primer and 125 ng of DNA template was added to a 0.5 
mL eppendorf tube on ice. The PCR was 30 cycles at 96°C for 30 seconds, 50°C for 15 
seconds and 60°C for 4 minutes. The reaction mixture was cooled to 4°C and 26 µL of 
precipitation solution (95% ethanol, 3 M NaOAc pH5.2) was added. Following a 10 minute 
incubation on ice, the reaction mixture was centrifuged at 13,000 x g for 30 minutes. The 
supernatant was removed and 200 µL of 70% ethanol was added. The reaction mixture was 
centrifuged again at 13,000 x g for 10 minutes. The supernatant was removed and tubes were 
placed on a heating block set to 65°C for 3 minutes to dry off the remaining ethanol. 11 µL 
of formamide was added and the tubes were heated to 95°C for 10 minutes to denature the 
DNA. Samples were then transferred to a loading plate and samples were run on a 3730 
DNA Analyser (Applied Biosystems). Sequences were aligned using BioEdit sequencing 
alignment software (Ibis Therapeutics). 
2.1.2 Cell culture techniques 
2.1.2.1 Reagents 
All cell culture medium and transfection reagents were purchased from Invitrogen. 6 well 
plates, 96 well plates and T75 flasks were purchased from VWR and 8 well chamberslides 
were purchased from Thermo Fischer Scientific. Bafilomycin was purchased from Abcam 
and used at a concentration of 200 nM. Cycloheximide was purchased from Sigma and used 
at a concentration of 50 µg/mL. MG132 was purchased from Enzo Life Sciences and used at 
a concentration of 50 µM. 
2.1.2.2 Cell culture of SK-N-SH cells 
SK-N-SH neuroblastoma cells were obtained from European Collection of Cell Cultures 
(ECCAC). The cells were cultured in Dulbecco’s modified Eagle’s medium F12 with 
GlutaMAX (DMEM F-12) (Invitrogen), supplemented with 10% (v/v) fetal calf serum 
(FCS) (Invitrogen), 100 U/mL penicillin and 100 µg/mL streptomycin (Invitrogen). Cells 
were grown at 37°C in 5% CO2. Cells were passaged when then reached 80-90% 
confluency. Cells were washed in Hank’s Balanced Salt solution (HBSS) (Invitrogen), 
incubated with 1 mL of trypsin (Invitrogen) for 3 minutes, then resuspended in 9 mL of 
DMEM F-12. Cells were counted with a glass haemocytometer and 6 well plates were 
seeded at a density of 5x10
5
 cells per well and 8 well chamber slides were seeded at a 
density of 5x10
4
 cells per well. T75 flasks were seeded at a 1:4 ratio. 
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2.1.2.3 Transfection of 8 well chamberslides 
SK-N-SH cells were transfected when they reached around 70% confluency using 
Lipofectamine
TM
 and Plus
TM
 reagents (Invitrogen). For each well, 200 ng of total DNA was 
added to 25 µL of DMEM F-12 serum free media (SFM) and 1 µL Plus. In a separate tube, 
0.5 µL of Lipofectamine was added to 100 µL SFM. Both tubes were incubated at 22°C for 
15 minutes. The tubes were subsequently mixed and incubated for a further 15 minutes. 
During this incubation period, cells were washed twice with HBSS. 100 µL of SFM was 
then added to the well. After 15 minutes, 125 µL of the mixture was added to the well. 
Following a 2 hour incubation at 37°C in 5% CO2, the media was removed and replaced 
with DMEM F-12 with 10% FCS. Cells were then grown for a further 24 hours prior to 
fixation. 
2.1.2.4 Transfection of 6 well plates 
For the transfection of 6 well plates, 500 ng/well of plasmid was added to 100 µL/well of 
SFM and the total DNA was made up to 2000 ng using pCMV3 stuffer plasmid. 8 µL/well 
of Plus reagent was added and the mixture was incubated for 15 minutes at 22°C. For each 
transfection reaction, 4 µL of Lipofectamine was added to 100 µL SFM and incubated for 15 
minutes. The two tubes were then mixed together and incubated for a further 15 minutes. 
During this incubation, SK-N-SH cells were washed twice in HBSS and 780 µL of SFM was 
added to each well. The transfection mixture was then added to the cells and incubated at 
37°C in 5% CO2 for 3 hours. The media was then removed and replaced with DMEM F-12 
containing 10% FCS. Cells were grown for a further 24 hours before being treated or 
harvested. 
2.1.2.5 Cell culture of human fibroblasts 
Control fibroblasts were provided by Professor Paul Chapple (Queen Mary University of 
London) and patient fibroblasts were obtained from the UCL Institute of Neurology 
BioBank, with the permission of Professor Michaela Auer-Grumbach (Vienna) and approval 
by the UCL Institute of Neurology ethics committee. Fibroblasts were maintained in T75 
flasks and grown in an incubator at 37°C and 5% CO2. Both control and patient fibroblasts 
grew at comparable rates and were split on the same day when they reached 90% 
confluency. The media was removed from the T75 flask and the fibroblasts were washed 
with 10 mL Dulbecco’s Phosphate-Buffered Saline (PBS) (Invitrogen). 1 mL of trypsin was 
added and the flask was placed back in to the incubator for 3 minutes. Fibroblasts were then 
resuspended in 9 mL of DMEM (high glucose, pyruvate) (Invitrogen) supplemented with 
10% FCS, 100 U/mL penicillin and 100 µg/mL streptomycin, and were subsequently seeded 
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into 6 well plates or 8 well chamberslides. Fibroblasts were not grown beyond P15. Control 
and patient fibroblasts were passage matched for all experiments. 
2.1.2.6 The knockdown of HSJ1 in control fibroblasts 
An adeno-associated virus containing mIR30 shRNA against HSJ1 was provided by 
Professor James Uney (University of Bristol) at a titre of 2x10
10
 virus particles (VP)/mL. 
50,000 control fibroblast cells were seeded per well of a 6 well plate. 24 hours post seeding, 
the virus was added directly to the well at the required multiplicity of infection (MOI). 24 
hours post transduction, the media was removed and replaced with fresh DMEM (high 
glucose, pyruvate) supplemented with 10% FCS. Cells were harvested following a further 24 
hour or 48 hour incubation period. 
2.1.2.7 The restoration of HSJ1 in patient fibroblasts 
Adeno-associated virus expressing either HSJ1a or HSJ1b was provided by Professor James 
Uney (University of Bristol) at a titre of 6x10
10
 VP/mL and 5x10
9
 VP/mL, respectively. 
50,000 patient fibroblasts cells were seeded per well of a 6 well plate, with 10,000 patient 
fibroblast cells seeded per well of an 8 well chamberslide. 24 hours post seeding, the virus 
was added directly to the well at the required MOI. 24 hours post transduction, the media 
was removed and replaced with fresh DMEM (high glucose, pyruvate) supplemented with 
10% FCS. Cells were harvested following a further 24 hour incubation period. 
2.1.3 Protein based techniques 
2.1.3.1 Preparation of cell lysates 
6 well plates were placed on ice, the media from each well was removed and cells were 
washed twice with PBS (137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM K2HPO4). 
Cells were then lysed with 200 µL RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 2 
mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) containing 2% mammalian 
protease inhibitor cocktail (PIC) and, where appropriate, 5% phosphatase inhibitor (Sigma) 
for 10 minutes. Lysates were collected in a 1.5 mL eppendorf then sonicated for 10 seconds. 
The eppendorfs were then placed on ice for 30 seconds before being sonicated again for 
another 10 seconds. Following sonication, lysates were centrifuged at 4°C for 10 minutes at 
13,000 x g. The supernatant was then removed and the protein concentration was determined 
using a bicinchroninic acid (BCA) Protein Assay kit (Pierce). 0, 0.125, 0.25, 0.5 and 1 
mg/mL bovine serum albumin (BSA) was used as standards and 10 µL of each concentration 
was added in triplicate to a 96 well plate. 10 µL of cell lysate was added in triplicate to 3 
separate wells of the plate. Reagent A was mixed with Reagent B in a 50:1 ratio and the 
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mixture was vortexed. 190 µL of the mixture was then added to each well. The wells were 
mixed by pipetting up and down 5 times using a multichannel pipette. The lid was placed 
over the plate and the plate was incubated for 30 minutes at 37°C. The absorbance was then 
measured on a spectrophotometer (Techan, SAFIRE) at 562 nm. The mean absorbance of 
the 3 wells was calculated and background readings were subtracted using the blank control 
(0 mg/mL BSA). A standard curve was then generated using the BSA standards and was 
used to calculate the protein concentration of the cell lysates. 
2.1.3.2 Immunoprecipitation  
24 hours post transfection, cells were placed on ice, the media was removed and the cells 
were washed twice in PBS. 500 µL of 1% n-Dodecyl-β-D-maltoside (DM) lysis buffer 
supplemented with 2% PIC was added to each well. After 10 minutes, cells were scrapped 
into a 1.5 mL eppendorf and sonicated briefly. 30 µL of lysate was removed to provide the 
input fraction. 400 µL of lysate was added to 50 µL of protein G magnetic Dynabeads 
(Invitrogen) that had been incubated overnight in 5% BSA, 0.02% Tween-20 in PBS. The 
lysate and beads were incubated with the appropriate antibody and the tubes were placed on 
a rotating wheel for 1 hour at room temperature. A Magnarack (Invitrogen) was used to 
remove the supernatant then the beads were washed 5 times in 1% DM lysis buffer with 
0.02% Tween-20. 20 µL of 2x SDS loading buffer (10% SDS, 20% glycerol, 0.1% 
Bromophenol Blue, 0.5 M Tris HCl , pH 6.8, 2.5% β-mercaptoethanol) was added to the 
beads and the tubes were vortexed briefly before being boiled at 95°C for 3 minutes. The 
Magnarack was used to remove the beads and the sample was then loading onto a 10% poly-
acrylamide gel. 
2.1.3.3 SDS-PAGE 
Samples were loaded onto a 10% or 12% resolving gel with a 4% stacking gel. Resolving 
gels were made with 1.5 mM Tris pH 8.8, 10-12% acrylamide, 0.1% SDS, 0.1% Ammonium 
persulphate (APS) and 0.05% TEMED. The 4% stacking gel was made from 0.5 mM Tris 
pH 6.8, 4% acrylamide, 0.1% SDS, 0.1% APS and 0.1% TEMED. Samples were run at 150 
V with a Tris-glycine running buffer (25 mM Tris-HCl, 250 mM glycine and 0.1% SDS) 
until the blue bromophenol dye reached the bottom of the gel. 
2.1.3.4 Western blot 
Proteins were transferred to a nitrocellulose membrane using a semi-dry electrophoretic 
transfer unit (BioRad). The nitrocellulose membrane was sandwiched between blotting paper 
that had been soaked in transfer buffer containing 25 mM Tris, 192 mM Glycine, 0.01% 
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SDS and 20% methanol. The unit was run for 20 minutes at 15 V, 0.4 Amps. Transfer of the 
proteins was confirmed by staining with Ponceau S (Sigma). The membrane was blocked for 
1 hour in 5% Marvel milk in 0.1% PBS Tween (blocking buffer). Subsequently the 
membrane was incubated overnight at 4°C with primary antibody diluted in blocking buffer 
(Table 2.3). The next day, the membrane was washed 3 times for 5 minutes in 0.1% PBS 
Tween before being incubated for 1 hour with the secondary antibody diluted in blocking 
buffer. Following a further 3 washes of 5 minutes each, immunostaining was detected using 
ECL Plus Chemiluminescence reagent (Amersham Biosciences), which was prepared by 
mixing 1 mL of reagent A with 25 µL of reagent B per membrane. Immunostaining was 
detected using X-ray film or a BioRad Chemidoc. For the detection of phosphorylated 
proteins, 5% BSA in TBS (50 mM Tris-HCl pH 7.6, 150 mM NaCl) with 0.1% Tween was 
used as the blocking buffer, with all wash steps performed using 0.1% TBS Tween.  
2.1.3.5 Protein quantification using ImageJ 
Protein quantification was performed using ImageJ (NIH). Protein levels were corrected for 
loading using β-actin or β-tubulin. Protein levels were then normalised as stated in the 
Figure legends. At least three biological replicates were performed for all experiments in 
which statistical significance was determined.  
2.1.3.6 Proteasome activity assay 
Proteasome activity was measured using a 20S Proteasome Assay kit (Millipore), according 
to the manufacturer’s protocol. 10 µg of control and patient fibroblast cell lysate was added 
in triplicate to a 96 well black plate (Sigma). 10 µL of 10x Assay buffer and 10 µL of 500 
µM MG132 was added to each well and the final volume was made up to 90 µL using Milli-
Q water. The plate was incubated for 15 minutes at room temperature. During this 
incubation period, 10 µg of cell lysate was added in triplicate to separate wells. This time, 
only 10x Assay buffer was added and the final volume was made up to 90 µL with Milli-Q 
water. Following the pre-incubation period, 10 µL of 10 mM Proteasome Substrate was 
added to each well (apart from the blank controls) and the wells were mixed by pipetting up 
and down five times using a multichannel pipette. The plate was then incubated for 1 hour at 
37°C. Fluorescence was measured on a spectrofluorometer (Techan, SAFIRE), using an 
excitation wavelength of 380 nm and an emission wavelength of 460 nm. The fluorescent 
intensity of the blank controls was averaged and subtracted from all readings. The average 
fluorescent intensity in the presence of MG132 was then subtracted from the readings in the 
absence of MG132, to give the proteasome-specific activity. The activity of the patient 
fibroblast cell lysate was then normalised to the activity of the control fibroblast cell lysate. 
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2.1.3.7 Immunocytochemistry 
Cells were washed twice in PBS before being fixed in 4% paraformaldehyde (PFA) (TAAB 
Laboratories) for 10 mintutes. Cells were washed in PBS then permeabilised in 0.1% Triton-
X for 10 minutes. Following three washes in PBS, cells were blocked for 1 hour in 3% BSA 
and 10% normal donkey serum in PBS. Primary antibodies were diluted in the blocking 
solution and cells were incubated overnight at 4°C (Table 2.3). Following three washes in 
PBS, cells were incubated with secondary antibodies, also diluted in blocking solution, for 1 
hour at room temperature. Cells were washed in PBS then incubated for 5 minutes with 2 
mg/mL 4’,6-diamidino-2-phenylindole (DAPI) (Sigma) at a 1:5000 dilution. Once washed 
for a final time, the chamber was removed and a coverslip was mounted using Fluorescent 
Mounting Medium (DAKO). 
2.1.3.8 Fluorescence microscopy 
SK-N-SH cells transfected with GFP-Q103 or GFP-SOD1 G93A were visualised on a Nikon 
Eclipse 80i fluorescent microscope. Inclusion incidence was calculated by counting the 
number of transfected cells containing inclusions. GFP-Q103 inclusions appear as large 
circular structures whereas GFP-SOD1 G93A appears as perinuclear aggregates that are 
excluded from the nucleus (Chapter 4). In each condition, at least 100 transfected cells were 
counted. Three biological replicates were performed. 
2.1.3.9 Confocal microscopy 
Images were acquired on a Zeiss LSM 700 confocal microscope using 40x or 63x oil 
immersion objectives. The excitation/emission spectrum of the channels used was as 
follows; DAPI 364/475-525 nm, Cy2 488/505-530 nm and Cy3 543/560 nm. Images were 
exported from Zeiss 2009 software (Carl Zeiss) to Adobe Photoshop (Adobe) and then 
presented in Adobe Illustrator (Adobe). 
2.1.4 Quantification of gene expression 
2.1.4.1 RNA extraction 
Total RNA extraction was performed using the RNeasy mini kit (Qiagen) following the 
manufacturer’s protocol. Cells were placed on ice, the media was removed from each well 
and the cells were washed twice in PBS. 350 µL of Buffer RLT was then added to each well. 
Following a 10 minute incubation, a cell scrapper was used to collect the lysate in a 1.5 mL 
eppendorf. The lysate was homogenised by passing the lysate 10 times through a small 20-
gauge needle. 1 volume of 70% ethanol was added and the lysate was mixed by pipetting up 
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and down 5 times. The lysate was then transferred to a RNeasy spin column and the tube 
was centrifuged for 20 seconds at 8000 x g. To digest DNase, 350 µL of Buffer RW1 was 
added to the column. The tube was centrifuged for 20 seconds at 8000 x g and the flow-
through was discarded. 10 µL of DNase stock solution was added to 70 µL Buffer RDD and 
the solution was mixed gently by inverting the tube. 80 µL of the DNase solution was then 
added to the membrane of the column and was left for 15 minutes at room temperature. 350 
µL of Buffer RW1 was added, the column was centrifuged for 20 seconds at 8000 x g and 
the flow-through was discarded. 500 µL of Buffer RPE was added and the column was 
centrifuged for 2 minutes at 8000 x g. The column was then transferred to a new 1.5 mL 
eppendorf, 50 µL of RNase free water was added and the tube was spun at 13,000 x g for 1 
minute to elute the RNA. RNA concentration was measured on a NanoDrop ND-1000 
spectrophotometer (Lab Tech). 
2.1.4.2 cDNA synthesis 
cDNA synthesis was performed using the SuperScript III First-strand synthesis system kit 
(Invitrogen). 5 µg of total RNA was added to a 0.5 mL eppendorf tube along with 1 µL 50 
µM oligo(dT)20, and 1 µL 10 mM dNTP, and the mixture was made up to 10 µL with DEPC-
treated water. The mixture was incubated at 65°C for 5 minutes, then placed on ice for 1 
minute. In a separate 0.5 mL eppendorf tube, 2 µL 10x RT buffer, 4 µL 25 mM MgCl2, 2 µL 
0.1 M DTT, 1 µL RNaseOUT (40 U/µL) and 1 µL SuperScript III RT (200 U/µL) was 
added. 10 µL of this mixture was then added to the RNA mixture and the eppendorf was 
incubated for 50 minutes at 50°C. The reaction was terminated by incubating the eppendorf 
at 85°C for 5 minutes. The reaction mixture was chilled on ice, then 1 µL of RNase H was 
added and the reaction mixture was then incubated at 37°C for 20 minutes. The cDNA 
synthesis reaction mixture was then stored at -20°C. 
2.1.4.3 qPCR 
50 ng of total cDNA, 200 nM forward primer, 200 nM reverse primer and 10 µL SYBR 
Green (Invitrogen) was added to a 96 well plate and the final volume was made up to 20 µL 
with Milli-Q water. Quantitative PCR was performed using an ABI Prism Real-time 
Sequence Detection System (Applied Biosciences) with 40 cycles at 95°C for 15 seconds 
then 60°C for 1 minute. Data was analysed using SDS 2.2.2 software (Applied Biosystems). 
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Table 2.3 Primary antibodies 
 
  
Antibody Host Company Dilutions 
ATF6 Rabbit 
Santa Cruz 
(22799) 
WB 1:1000 
β-actin Mouse 
Santa Cruz 
(47778) 
WB 1:1000 
BiP Rabbit 
Sigma 
(G8919) 
WB 1:1000 
ICC 1:750 
β-tubulin Mouse 
Sigma 
(T4026) 
WB 1:1000 
β-III-tubulin Mouse 
Abcam 
(78078) 
ICC 1:750 
β-III-tubulin Rabbit 
Abcam 
(18207) 
ICC 1:750 
eIF2α Rabbit 
Cell Signalling 
(5324) 
WB 1:1000 
p-eIF2α Rabbit 
Sigma 
(SAB4504385) 
WB 1:1000 
FLAG Rabbit 
Sigma 
(M7425) 
WB 1:500 
ICC 1:200 
IP 1:200 
GADD34 Rabbit 
Protein Tech 
(10449) 
WB 1:1000 
HSJ1 Sheep In house (S653) 
WB 1:1000 
ICC 1:500 
IRE1 Rabbit 
Cell Signalling 
(3294) 
WB 1:1000 
p-IRE1 Rabbit 
Novus Biologicals 
(NB100-2323) 
WB 1:1000 
LC3B Rabbit 
Cell Signalling 
(3868) 
WB 1:1000 
Myc Mouse 
Sigma 
(M4439) 
WB 1:1000 
ICC 1:200 
IP 1:200 
PERK Rabbit 
Cell Signalling 
(5683) 
WB 1:1000 
p-PERK Rabbit 
Cell Signalling 
(3179) 
WB 1:1000 
p62 Rabbit 
Abcam 
(56416) 
WB 1:1000 
ICC 1:750 
Ubiquitin Rabbit 
DAKO 
Z0458 
WB 1:1000 
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Table 2.4 Secondary antibodies 
 
 
 
  
Antibody Host Company Dilutions 
Anti-mouse IgG (H+L) 
Cy2 and Cy3 
Donkey 
Jackson 
Immunoresearch 
1:200 
Anti-rabbit IgG (H+L) 
Cy2 and Cy3 
Donkey 
Jackson 
Immunoresearch 
1:200 
Anti-sheep IgG (H+L) 
Cy2 and Cy3 
Donkey 
Jackson 
Immunoresearch 
1:200 
Anti-mouse IgG (H+L) 
peroxidise conjugated 
Goat Pierce 1:40,000 
Anti-rabbit IgG (H+L) 
peroxidise conjugated 
Goat Pierce 1:40,000 
Anti-sheep IgG (H+L) 
peroxidise conjugated 
Goat Piece 1;40,000 
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2.2 In vivo techniques 
All procedures were conducted according to the Home Office (UK) regulations under the 
Animals (Scientific Procedures) Act of 1986 and with local UCL Institute of Neurology and 
UCL Institute of Ophthalmology ethic committee approval. Project licence number: 
70/06976, personal licence number: 70/24130. 
2.2.1 Animal maintenance 
Transgenic Hb9:GFP
+/-
 mice were purchased from the Jackson Laboratory (Strain: B6.Cg-
Tg(Hlxb9-GFP)1Tmj/J, Stock number: 005029). The colony was maintained in a 
heterozygous state through breeding with C57BL/6 mice. Hb9:GFP
+/-
 mice and the 
subsequent crosses were maintained at the Denny Brown Laboratories, UCL Institute of 
Neurology, London, UK. Hsj1
-/-
 mice were previously obtained from GenOway (Wendy 
Mustill, UCL, Thesis) and were bred on a C57BL/6 background. Hsj1
-/-
 and C57BL/6 wild-
type mice were maintained at UCL Institute of Ophthalmology, London, UK. Mice were 
housed at 21°C ± 1°C with relative humidity 55% ± 10% and were maintained on a 12:12 
light dark cycle with access to food and water ad libitum. 
2.2.2 Genotyping 
DNA was extracted from ear biopsies using the Wizard SV Genomic DNA purification kit 
(Promega). Each ear biopsy was placed in a 1.5 mL eppendorf tube and incubated overnight 
at 55°C with 100 µL Nuclei Lysis solution, 25 µL EDTA, 20 µL proteinase K and 5 µL 
RNase A solution. Following incubation, 250 µL of Wizard SV Lysis buffer was added to 
each eppendorf tube and the tube was briefly vortexed. The lysates was then transferred to a 
Wizard SV minicolumn. The columns were spun at 13,000 x g for 3 minutes. The flow-
through liquid was discarded from the collection tube and samples were spun again at 
13,000 x g for 1 minute. The flow-through liquid was discarded and 650 µL Column Wash 
solution was added to each column. Columns were spun for 1 minute and the liquid was 
discarded. This washing step was repeated 4 times. Following the last wash, the column was 
spun at 13,000 x g for 2 minutes to dry the column. Columns were then transferred to a 1.5 
mL eppendorf and 100 µL of nuclease free water was added to each column. After a 2 
minute incubation at room temperature, columns were spun at 12,000 x g for 1 minute. The 
column was then discarded and the purified DNA was stored at 4°C. 
2.2.2.1 GFP PCR 
2.5 µL of genomic DNA was added to 6.25 µL GoTaq (Promega), 1.5 µL 10 µM oIM0872 
primer, 1.5 µL 10 µM oIM1416 primer and 1.25 µL Milli-Q water. The reaction cycle was 
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as follows; initial denaturation at 94°C for 2 minutes, followed by 30 cycles of 94°C for 30 
seconds, 65°C for 30 seconds and 68°C for 2 minutes. The PCR product was then run on a 
1% agarose gel and the DNA was visualised on a UV transilluminator. A band at 173 bp 
indicated the presence of the GFP transgene. 
2.2.2.2 HSJ1 PCR 
2.5 µL genomic DNA was added to 6.25 µL GoTaq, 0.6 µL 10 µM GX2478, 0.6 µL 10 µM 
Int2F, 1.2 µL 10 µM DloxP and 1.35 µL Milli-Q water. The reaction cycle was as follows; 
initial denaturation at 94°C for 5 minutes, followed by 40 cycles of 94°C for 30 seconds, 
65°C for 30 seconds and 68°C for 90 seconds, with a final elongation step at 68°C for 8 
minutes. PCR products were run on a 1% agarose gel and were visualised on a UV 
transilluminator. A PCR product at 850 bp indicates a Hsj1
+/+
 genotype, whereas a band at 
650 bp indicates a Hsj1
-/- 
genotype. The presence of both bands indicates the mouse is a 
heterozygote. 
2.2.3 Transcardial perfusion 
Mice of the required age were terminally anaesthetised with an overdose of Euthasol (100 
mg/kg), administered via an intraperitoneal injection. When the mouse became unresponsive 
to toe-pinch, a lateral incision was made above the abdomen and the rib cage was exposed. 
The rib cage was removed using sharp scissors, allowing access to the heart. Whilst holding 
the heart with forceps, a needle (attached to the perfusion pump via connective tubing) was 
inserted into the left ventricle. The right atrium was cut with scissors to create an outlet for 
the blood. 0.9% saline was then pumped through the mouse until all the blood had been 
drained from the body. At this point, the mouse was perfused with 40 mL 4% PFA. 
Following perfusion, the spinal cord was dissected and post-fixed overnight in 4% PFA at 
4°C. The spinal cord was then cryoprotected in 30% sucrose in PBS for 24 hours. 
2.2.4 The preparation of spinal cords for cryosectioning 
The L2-L6 lumbar region of the spinal cord was dissected under a light dissecting 
microscope (Leica) (Figure 2). The lumbar region was then placed upright into a mould 
containing OCT mounting medium (CellPath). The base of the mould was then immersed in 
ice-cold acetone until the OCT mounting medium froze. Once the tissue had been frozen, 
samples were wrapped in foil and kept at -80°C. 
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Figure 2: Diagram highlighting the lumbar region of the spinal cord. The enlarged 
lumbar region of the spinal cord is shown in green, with 5 pairs of lumbar nerves (L2-L6). 
Figure from uahealth.com. 
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2.2.5 Motor neuron counts 
Spinal cords were sectioned into 20 µm slices on a cryostat (Leica) and mounted onto 
Superfrost Plus microscope slides (VWR). The slides were kept at -20°C until they were 
required. Slides were allowed to dry for 30 minutes upon removal from the freezer. Slides 
were immersed in PBS for 5 minutes before being immersed in 0.3% gallocyanine solution 
(Sigma) for 1.5 hours. The slides were then washed in increasing ethanol concentrations, 
with 5 minutes in 70% ethanol, 2 minutes in 70% ethanol, 2 minutes in 90% ethanol and 2 
minutes in absolute ethanol. Slides were then transferred to HistoClear (National 
Diagnostics). Following a 5 minute incubation, slides were incubated in fresh HistoClear 
solution for a further 5 minutes. After this time, DPX mounting medium (Sigma) was placed 
on the slides and coverslips were added. Slides were wrapped in foil and allowed to dry 
overnight at room temperature. Gallocyanine-stained sections were visualised on a Nikon 
Eclipse 80i Light microscope. Motor neurons were counted based on established criteria. 
Only large, polygonal cells located in the ventral horns of the spinal cord with a darkly 
stained cytoplasm, a pale nucleus and a darkly stained nucleolus were counted. Motor 
neurons were counted in every 4
th
 consecutive section, in order to avoid counting the same 
motor neuron twice. At least 30 sections were counted per animal. 
2.2.6 Immunohistochemistry 
Slides were air dried at room temperature for 30 minutes. An ImmEdge hydrophobic pen 
(Vector Laboratories) was then used to draw a barrier around the sections. Slides were then 
washed in PBS for 5 minutes before being incubated with 0.2% Triton-X100 in PBS for 20 
minutes. Sections were then blocked in 10% normal donkey serum in PBS and incubated 
overnight at 4°C with primary antibody diluted in blocking solution. Following overnight 
incubation, slides were washed 3 times for 5 minutes in PBS. Slides were then incubated 
with secondary antibody for 1 hour at room temperature before being washed 3 times for 5 
minutes in PBS. Slides were finally mounted with coverslips using fluorescent mounting 
medium. 
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Chapter 3 – The potential interaction of HSJ1 with UBL proteins 
3.1 Introduction 
HSJ1a is a potent suppressor of protein aggregation and can significantly reduce inclusion 
incidence in cell models of HD, PD and ALS (Westhoff et al. 2005, Howarth et al. 2007, 
Rose et al. 2011, Novoselov et al. 2013). In cell models of ALS, the overexpression of 
HSJ1a reduced the aggregation of mutant SOD1, a protein commonly mutated in familial 
cases of the disease (Novoselov et al. 2013). In 2011, ubiquilin-2 was identified as a novel 
causative gene in X-linked ALS (Deng et al. 2011). As with mutations in SOD1, mutations 
in ubiquilin-2 resulted in the aggregation of the protein, with the presence of cytoplasmic 
inclusions positive for ubiquilin-2 in the motor neurons of patient spinal cords (Deng et al. 
2011). Interestingly, ubiquilin-2 has been identified as a component of cytoplasmic 
inclusions in ALS patients lacking mutations in ubiquilin-2, highlighting a potential role for 
ubiquilin-2 in the pathogenesis of ALS (Zhang et al. 2014). Based on the ability of HSJ1a to 
reduce the aggregation of ALS-associated proteins, I sought to examine whether HSJ1a 
could potentially modulate mutant ubiquilin-2 aggregation in cells. 
Ubiquilin-2 is a member of the ubiquilin family. The human genome encodes four ubiquilin 
genes, each located on a different chromosome and exhibiting different patterns of 
expression. Ubiquilin-1 is ubiquitously expressed, with ubiquilin-2 and ubiquilin-4 
expressed in most tissues. Ubiquilin-3 expression is more restricted and is only detected in 
the testis (Conklin et al. 2000). The four isoforms are highly conserved among mammals 
and share a high degree of sequence and domain homology. All isoforms contain an N-
terminal ubiquitin-like (UBL) domain and a C-terminal ubiquitin-binding (UBA) domain. 
The UBL domain interacts with the proteasome, whereas the UBA domain binds to 
polyubiquitin, with a high affinity for both K48 and K63-linked ubiquitin chains (Kleijnen et 
al. 2000, Zhang et al. 2008). The presence of UBL and UBA domains enables the ubiquilins 
to act as shuttles, binding to ubiquitylated proteins and delivering them to the proteasome for 
degradation. The central region between the UBL and UBA domains is variable among the 
different isoforms. Unlike other ubiquilin proteins, the central region of ubiquilin-2 has a 
unique repeat region containing 12 PXX tandem repeats. All five patient mutations 
identified by Deng et al. (2011) involved the substitution of a proline residue in the PXX 
repeat region (Figure 3). 
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Figure 3 The functional domains of ubiquilin-2. Ubiquilin-2 contains an N-terminal 
ubiquitin-like domain (UBL), four heat shock-chaperonin binding motifs (STI1), 12 PXX 
repeats and a C-terminal ubiquitin binding domain (UBA). The ALS-linked mutations in the 
PXX region are highlighted. Figure from Deng et al. 2011. 
 
To understand the role of ubiquilin-2 in ALS, research has focussed on characterising the 
function of ubiquilin-2 through the identification of specific binding partners. Recently, 
ubiquitin regulatory X domain-containing protein 8 (UBXD8) was shown to co-
immunoprecipitate with ubiquilin-2, identifying the protein as an ubiquilin-2 binding partner 
(Xia et al. 2014). The binding affinity for UBXD8 was impaired in the presence of a 
truncated ubiquilin-2 protein lacking the PXX region and UBA domain, implying that 
ubiquilin-2 binds to UBXD8 via its C-terminal domains (Xia et al. 2014). UBXD8 is an ER 
transmembrane protein that mediates the translocation of ERAD substrates to the cytosol 
(Alexandru et al. 2008). An interaction between the two proteins suggests that ubiquilin-2 
may function in ERAD, possibly delivering ERAD substrates to the proteasome upon their 
release from the ER. Indeed, the knockdown of ubiquilin-2 in HeLa cells impaired the 
degradation of α1-anti trypsin null Hong Kong mutant, a misfolded luminal ERAD substrate 
(Xia et al. 2014).  
In addition to functioning in ERAD, accumulating evidence suggests that ubiquilin-2 plays a 
prominent role in autophagy. Ubiquilin-2 co-localised with autophagosomes in HeLa cells 
and co-immunoprecipitated with LC3 (N’diaye et al. 2009, Rothenberg et al. 2010). The 
interaction was dependent on the UBA domain of ubiquilin-2, however the binding to LC3 
appeared to be indirect; a GST-pulldown assay failed to detect any strong binding between 
purified ubiquilin-2 and LC3 (Rothenberg et al. 2010). Ubiquilin-2 is degraded by 
autophagy; therefore the protein was proposed to act as a selective adaptor, recruiting 
ubiquitylated cargo into the autophagosome through an indirect interaction with LC3 
(Rothenberg et al. 2010). The knockdown of ubiquilin-2 inhibited the degradation of 
autophagosomes, rendering cells more susceptible to death upon starvation (N’diaye et al. 
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2009). The impaired fusion of autophagosomes with autolysosomes suggests that ubiquilin-2 
may have a broader function in autophagy, rather than simply acting as an adaptor protein.  
Interestingly, HSJ1a has been identified as a binding partner of ubiquilin-1 (Heir et al. 
2006). The binding was dependent on the UBL domain of ubiquilin-1 and the UIMs of 
HSJ1a (Heir et al. 2006). Considering the conservation of the UBL domain among the 
ubiquilin isoforms, the data presents the possibility that HSJ1a may also bind to ubiquilin-2, 
with both proteins potentially co-operating to target misfolded, ubiquitylated proteins for 
degradation. Interestingly, investigations into the anti-aggregation function of HSJ1a suggest 
that the protein may indeed co-operate with another protein to target misfolded substrates for 
degradation. Both UIM1 and UIM2 of HSJ1a are required to fully counteract polyQ 
aggregation (Labbadia et al. 2012), despite the fact that only UIM2 appears to bind to 
polyubiquitin chains with high affinity (Dr Sergey Novoselov, personal communications). 
The role of UIM1 in the anti-aggregation process is therefore unknown; however, it was 
hypothesised that UIM1 may function to bind to UBL-containing proteins. Based on these 
findings, the ability of HSJ1a to bind to ubiquilin-1 in a UIM-dependent manner and the 
association of both HSJ1 and ubiquilin-2 with motor neuron degeneration, I sought to test 
the hypothesis that ubiquilin-2 is a binding partner of HSJ1a. To test this hypothesis, the 
immunopurification and localisation of tagged ubiquilin-2 and tagged HSJ1a was assessed 
using SK-N-SH neuroblastoma cells. Binding between tagged ubiquilin-2 and tagged HSJ1a 
domain mutants was also examined. The ability of HSJ1a to bind to ubiquilin-2 mutants was 
also investigated, to examine if HSJ1a could potentially modulate mutant ubiquilin-2 
aggregation in cells. 
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3.2 Results 
3.2.1 HSJ1a co-localises and co-immunopurifies with ubiquilin-2 
The cellular localisation of FLAG-tagged ubiquilin-2 (FLAG-ubiquilin-2) was examined by 
immunocytochemistry. SK-N-SH cells were transfected with FLAG-ubiquilin-2 and 24 
hours post transfection, cells were fixed and immunostained with a FLAG antibody. FLAG-
ubiquilin-2 appeared both diffuse in the cytoplasm and in multiple punctate structures, as 
previously described (Figure 3.1A) (Osaka et al. 2015, Xia et al. 2014, Rothenberg et al. 
2010, N’diaye et al. 2009). The co-transfection of SK-N-SH cells with FLAG-ubiquilin-2 
and myc-HSJ1a resulted in myc-HSJ1a being recruited to the FLAG-ubiquilin-2 punctate 
structures (Figure 3.1C). Myc-HSJ1a did not form punctate structures in the absence of 
FLAG-ubiquilin-2 (Figure 3.1B). The recruitment of HSJ1a to ubiquilin-2 puncta suggested 
that the two proteins might interact. To test this possibility, a co-immunopurification assay 
was performed. SK-N-SH cells were transfected with FLAG-ubiquilin-2 and myc-HSJ1a.  
24 hours post transfection, cells were lysed and lysates were immunopurified for 1 hour with 
a FLAG, myc or IgG control antibody. Purified protein was then resolved by SDS-PAGE 
and Western blot analysis was performed using a FLAG or a HSJ1 antibody. A small 
proportion of myc-HSJ1a was detected in the FLAG purifications, suggesting myc-HSJ1a 
may bind to FLAG-ubiquilin-2 (Figure 3.1D). Myc-HSJ1a was not enriched with a control 
antibody (IgG), confirming the specificity of the interaction. Unfortunately, both a FLAG 
and ubiquilin-2 antibody were poor at detecting FLAG-ubiquilin-2 by Western blot. The 
efficiency of the FLAG-ubiquilin-2 immunopurification could therefore not be determined, 
along with the ability of anti-myc to co-immunopurify FLAG-ubiquilin-2 with myc-HSJ1a. 
3.2.2 HSJ1a ∆UIM fails to co-localise and co-immunopurify with ubiquilin-2 
The co-localisation and co-immunopurification of myc-HSJ1a and FLAG-ubiquilin-2 
suggested that the two proteins interact. To examine whether the interaction was dependent 
on the UIMs of HSJ1a, the ability of anti-FLAG to co-immunopurify an HSJ1a mutant 
containing four amino acid substitutions that disrupts the function of both UIMs (myc-
HSJ1a-∆UIM-S219A/E222A/S262A/E265A) was assessed (Westhoff et al. 2005). SK-N-SH 
cells were transfected with FLAG-ubiquilin-2 and either wild-type myc-HSJ1a (WT) or 
myc-HSJ1a-∆UIM (∆UIM) and immunopurification of cell lysates was subsequently 
performed. Unlike myc-HSJ1a WT, anti-FLAG failed to immunopurify myc-HSJ1a-∆UIM, 
suggesting that the binding of HSJ1a to ubiquilin-2 is dependent on the UIMs (Figure 3.2A). 
To confirm that FLAG-ubiquilin-2 lacks the ability to bind to myc-HSJ1a-∆UIM, the 
localisation of the two proteins was examined by immunocytochemistry. FLAG-ubiquilin-2 
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and myc-HSJ1a-∆UIM failed to co-localise (Figure 3.2B), supporting the notion that the 
binding between the two proteins is dependent on the UIMs of HSJ1a. 
3.2.3 The binding of HSJ1a to ubiquilin-2 is dependent on UIM2 
HSJ1 has two UIMs; to identify which UIM ubiquilin-2 binds to, the binding of FLAG-
ubiquilin-2 to myc-HSJ1a mutants with either a functionally deficient UIM1 (myc-HSJ1a-
∆UIM1-S219A/E222A) or UIM2 (myc-HSJ1a-∆UIM2-S262A/E265A) domain was probed 
(Westhoff et al. 2005). Anti-FLAG was able to immunopurify myc-HSJ1a-∆UIM1 with 
FLAG-ubiquilin-2, but was unable to purify myc-HSJ1a-∆UIM2 (Figure 3.3A). Consistent 
with this observation, myc-HSJ1a-∆UIM1 retained the ability to be recruited to FLAG-
ubiquilin-2 puncta, whereas myc-HSJ1a-∆UIM2 showed no co-localisation with FLAG-
ubiquilin-2 (Figure 3.3B). The binding between ubiquilin-2 and HSJ1a therefore appears to 
be dependent on UIM2. 
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Figure 3.1 HSJ1a co-localises and co-immunopurifies with ubiquilin-2. A: SK-N-SH 
cells were transfected with FLAG-ubiquilin-2. 24 hours post transfection, cells were fixed in 
4% PFA, permeabilised with 0.1% Triton-X100 and immunostained with a rabbit FLAG 
antibody at a dilution of 1:200 (Cy3, red). Cells were imaged on a Zeiss LSM 700 confocal 
microscope. Arrows highlight punctate structures. Scale bar, 10 µm (n=3). B: SK-N-SH 
cells were transfected with myc-HSJ1a. 24 hours post transfection, cells were fixed in 4% 
PFA, permeabilised with 0.1% Triton-X100 and immunostained with a sheep HSJ1 antibody 
at a dilution of 1:200 (Cy2, green). Cells were imaged on a Zeiss LSM 700 confocal 
microscope. Scale bar, 10 µm (n=3). C: SK-N-SH cells were transfected with FLAG-
ubiquilin-2 and myc-HSJ1a. 24 hours post transfection, cells were fixed, immunostained and 
imaged as described above. Arrows highlight examples of punctate structures where the two 
proteins co-localise. Scale bar, 10 µm (n=3). D: SK-N-SH cells were transfected with 
FLAG-ubiquilin-2 and myc-HSJ1a. 24 hours post transfection, cells were lysed and lysates 
were incubated with protein G Dynabeads and either a FLAG, myc or IgG control antibody 
(1:200). After a one hour incubation on a rotating wheel, purified immuno-complexes were 
then resolved by SDS-PAGE and Western blot analysis was performed using a sheep HSJ1 
antibody at a 1:1000 dilution (n=3).  
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Figure 3.2 HSJ1a-∆UIM fails to co-immunopurify and co-localise with ubiquilin-2. A: 
SK-N-SH cells were transfected with FLAG-ubiquilin-2 and either myc-HSJ1a (WT) or 
myc-HSJ1a-∆UIM (∆UIM). 24 hours post transfection, cell lysates were incubated with 
protein G Dynabeads and either a FLAG, myc or IgG control antibody (1:200). After a one 
hour incubation on a rotating wheel, purified immuno-complexes were resolved by SDS-
PAGE and Western blot analysis was performed using a sheep HSJ1 antibody at a 1:1000 
dilution. (n=3). B: SK-N-SH cells were transfected with FLAG-ubiquilin-2 and myc-HSJ1a-
∆UIM. Cells were subsequently fixed in 4% PFA, permeabilised in 0.1% Triton-X100 and 
immunostained with FLAG (Cy3, red) and HSJ1 antibodies (Cy2, green) at a dilution of 
1:200. Cells were imaged on a Zeiss LSM 700 confocal microscope. Scale bar, 10 µm (n=3). 
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Figure 3.3 HSJ1a-∆UIM2 fails to co-immunopurify and co-localise with ubiquilin-2. A: 
SK-N-SH cells were transfected with FLAG-ubiquilin-2 and either myc-HSJ1a-∆UIM1 or 
myc-HSJ1a-∆UIM2 mutants. 24 hours post transfection, cell lysates were incubated with 
protein G Dynabeads and either a FLAG, myc or IgG control antibody (1:200). After a one 
hour incubation on a rotating wheel, purified immuno-complexes were resolved by SDS-
PAGE and Western blot analysis was performed using a sheep HSJ1 antibody at a 1:1000 
dilution. (n=3) B: SK-N-SH cells were transfected with FLAG-ubiquilin-2 and either myc-
HSJ1a-∆UIM1 or myc-HSJ1a-∆UIM2. Cells were subsequently fixed in 4% PFA, 
permeabilised in 0.1% Triton-X100 and immunostained with FLAG (Cy3, red) and HSJ1 
antibodies (Cy2, green) at a dilution of 1:200. Cells were imaged on a Zeiss LSM 700 
confocal microscope. Arrows highlight punctate structures where the two proteins co-
localise. Scale bar, 10 µm (n=3). 
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3.2.4 Ubiquilin-2 localises to autophagosomes upon the induction of autophagy 
Having established an interaction between HSJ1a and ubiquilin-2, I next sought to 
characterise the nature of the punctate structures that HSJ1a was recruited to. Previous 
studies showed that ubiquilin-2 puncta co-localise with the autophagosome marker, LC3 
(N’diaye et al. 2009, Rothenberg et al. 2010). The localisation of LC3 in respect to 
ubiquilin-2 was therefore examined. SK-N-SH cells were transfected with FLAG-ubiquilin-
2 and GFP-LC3 and were subsequently immunostained with a FLAG antibody. GFP-LC3 
showed a diffuse distribution in both the cytoplasm and the nucleus. A small number of GFP 
positive punctate structures, indicative of autophagosomes, were observed, which appeared 
to co-localise with a small proportion of FLAG-ubiquilin-2 puncta (Figure 3.4). The 
majority of FLAG-ubiquilin-2 puncta, however, did not show co-localisation with GFP-LC3. 
To determine whether GFP-LC3 and FLAG-ubiquilin-2 co-localise upon the induction of 
autophagy, SK-N-SH cells transfected with FLAG-ubiquilin-2 and GFP-LC3 were starved 
of amino acids for 3 hours. Following starvation, multiple GFP positive punctate structures 
were observed, with extensive co-localisation with FLAG-ubiquilin-2 puncta (Figure 3.4). 
FLAG-ubiquilin-2 therefore shows increased localisation to autophagosomes upon the 
induction of autophagy.  
3.2.5 HSJ1a co-immunopurifies with LC3 under basal conditions and upon the 
induction of autophagy 
Ubiquilin-2 has been reported to co-immunoprecipitate with LC3, although the interaction 
appears to be indirect (Rothenberg et al. 2010). To investigate whether HSJ1a forms part of 
the complex that links ubiquilin-2 to LC3, the binding of HSJ1a to LC3 was examined. 
Considering that FLAG-ubiquilin-2 shows increased localisation to autophagosomes upon 
the induction of autophagy, the interaction between GFP-LC3 and myc-HSJ1a was 
examined in the absence and presence of amino acid starvation. SK-N-SH cells were 
transfected with GFP-LC3 and myc-HSJ1a. The transfected cells were then untreated or 
starved of amino acids for 3 hours. Cell lysates were subsequently immunopurified with a 
GFP or myc antibody. Purified protein was resolved by SDS-PAGE and the presence of 
GFP-LC3 in GFP and myc purifications was probed. GFP-LC3 co-immunopurified with 
myc-HSJ1a under basal conditions, suggesting that the proteins do indeed interact (Figure 
3.5). GFP-LC3 also co-immunopurified with myc-HSJ1a upon the induction of autophagy. 
Upon the induction of autophagy, a faint band was detected beneath GFP-LC3 in both the 
GFP and myc purifications, corresponding in size to the autophagosome-associated isoform 
GFP-LC3-II. Neither GFP-LC3-I nor GFP-LC3-II was not enriched with an IgG antibody, 
confirming the specificity of the interaction.  
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Figure 3.4 Ubiquilin-2 puncta co-localise with LC3 upon the induction of autophagy. 
SK-N-SH cells were transfected with FLAG-ubiquilin-2 and GFP-LC3. 24 hours post 
transfection, cells were untreated or incubated for 3 hours in HBSS culture medium that 
lacked amino acids. Following the incubation period, cells were fixed in 4% PFA, 
permeabilised with 0.1% Triton-X100 and immunostained with a FLAG antibody at a 1:200 
dilution (GFP-LC3 green, FLAG-ubiquilin-2 red). Cells were imaged on a Zeiss LSM 700 
confocal microscope. Scale bar, 10 µm (n=3).  
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Figure 3.5 GFP-LC3 co-immunopurifies with HSJ1a. A: SK-N-SH cells were transfected 
with GFP-LC3 and myc-HSJ1a. 24 hours post transfection, cells were untreated or starved of 
amino acids for 3 hours in HBSS medium. Cells were lysed and lysates were incubated with 
protein G Dynabeads and either a GFP, myc, or IgG control antibody, all at a dilution of 
1:200. After a one hour incubation on a rotating wheel, purifications were resolved by SDS-
PAGE and Western blot analysis was performed using a mouse GFP antibody at a 1:1000 
dilution (n=3).  
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3.2.6 Characterising ubiquilin-2 mutants 
Five mutations in ubiquilin-2 were identified in families with X-linked ALS (Deng et al. 
2011). I aimed to characterise the expression and localisation of the five ubiquilin-2 mutants 
and determine whether they retained the ability to bind to HSJ1a. The five patient mutations 
reported by Deng et al. (2011) (P497H, P497S, P506T, P509S and P525S) were introduced 
into the FLAG-ubiquilin-2 construct using site directed mutagenesis. To compare the 
expression levels of wild-type and mutant ubiquilin-2, SK-N-SH cells were transfected with 
either wild-type FLAG-ubiquilin-2 or one of the five FLAG-ubiquilin-2 mutants. 24 hours 
post transfection, cells were lysed and FLAG-ubiquilin-2 protein levels were determined by 
Western blot analysis. Although the signal was low, four of the FLAG-ubiquilin-2 mutants 
showed similar expression levels compared to wild-type FLAG-ubiquilin-2, with FLAG-
ubiquilin-2 P509S showing slightly higher expression levels (Figure 3.6). 
To characterise whether the patient mutations affected the localisation of ubiquilin-2, the 
localisation of the five ubiquilin-2 mutants was examined by immunocytochemistry. As with 
wild-type FLAG-ubiquilin-2, all five FLAG-ubiquilin-2 mutants appeared both diffuse in the 
cytoplasm and in multiple punctate structures (Figure 3.7). Interestingly, a proportion of 
these mutant FLAG-ubiquilin-2 punctate structures appeared larger than those observed with 
wild-type FLAG-ubiquilin-2. To investigate this observation in more detail, the number and 
size of puncta formed by wild-type and mutant FLAG-ubiquilin-2 was determined. There 
was no significant difference in the average number of puncta per cell; wild-type FLAG-
ubiquilin-2 and mutant FLAG-ubiquilin-2 all exhibited an average of between 8 and 9 
puncta per cell (Figure 3.8). However, three of the ubiquilin-2 mutants, FLAG-ubiquilin-2 
P506T, P509S and P525S, displayed a significant increase in the average size of the puncta 
formed (Figure 3.9). Wild-type FLAG-ubiquilin-2 formed puncta with an average area of 
127 nm
2
, whereas FLAG-ubiquilin-2 P506T, P509S and P525S formed puncta with an 
average area of 159 nm
2
, 149 nm
2
 and 153 nm
2
, respectively. FLAG-ubiquilin-2 P497H and 
FLAG-ubiquilin-2 P497S showed no significant difference in average puncta size when 
compared to the wild-type protein, with an average area of 138 nm
2
 and 133 nm
2
, 
respectively. 
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Figure 3.6 Protein expression levels of wild-type and mutant ubiquilin-2. SK-N-SH cells 
were transfected with either wild-type FLAG-ubiquilin-2 or FLAG-ubiquilin-2 P497H, 
P497S, P506T, P509S or P525S. 24 hours post transfection, cell lysates were resolved by 
SDS-PAGE and Western blot analysis was performed using a monoclonal mouse FLAG 
antibody (1:500). A monoclonal mouse β-actin antibody (1:5000) was used as a loading 
control (n=2).   
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Figure 3.7 The localisation of ubiquilin-2 mutants. SK-N-SH cells were transfected with 
either wild-type FLAG-ubiquilin-2 or FLAG-ubiquilin-2 P497H, P497S, P506T, P509S or 
P525S. 24 hours post transfection, cells were fixed in 4% PFA, permeabilised in 0.1% 
Triton-X100 and immunostained with a rabbit FLAG (Cy3, red) antibody at a dilution of 
1:200. Cells were imaged on a Zeiss LSM 700 confocal microscope. Arrows highlight 
examples of the punctate structures. Scale bar, 10 µm (n=3). 
  
Chapter 3 
89 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 The average number of ubiquilin-2 puncta in transfected SK-N-SH cells. 
SK-N-SH cells were transfected with either wild-type FLAG-ubiquilin-2 or FLAG-
ubiquilin-2 P497H, P497S, P506T, P509S or P525S. 24 hours post transfection, cells were 
fixed in 4% PFA, permeabilised in 0.1% Triton-X100 and immunostained with a rabbit 
FLAG (Cy3, red) antibody at a dilution of 1:200. The number of FLAG-ubiquilin-2 puncta 
was counted in at least 50 transfected cells per n using a Nikon Eclipse 80i Fluorescence 
microscope. Error bars represent ± SD (N.S one-way ANOVA, n=3). 
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Figure 3.9 The average size of ubiquilin-2 puncta in transfected SK-N-SH cells. SK-N-
SH cells were transfected with either wild-type FLAG-ubiquilin-2 or FLAG-ubiquilin-2 
P497H, P497S, P506T, P509S or P525S. 24 hours post transfection, cells were fixed in 4% 
PFA, permeabilised in 0.1% Triton-X100 and immunostained with a rabbit FLAG (Cy3, red) 
antibody at a dilution of 1:200. Cells were imaged on a Zeiss LSM 700 confocal microscope. 
The average size of the puncta in a transfected cell was determined using ImageJ. Error bars 
represent ± SD (** P < 0.01, one-way ANOVA with post hoc Tukey test, n=3). 
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3.2.7 HSJ1a co-localises and co-immunopurifies with ubiquilin-2 mutants 
To determine whether these patient mutations affected the binding of HSJ1a to ubiquilin-2, 
SK-N-SH cells were transfected with myc-HSJ1a and either wild-type or mutant FLAG-
ubiquilin-2 and an immunopurification assay was performed. Myc-HSJ1a co-
immunopurified with all five FLAG-ubiquilin-2 mutants and similar levels of myc-HSJ1a 
was purified in the presence of either wild-type or mutant FLAG-ubiquilin-2 (Figure 3.10).  
To confirm the interaction between HSJ1a and mutant ubiquilin-2, SK-N-SH cells were 
transfected with myc-HSJ1a and one of the five FLAG-ubiquilin-2 mutants and their 
localisation was determined. As observed with wild-type FLAG-ubiquilin-2, myc-HSJ1a 
was recruited to the puncta structures formed by the FLAG-ubiquilin-2 mutants (Figure 3.11 
and 3.12). Myc-HSJ1a was also recruited to the larger punctate structures formed by the 
mutants. 
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Figure 3.10 HSJ1a co-immunopurifies with all five ubiquilin-2 mutants. SK-N-SH cells 
were transfected with myc-HSJ1a and FLAG-ubiquilin-2 P497H, P497S, P506T, P509S or 
P525S. 24 hours post transfection, cell lysates were incubated with protein G Dynabeads and 
either a FLAG, myc or IgG control antibody (1:200). After a one hour incubation on a 
rotating wheel, purified immuno-complexes were resolved by SDS-PAGE and Western blot 
analysis was performed using a HSJ1 antibody at a 1:1000 dilution (n=3). 
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Figure 3.11 HSJ1a co-localises with mutant ubiquilin-2 puncta. SK-N-SH cells were 
transfected with myc-HSJ1a and FLAG-ubiquilin-2 P497H or P497S. 24 hours post 
transfection, cells were fixed in 4% PFA, permeabilised in 0.1% Triton-X100 and 
immunostained with a rabbit FLAG antibody (Cy3, red)  and a sheep HSJ1 antibody (Cy2, 
green), both at a dilution of 1:200. Cells were imaged on a Zeiss LSM 700 confocal 
microscope. Arrows highlight punctate structures where the two proteins co-localise. Scale 
bar, 10 µm (n=3). 
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Figure 3.12 HSJ1a co-localises with mutant ubiquilin-2 puncta. SK-N-SH cells were 
transfected with myc-HSJ1a and FLAG-ubiquilin-2 P506T, P509S or P525S. 24 hours post 
transfection, cells were fixed in 4% PFA, permeabilised in 0.1% Triton-X100 and 
immunostained with a rabbit FLAG antibody (Cy3, red)  and a sheep HSJ1 antibody (Cy2, 
green), both at a dilution of 1:200. Cells were imaged on a Zeiss LSM 700 confocal 
microscope. Arrows highlight puncta structures where the two proteins co-localise. Scale 
bar, 10 µm (n=3). 
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3.3 Discussion 
HSJ1a has previously been identified to interact with the UBL-containing protein ubiquilin-1 
(Heir et al. 2006). The interaction was dependent on the UBL domain of ubiquilin-1 and the 
UIMs of HSJ1a (Heir et al. 2006). Considering the conserved nature of the UBL domain 
among ubiquilin isoforms, the interaction raised the possibility that HSJ1a may also interact 
with ubiquilin-2, a protein recently associated with X-linked ALS (Deng et al. 2011). I 
therefore aimed to ascertain whether HSJ1a could interact with ubiquilin-2 and, if so, 
determine whether the interaction was dependent on the UIMs of HSJ1a. Furthermore, I 
aimed to investigate whether, like mutant SOD1, (Novoselov et al. 2013) HSJ1a could 
potentially suppress the aggregation of mutant ubiquilin-2 in a cell model of ALS. 
The anti-aggregation function of HSJ1a towards polyQ was dependent on both UIM1 and 
UIM2, despite the fact that only UIM2 binds to polyubiquitin chains with high affinity (Dr 
Sergey Novoselov, personal communications). It was therefore hypothesised that UIM1 may 
function to bind to a UBL-containing protein. Considering that ubiquilin-2 also functions in 
protein degradation and that both HSJ1 and ubiquilin-2 are associated with motor neuron 
degeneration, ubiquilin-2 represented a possible candidate for potentially co-operating with 
HSJ1a to target misfolded, ubiquitylated proteins for degradation. The immunopurification 
and localisation data presented in this Chapter revealed that HSJ1a does indeed interact with 
ubiquilin-2; however, this interaction was not dependent on UIM1 of HSJ1a. The role of 
UIM1 in the anti-aggregation process therefore remains uncharacterised.  
The binding of HSJ1a to ubiquilin-2 was dependent on UIM2 rather than UIM1. The 
inability of UIM1 to bind to ubiquilin-2 supports the notion that UIM1 and UIM2 of HSJ1a 
have distinct binding preferences. Interestingly, UIM1 and UIM2 of Eps15, a protein that 
functions in the sorting of substrates for endocytosis and lysosomal degradation, also display 
distinct binding properties, with UIM1 binding specifically to UBL proteins and UIM2 
preferentially binding to polyubiquitin chains (Regan-Klapisz et al. 2005). The preference of 
Eps15 UIM2 for polyubiquitin chains was proposed to be mediated by the presence of a 
double-sided motif in UIM2, formed by key amino acids being repeated two residues along 
the UIM2 sequence (Hirano et al. 2006). The double-sided motif enables UIM2 to bind two 
ubiquitin molecules instead of one, enabling Eps15 UIM2 to bind to polyubiquitin chains 
with high affinity (Hirano et al. 2006). UIM2 of HSJ1a was also identified as a double-sided 
UIM (Hirano et al. 2006). The double-sided motif of HSJ1a UIM2, compared to the single-
sided motif of HSJ1a UIM1, likely accounts for the observation that only UIM2 of HSJ1a 
binds strongly to polyubiquitin chains. It is therefore possible that the single or double-sided 
nature of the UIM accounts for the different binding properties of the two HSJ1a motifs. 
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Considering that UIM2 appears to be primed to bind to polyubiquitin chains, it is interesting 
to consider whether UIM2 mediates its interaction with ubiquilin-2 directly, via the UBL 
domain, or indirectly, via the ubiquitylated cargo bound to the UBA domain of ubiquilin-2. 
Direct binding of UIM2 to the UBL domain would suggest that, unlike UIM2 of Eps15, 
UIM2 of HSJ1a can bind to both polyubiquitin chains and UBL proteins. Determining the 
mode of interaction will therefore be important for clarifying the binding properties of 
HSJ1a UIM2. The dependence on either the UBL or UBA domain could be examined by 
assessing the ability of ubiquilin-2 mutants lacking the UBL or UBA domain to co-
immunopurify and co-localise with HSJ1a. 
Establishing the mode of interaction could provide insights into the function of HSJ1a 
binding. The indirect binding of ubiquilin-2 via the ubiquitylated cargo would suggest that 
HSJ1a functions to protect the chains from ubiquitin hydrolases, ensuring the efficient 
delivery of ubiquilin-2 substrates to the proteasome for degradation (Westhoff et al. 2005). 
Previous reports suggested that the direct binding of UIM-containing proteins to the UBL 
domain prevents the interaction of ubiquilin with the proteasome, diverting the cargo away 
from the degradation pathway (Heir et al. 2006). The direct binding of HSJ1a UIM2 to the 
UBL domain may therefore function to divert ubiquitylated cargo away from the 
proteasome, possible promoting autophagy-mediated degradation instead. However, HSJ1a 
itself has been shown to interact with the proteasome (Westhoff et al. 2005), therefore it is 
unclear whether the binding of HSJ1a to the UBL domain would alter the fate of the 
ubiquilin-2 cargo.  
Endogenous and heterologously expressed ubiquilin-2 has been shown to adopt punctate 
structures in multiple neuronal cell types (N’diaye et al. 2009, Rothenberg et al. 2010, 
Osaka et al. 2015). The puncta have been found to co-localise with endogenous and GFP-
LC3, suggesting that the structures represent autophagosomes (N’diaye et al. 2009, 
Rothenberg et al. 2010). Here, the transfection of FLAG-ubiquilin-2 in SK-N-SH cells also 
resulted in the formation of punctate structures; however, under basal conditions, the puncta 
showed limited co-localisation with GFP-LC3, which formed relatively few autophagosome 
structures in transfected cells. The majority of FLAG-ubiquilin-2 puncta do therefore not 
appear to represent autophagosomes. In transfected N2a and HeLa cells, ubiquilin-2 puncta 
showed co-localisation with optineurin, a protein proposed to function in endosome 
recycling and endocytic trafficking (Osaka et al. 2015, Nagabhushana et al. 2010). The co-
localisation of the two proteins implied that ubiquilin-2 may be present in endosomes and 
indeed, ubiquilin-2 puncta co-localised with GFP-Rab11, a marker of recycling endosomes 
(Osaka et al. 2015). Interestingly, recycling endosomes have been demonstrated to 
contribute to autophagosome formation upon amino acid starvation (Longatti et al. 2012). 
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The incorporation of recycling endosomes into autophagosomes could explain the extensive 
co-localisation observed between GFP-LC3 and FLAG-ubiquilin-2 upon amino acid 
starvation. Such an observation has been previously reported. The co-localisation of 
ubiquilin-2 puncta with endogenous autophagosome markers such as LC3, p62 and ULK1 
was substantially increased upon amino acid starvation (Osaka et al. 2015). The degree to 
which ubiquilin-2 co-localises with LC3 therefore appears to be dictated by the demand for 
autophagosome formation. This can vary in different cell types, possibly explaining why 
some cell types show greater co-localisation between LC3 and ubiquilin-2. It will be 
important in future studies to confirm the nature of the ubiquilin-2 puncta formed in SK-N-
SH cells and determine whether they do indeed represent recycling endosomes. 
In view of the co-localisation between GFP-LC3 and FLAG-ubiquilin-2 upon amino acid 
starvation, I sought to examine whether HSJ1a forms part of the complex that links 
ubiquilin-2 to LC3. LC3-interacting proteins have been identified to bind to LC3 via a LC3-
interacting region (LIR), a motif with the consensus sequence of W/Y/FXXL/I/V (Ichimura 
et al. 2008). Interestingly, HSJ1 contains 8 such motifs (Figure 3.13), therefore, in theory; 
HSJ1 has the capabilities to bind directly to LC3. GFP-LC3 co-immunopurified with myc-
HSJ1a under both basal conditions and upon amino acid starvation. Upon amino acid 
starvation, both GFP-LC3-I and GFP-LC3-II were immunopurified with myc-HSJ1a, 
although the levels of GFP-LC3-II immunopurified were substantially lower than the levels 
of GFP-LC3-I. HSJ1a therefore appears to interact with the cytosolic isoform LC3-I and the 
autophagosome-associated isoform LC3-II. It will be important to validate the interaction in 
the future, ideally using endogenous LC3, in order to verify that the interaction is not an 
artefact caused by the overexpression of the two proteins. The significance of HSJ1a binding 
to LC3-I is unclear, however, it could possibly indicate that HSJ1a is involved in the 
turnover of LC3-I. On the other hand, the binding of HSJ1a to LC3-II is an interesting 
concept. Binding to LC3-II would suggest that HSJ1a acts as a selective adaptor, recruiting 
ubiquitylated cargo into the autophagosome either through the direct binding of HSJ1a client 
proteins or, alternatively, though an interaction with ubiquilin-1 and ubiquilin-2, or other 
UBL proteins. To classify HSJ1a as an adaptor protein, the localisation of HSJ1a to 
autophagosomes would need to be established. Furthermore, it would be need to be shown 
that HSJ1a is degraded upon the induction of autophagy.  
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MASYYEILDVPRSASADDIKKAYRRKALQWHPDKNPDNKEFAEKKFKEVAEAYEVL
SDKHKREIYDRYGREGLTGTGTGPSRAEAGSGGPGFTFTFRSPEEVFREFFGSGDP
FAELFDDLGPFSELQNRGSRHSGPFFTFSSSFPGHSDFSSSSFSFSPGAGAFRSVS
TSTTFVQGRRITTRRIMENGQERVEVEEDGQLKSVTINGVPDDLALGLELSRREQQ
PSVTSRSGGTQVQQTPASCPLDSDLSEDEDLQLAMAYSLSEMEAAGKKPADVF 
 
 
Figure 3.13 Predicted LC3-interacting regions (LIRs) in HSJ1a. LIRs with the consensus 
sequence W/Y/FXXL/I/V are highlighted in yellow. Where two LIRs overlap or where one 
LIR follows another, the second LIR is underlined. 
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Five mutations in ubiquilin-2 were initially reported by Deng et al. (2011) in families with 
X-linked ALS. Since this first report, other ubiquilin-2 patient mutations have been 
identified, with all mutations identified to date located in or around the PXX repeat region 
(Milliecamps et al. 2012, Gellera et al. 2013, Fahed et al. 2014). Investigations have focused 
on dissecting how mutations in the PXX repeat region cause motor neuron degeneration. 
One possible mechanism involves impaired proteostasis, with Deng et al. (2011) identifying 
that the ubiquilin-2 mutants have a reduced ability to target substrates to the proteasome for 
degradation. Furthermore, ubiquilin-2 mutants showed a reduced binding affinity for 
UBXD8, resulting in the accumulation of an ERAD reporter substrate (Xia et al. 2014). 
However, in vivo studies suggest that disease pathogenesis is driven by a toxic gain of 
function rather than a loss of function. Ubiquilin-2 knockout rats appeared healthy, with no 
observable phenotype, whereas transgenic rats overexpressing ubiquilin-2 P497H showed 
cognitive defects, with the progressive loss of neurons in the motor cortex (Wu et al. 2015). 
Prior to neuronal loss, ubiquilin-2 aggregates were observed, as seen in patient post mortem 
examinations (Deng et al. 2011). Ubiquilin-2 mutants were also shown to aggregate into 
cytoplasmic inclusions in transfected cells (Osaka et al. 2015, Xia et al. 2014). Here, I show 
that three of the ubiquilin-2 mutants, FLAG-ubiquilin-2 P506T, P509S and P525S form 
punctate structures that are significantly larger than those formed by wild-type ubiquilin-2. It 
is possible that the larger structures represent inclusions or potentially aggresomes, formed 
by the deposition of misfolded ubiquilin-2 protein. To determine whether the larger 
structures represent aggresomes, the localisation of mutant ubiquilin-2 puncta with 
aggresome markers could be examined. Aggresomes form at the microtubule-organising 
centre (MTOC), therefore a MTOC marker such as pericentrin could be used. Another 
characteristic feature of aggresomes is the deposition of intermediate filaments around the 
structure, therefore staining for an intermediate filament could provide another suitable 
marker. 
HSJ1a retained the ability to bind to the ubiquilin-2 mutants and was recruited to both the 
small and large punctate structures. If the larger punctate structures do represent inclusions, 
it will be interesting to determine whether HSJ1a is able to bind mutant ubiquilin-2 as a 
client protein and reduce its aggregation either by promoting its refolding or degradation 
(Rose et al. 2011, Westhoff et al. 2005). Future studies should therefore focus on examining 
the effect of HSJ1a overexpression on mutant ubiquilin-2 protein levels as well as the effect 
on the number and size of mutant ubiquilin-2 punctate structures. The overexpression of 
HSJ1a in a mouse model of ALS protected motor neurons against SOD1 G93A-induced 
toxicity, reducing SOD1 G93A aggregation and resulting in an increase in motor unit 
number and an increase in motor neuron survival (Novoselov et al. 2013). It would be 
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interesting to determine whether HSJ1a can also protect motor neurons against ubiquilin-2 
mediated toxicity. Such a protective response would further highlight the important role of 
HSJ1 in motor neuron survival. 
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Chapter 4 – Investigating the pathogenicity of HSJ1-Y5C 
4.1 Introduction 
dHMN and CMT2 are caused by the progressive degeneration of lower motor neurons. 
Clinically, there is significant overlap between dHMN and CMT2, with weakness and 
wasting of the lower limb muscles being the predominant phenotype of both diseases (Reilly 
et al. 2011, Rossor et al. 2012, Baets et al. 2014). The presence of sensory deficits, in 
addition to motor disturbances, differentiates CMT2 from dHMN. As discussed in Chapter 
1, a range of causative genes for dHMN and CMT2 have been identified, with mutations in 
the same gene causing both phenotypes. Although the majority of disease-causing mutations 
are unsolved, novel causative genes are continuing to emerge. Recently, three mutations in 
HSJ1 have been reported in two families with dHMN and one family with CMT2 (Blumen 
et al. 2012, Gess et al. 2014). 
In 2012, Blumen et al. were the first group to report a mutation in HSJ1 in three siblings 
with dHMN. The three siblings, from a consanguineous Jewish Moroccan family, reported 
symptom onset at 18, 23 and 20 years of age and initial symptoms were described as 
difficulties with walking, gait abnormalities and foot drop. At the time of presentation all 
three siblings showed progressive weakness, hypotonia and atrophy of the distal lower 
limbs. Plantar responses were flexor but ankle and knee jerk reflexes were absent. The distal 
hand muscles were unaffected. A follow up examination revealed severe distal weakness and 
atrophy, with swelling of the ankles and feet. The upper limbs were relatively spared 
although bicep and tricep jerks were absent. Nerve conductions studies revealed a normal 
median motor nerve velocity and no sensory deficits were recorded clinically or 
electrophysiologically. 
Gess et al. (2014) identified a second mutation in HSJ1 in two siblings with dHMN from a 
consanguineous Turkish family. As with the Moroccan family, symptom onset occurred in 
early adulthood, at 16 and 19 years of age. Initial symptoms were also described as 
difficulties with walking, with gait abnormalities and frequent stumbling. At the time of 
presentation the siblings exhibited mild atrophy of the peroneal and gastrocnemic muscles in 
the leg. In addition, mild bilateral paralysis of foot and toe dorsiflexion was observed. The 
siblings also presented with mild pareses of knee flexion. No sensory symptoms were 
observed and nerve conduction studies confirmed a lack of sensory involvement.  
In both families, dHMN was associated with an autosomal recessive pattern of inheritance. 
In the Moroccan family, a homozygous c.352+1 G>A mutation was identified in HSJ1, 
abolishing the donor splice site of intron 5 (Blumen et al. 2012). The mutation led to 
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abnormal splicing events, with two additional HSJ1 transcripts observed in patient 
fibroblasts. The additional transcripts retained either the partial or full sequence of intron 5, 
with both transcripts carrying a premature stop codon. At the protein level, patient 
fibroblasts showed reduced expression of HSJ1b, with no detectable levels of HSJ1a 
(Blumen et al. 2012). In the Turkish family, a homozygous c.229+1 G>A mutation was 
identified, abolishing the donor splice site of intron 4 (Gess et al. 2014). The mutation led to 
the abnormal splicing of HSJ1, with the retention of intron 4 in the transcript. Unlike HSJ1 
c.352+1 G>A, the correctly spliced transcript was absent from patient fibroblasts. At the 
protein level, patient fibroblasts showed no detectable levels of either HSJ1 isoform (Gess et 
al. 2014). 
A third mutation in HSJ1 was identified in two siblings with CMT2 (Gess et al. 2014). The 
two siblings, from an Austrian family, reported symptom onset at 30 and 23 years of age. 
Initial symptoms included an unstable gait and numbness of the distal lower limbs. At the 
time of presentation the two siblings showed peroneal and gastrocnemic muscle atrophy 
with a reduced sensation to touch. Incomplete paralysis of foot and toe dorsiflexion was also 
observed. Ankle and knee jerk reflexes were absent, as were reflexes of the upper limbs. 
Median motor nerve conduction velocities were normal in both siblings. Sensory nerve 
conduction studies were not performed, however the presence of sensory symptoms was 
indicative of CMT2 rather than dHMN. A comparison of the clinical phenotypes described 
for all three families is summarised in Table 4. 
Whole-exome sequencing of the patients revealed the homozygous missense mutation 
c.14A>G in HSJ1, resulting in the substitution of a tyrosine for a cysteine at residue 5. As 
with the previous two HSJ1 mutations, the third mutation also showed an autosomal 
recessive pattern of inheritance. Residue 5 of HSJ1 is located in the J domain and is highly 
conserved in HSJ1 orthologs across multiple species (Figure 4). The Y5C substitution was 
classified as disease-related by several different automatic algorithms, suggesting that 
residue 5 is critical for the structure and/or function of HSJ1. 
Our lab was asked to investigate the pathogenicity of the c.14A>G substitution by Professor 
Michaela Auer-Grumbach (Vienna) who had identified the variant in her patients. For the 
mutation to be characterised as pathogenic, the substitution should confer a loss of function 
phenotype on HSJ1, as indicated by the recessive mode of inheritance. A loss of HSJ1 
function may be driven by a reduction in protein levels, impaired activity or the mis-
localisation of the protein. To determine whether the Y5C substitution does impart a loss of 
function phenotype on HSJ1, HSJ1-Y5C plasmids were created and the expression, function 
and localisation of HSJ1-Y5C was examined in SK-N-SH neuroblastoma cells. 
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Table 4 A summary of the clinical phenotype of the patients from the three families 
with mutations in HSJ1. NR – not reported. (Blumen et al. 2012, Gess et al. 2014). 
 
  
 
Family I  
(Moroccan) 
Family II  
(Turkish) 
Family III 
(Austrian) 
Patient I II III I II I II 
Age of onset 
(yrs) 
18 23 20 16 19 30 23 
Lower limb 
atrophy 
Yes Yes Yes Yes Yes Yes Yes 
Paralysis of 
foot and toe 
dorsiflexion 
NR NR NR Yes Yes Yes Yes 
Ankle and 
knee jerk 
reflexes 
Absent Absent Absent NR NR Absent Absent 
Biceps and 
triceps jerk 
reflexes 
Absent Absent Absent NR NR Absent Absent 
Knee flexion NR NR NR Reduced Reduced Reduced Reduced 
Sensory 
abnormalities 
No No No No No Yes Yes 
Chapter 4 
104 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Homo sapiens       MASYYEILDVPRSASADDIKKAYR 
  Mus musculus        MASYYEILDVPRSASADDIKKAYR 
  Bos taurus       MASYYEILDVPRSAFPDDIKKAYR 
  Danio rerio        MVDYYDVLGVSRSASPDDIKKAYR 
  Drosophila melanogaster (MRJ)    MVDYYKILDVSRSATDSEVKKAYR 
  Caenorhabditis elegans (DNJ-24)    EDSPYITLGISSTSDDVEIKKAYR 
  Saacharomyces cerevisiae (SIS1)    ETKLYDLLGVSPSANEQELKKGYR 
  Eschericia coli (DNAJ)        KQDYYEILGVSKTAEEREIRKAYK 
 
 
Figure 4 The J domain structure of HSJ1 and the multiple sequence alignment of the 
region around Y5 of human HSJ1 and several orthologues. The structure of HSJ1’s J 
domain. Y5 lies in helix I of the J domain, formed from residues 4-7. PBD: 1XBL. Y5, 
highlighted in red, is highly conserved across several orthologues.  
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4.2 Results 
4.2.1 The Y5C substitution increases the turnover of HSJ1 
Site directed mutagenesis was used to introduce the c.14A>G substitution into the cDNA of 
untagged HSJ1a and HSJ1b plasmids, generating HSJ1a-Y5C and HSJ1b-Y5C plasmids. To 
determine if the Y5C substitution affected the expression level of HSJ1a and HSJ1b, SK-N-
SH neuroblastoma cells were transiently transfected with either a wild-type or mutant 
isoform of HSJ1. 24 hours post transfection, cells were lysed and the expression level of 
wild-type and mutant HSJ1 was compared by Western blot analysis. HSJ1 levels were 
corrected for loading using β-tubulin and the level of HSJ1a-Y5C and HSJ1b-Y5C was 
normalised to the expression of the corresponding wild-type isoform. Both HSJ1a-Y5C and 
HSJ1b-Y5C showed a significant reduction in expression levels compared to wild-type 
HSJ1a and HSJ1b (Figure 4.1). HSJ1a-Y5C showed a 37% reduction in expression levels 
compared to wild-type HSJ1a, with HSJ1b-Y5C showing a 48% reduction in expression 
levels compared to wild-type HSJ1b. 
To determine if the reduction in expression levels was due to a shorter half-life of HSJ1-
Y5C, the level of wild-type and mutant HSJ1 was compared following treatment with the 
protein synthesis inhibitor, cycloheximide. SK-N-SH cells were transfected with either a 
wild-type or mutant HSJ1 isoform then treated with 50 µM of cycloheximide for 0, 1, 2 or 4 
hours. HSJ1 levels were then determined by Western blot analysis (Figure 4.2). The 
expression level of HSJ1 at each time point was corrected for loading using β-tubulin, then 
normalised to the level of HSJ1 at 0 hours. The percentage of HSJ1 remaining over time was 
then quantified. Both isoforms of wild-type HSJ1 showed no change in protein levels over 
the 4 hour treatment, suggesting that the heterologous protein is stable. In contrast, HSJ1a-
Y5C and HSJ1b-Y5C showed a progressive decline in protein levels, initiating after 1 hour. 
At 2 hours, both HSJ1a-Y5C and HSJ1b-Y5C showed a 15% loss of protein, with a 
significant loss of 55% and 42%, respectively, observed at 4 hours. There was no significant 
difference in the rate of protein loss between the two mutant isoforms. The data therefore 
suggests that the Y5C substitution increases the turnover rate of HSJ1 compared to the wild-
type protein. 
4.2.2 HSJ1-Y5C is targeted to the proteasome for degradation 
To establish whether HSJ1-Y5C was degraded by autophagy or the UPS, SK-N-SH cells 
transfected with either a wild-type or mutant HSJ1 isoform were treated for 4 hours with 
bafilomycin, to inhibit autophagy, or MG132, to inhibit the proteasome. HSJ1 protein levels 
were then determined by Western blot analysis. HSJ1 levels were corrected for loading then 
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normalised to the level of the corresponding wild-type HSJ1 isoform in untreated transfected 
cells. The reduced levels of both isoforms of HSJ1-Y5C could be partially restored 
following treatment with MG132 (Figure 4.3). The level of HSJ1a-Y5C increased by 19% 
over the 4 hour treatment with MG132, such that HSJ1a-Y5C was only 18% lower than 
wild-type HSJ1a at 4 hours, compared to the 37% reduction observed in untreated cells. 
Similarly, HSJ1b-Y5C levels increased by 26% in the presence of MG132, resulting in only 
a 20% reduction in protein levels compared to wild-type HSJ1b at 4 hours. Interestingly, 
both HSJ1a-Y5C and HSJ1b-Y5C levels were found to be further reduced in the presence of 
bafilomycin compared to untreated cells. HSJ1a-Y5C levels were reduced by an additional 
12%, with HSJ1b-Y5C levels reduced by a further 11%. In the case of HSJ1a-Y5C, this 
decrease was found to be significant. No change in wild-type HSJ1 protein levels was 
observed in the presence of bafilomycin or MG132, in agreement with the cycloheximide 
data showing that the wild-type protein is stable. The results therefore confirm that both 
isoforms of HSJ1-Y5C are degraded at a higher rate than wild-type HSJ1 isoforms, with 
degradation being mediated by the proteasome. 
 
  
Chapter 4 
107 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 HSJ1-Y5C shows reduced expression levels compared to wild-type HSJ1. A: 
SK-N-SH cells were transfected with either a wild-type HSJ1 or HSJ1-Y5C isoform. 24 
hours post transfection, cells were lysed and 15 µg of total protein was resolved by SDS-
PAGE. Western blot analysis was performed using a polyclonal sheep HSJ1 antibody used 
at a dilution of 1:1000, and a monoclonal β-tubulin antibody used at 1:5000. B: Western 
blots of HSJ1 and β-tubulin were analysed using ImageJ. The level of HSJ1 was corrected 
for loading using β-tubulin. HSJ1a-Y5C and HSJ1b-Y5C levels were then normalised to the 
level of the wild-type HSJ1 isoform. Error bars represent ± SD (*** P <0.001, Student’s t-
test, n=3). 
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Figure 4.2 HSJ1-Y5C is degraded at a higher rate than wild-type HSJ1. A: SK-N-SH 
cells transfected with a wild-type or HSJ1-Y5C isoform were treated for 0, 1, 2 or 4 hours 
with 50 µg/mL cycloheximide. Samples were resolved by SDS-PAGE. Western blot 
analysis was performed using a polyclonal sheep HSJ1 antibody (1:1000) and a monoclonal 
β-tubulin antibody (1:5000). B: Western blots of HSJ1 and β-tubulin were analysed by 
ImageJ. The level of HSJ1 was corrected for β-tubulin and then normalised to the level of 
HSJ1 at 0 hours. The percentage of HSJ1 remaining over time was then quantified. Error 
bars represent ± SD (*** P <0.001, Student’s t-test, n=3). 
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Figure 4.3 HSJ1-Y5C levels are partially restored in the presence of MG132. A: SK-N-
SH cells were transfected with a wild-type HSJ1 or HSJ1-Y5C isoform. 24 hours post 
transfection, cells were either untreated or incubated with bafilomycin (200 nM) or MG132 
(50 µM) for 4 hours. Cells were then harvested and 15 µg of total protein was resolved by 
SDS-PAGE. Western blot analysis was performed using a polyclonal sheep HSJ1 antibody 
(1:1000) and a monoclonal β-tubulin antibody (1:5000). B: Western blots were analysed 
using ImageJ. The level of HSJ1 was corrected for loading and then normalised to the level 
of wild-type HSJ1 in untreated transfected cells. Error bars represent ± SD (* P <0.05, ** P 
<0.01, one-way ANOVA with post hoc Tukey test, n=4).  
Chapter 4 
110 
 
4.2.3 HSJ1-Y5C retains its normal localisation 
To examine the localisation of the remaining HSJ1-Y5C protein, SK-N-SH cells were 
transfected with wild-type or mutant HSJ1 and 24 hours post transfection cells were fixed 
and stained for HSJ1 (Figure 4.4). Although the fluorescent intensity was reduced, both 
mutant isoforms retained their normal localisation, with HSJ1a-Y5C appearing diffuse in the 
cytoplasm and the nucleus, and HSJ1b-Y5C displaying an ER staining pattern. The 
localisation of HSJ1b-Y5C to the cytoplasmic face of the ER was confirmed by its co-
localisation with the ER chaperone, BiP (Chapple and Cheetham 2003). These results 
suggest that HSJ1-Y5C retains its normal localisation. 
4.2.4 HSJ1a-Y5C retains its anti-aggregation function 
Residue 5 of HSJ1 lies in helix I of the highly conserved J domain (Gao et al. 2012). To 
determine if the Y5C substitution affects the J domain activity of the remaining protein, the 
ability of HSJ1a-Y5C to target misfolded proteins for degradation, a process dependent on a 
functional J domain and UIMs, was assessed (Westhoff et al. 2005, Novoselov et al. 2013). 
SOD1 G93A and Q103 inclusion formation was examined in the presence of wild-type 
HSJ1a, HSJ1a-Y5C or the J domain mutant HSJ1a-H31Q. In order to accurately compare 
the ability of wild-type HSJ1a, HSJ1a-Y5C and HSJ1a-H31Q to reduce inclusion formation, 
it was important to avoid saturating amounts of HSJ1a in the assay. Titration curves were 
therefore generated in order to establish the amount of HSJ1a that gave a linear dose 
response. SK-N-SH cells were transfected with 50 ng of GFP-SOD1 G93A or GFP-Q103 
and 0, 5, 15, 25, 50, 75 or 100 ng of wild-type HSJ1a. 24 hours post transfection, cells were 
fixed and the percentage of transfected cells containing inclusions was assessed as described 
in Chapter 2. For both GFP-SOD1 G93A and GFP-Q103 a significant linear decrease in the 
percentage of transfected cells containing inclusions was observed between 5 ng and 25 ng 
of HSJ1a, with the response plateauing between 30 ng and 100 ng (Figure 4.5). 15 ng of 
HSJ1a was therefore used in the assays. The transfection of SK-N-SH cells with GFP-SOD1 
G93A resulted in 25.6% of transfected cells containing perinuclear inclusions (Figure 4.6). 
The co-transfection of GFP-SOD1 G93A with wild-type HSJ1a reduced the percentage of 
transfected cells containing inclusions from 25.6% to 16.4%, a reduction of 36% (as 
observed in Figure 4.5). In contrast, HSJ1a-H31Q was unable to significantly reduce 
inclusion incidence. HSJ1a-Y5C was found to be significantly more effective than HSJ1a-
H31Q but less effective than wild-type HSJ1a, reducing inclusion incidence from 25.6% to 
20.1%. This is a reduction of 22%, compared to 36% observed in the presence of wild-type 
HSJ1a. Similar results were observed for GFP-Q103 (Figure 4.7). The co-transfection of 
GFP-Q103 and wild-type HSJ1a reduced the percentage of cells containing inclusions from 
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33.7% to 18.8%, a reduction of 44%. As seen with GFP-SOD1 G93A, the reduction in 
inclusion incidence was abolished in the presence of HSJ1a-H31Q. HSJ1a-Y5C was able to 
significantly reduce the percentage of transfected cells containing inclusions from 33.7% to 
23.2%. This reduction of 31% was significantly lower than the 44% reduction observed in 
the presence of wild-type HSJ1a. Overall, the data suggests that HSJ1a-Y5C retains some 
functionality. 
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Figure 4.4 The Y5C substitution does not affect the localisation of HSJ1. A: SK-N-SH 
cells were transfected with wild-type HSJ1a or HSJ1a-Y5C. 24 hours post transfection, cells 
were fixed in 4% PFA and permeabilised in 0.1% Triton-X. Cells were immunostained with 
a sheep HSJ1 antibody (1:200) and cells were imaged using a Zeiss LSM 700 confocal 
microscope. Scale bar: 10 µm. B: SK-N-SH cells were transfected with wild-type HSJ1b or 
HSJ1b-Y5C. 24 hours post transfection, cells were fixed in 4% PFA and permeabilised in 
0.1% Triton-X. Cells were immunostained with sheep HSJ1 antibody (1:200) (Cy2 green) 
and a rabbit BiP antibody (1:200) (Cy3 red). Cells were imaged using a Zeiss LSM 700 
confocal microscope. Scale bar: 10 µm (n=3). 
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Figure 4.5 Titration curves demonstrate that wild-type HSJ1a reduces GFP-SOD1 
G93A and GFP-Q103 inclusions formation in a concentration-dependent manner. SK-
N-SH cells were transfected with 50 ng of GFP-SOD1 G93A (A) or GFP-Q103 (B) and 0, 5, 
15, 25, 50, 75 or 100 ng of HSJ1a. 24 hours post transfection cells were fixed in 4% PFA. 
Cells were counted on a Nikon Eclipse 80i fluorescent light microscope. The number of 
transfected cells containing inclusions was divided by the total number of transfected cells 
and expressed as a percentage (n=3). 
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Figure 4.6 The effect of wild-type HSJ1a, HSJ1a-Y5C and HSJ1a-H31Q on GFP-SOD1 
G93A inclusion formation. A: SK-N-SH cells were transfected with 50 ng of GFP-SOD1 
G93A and 15 ng of wild-type HSJ1a, HSJ1a-Y5C or HSJ1a-H31Q. 24 hours post 
transfection, cells were fixed in 4% PFA. Representative images of GFP-SOD1 G93A 
inclusions in the absence or presence of wild-type HSJ1a, HSJ1a-Y5C or HSJ1a-H31Q. 
Images were taken on a Zeiss LSM 700 confocal microscope. Scale bar: 10 µm. B: The 
number of transfected cells containing inclusions was counted on a Nikon Eclipse 80i 
fluorescent light microscope and expressed as a percentage of the total number of transfected 
cells. Error bars represent ± SD. (** P <0.01, *** P < 0.001 Student’s t-test, n=3).  
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Figure 4.7 The effect of wild-type HSJ1a, HSJ1a-Y5C and HSJ1a-H31Q on GFP-Q103 
inclusion formation. A: SK-N-SH cells were transfected with 50 ng of GFP-Q103 and 15 
ng of wild-type HSJ1a, HSJ1a-Y5C or HSJ1a-H31Q. 24 hours post transfection, cells were 
fixed in 4% PFA. Representative images of GFP-Q103 inclusions in the absence or presence 
of wild-type HSJ1a, HSJ1a-Y5C or HSJ1a-H31Q. Images were taken on a Zeiss LSM 700 
confocal microscope. Scale bar: 10 µm. B: The number of transfected cells containing 
inclusions was counted on a Nikon Eclipse 80i fluorescent light microscope and expressed 
as a percentage of the total number of transfected cells. Error bars represent ± SD (** P 
<0.01, *** P < 0.001 Student’s t-test, n=3).  
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4.2.5 HSJ1a-Y5C retains the ability to interact with LC3 
In the previous Chapter, HSJ1a was shown to co-immunopurify LC3, suggesting a potential 
interaction between the two proteins. As discussed in Chapter 3, it is possible that the 
interaction is direct, mediated by an LC3-interacting region (LIR) in HSJ1. Interestingly, one 
of the eight predicted LIR sequences in HSJ1 encompasses residues 5 to 8 (YXXL) (Figure 
3.13). The Y5C substitution would be predicted to abolish the LIR sequence. To investigate 
whether residue 5 forms an LIR critical for LC3 binding, the ability of HSJ1a-Y5C to co-
immunopurify LC3 was examined. A myc-HSJ1a-Y5C plasmid was generated using site 
directed mutagenesis. SK-N-SH cells were then transfected with GFP-LC3 and either wild-
type myc-HSJ1a (WT) or myc-HSJ1a-Y5C (Y5C). 24 hours post transfection, cell lysates 
were immunopurified with a GFP, myc or IgG antibody. Purifications were then resolved by 
SDS-PAGE and Western blot analysis was performed with a GFP antibody. A 43 kDa band 
corresponding to GFP-LC3 was detected in both GFP and myc purifications (Figure 4.8). No 
band was detected in the IgG purifications, confirming the specificity of the interaction. 
GFP-LC3 was immunopurified in the presence of myc-HSJ1a or myc-HSJ1a-Y5C, 
suggesting that the Y5C substitution does not abolish the observed interaction between 
HSJ1a and LC3. 
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Figure 4.8 HSJ1a-Y5C retains the ability to interact with LC3. SK-N-SH cells were 
transfected with GFP-LC3 and either wild-type myc-HSJ1a (WT) or myc-HSJ1a-Y5C 
(Y5C). 24 hours post transfection, cell lysates were incubated with protein G Dynabeads and 
either a GFP, myc or IgG antibody (1:200). After a one hour incubation on a rotating wheel, 
purified immuno-complexes were resolved by SDS-PAGE and Western blot analysis was 
performed using a mouse monoclonal GFP antibody at a 1:1000 dilution (n=3). 
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4.3 Discussion 
A c.14A>G homozygous variant was identified in HSJ1 in two siblings with autosomal 
recessive CMT2. The mutation, resulting in a Y5C substitution at the protein level, was 
predicted to be disease-causing, however the pathogenicity of the mutation had not been 
confirmed. I sought to determine whether the Y5C substitution was indeed pathogenic.  
The tyrosine residue in question lies in the first α-helix of HSJ1 (Gao et al. 2012). 
Interestingly, the multiple alignment of over 200 J domain sequences revealed that this 
residue in particular is one of a handful of amino acids that shows more than 90% sequence 
conservation across all three classes of DnaJ proteins (Hennessy et al. 2000). Such a high 
degree of sequence conservation indicates that the tyrosine residue is critical to the structure 
or function of the J domain. Based on the structural analysis of E. coli DnaJ, the conserved 
tyrosine residue was predicted to primarily adopt a structural role (Hennessy et al. 2000, 
Hennessy et al. 2005). The tyrosine side chain was found to project outwards from helix I; 
such an orientation was proposed to enable the aromatic ring to interact with residues in 
helix II, III and IV. The formation of inter-helix interactions is likely to be critical for 
ensuring the stability of the J domain structure.  
The increased turnover of HSJ1-Y5C in SK-N-SH cells supports the hypothesis that the 
tyrosine residue is a key mediator of HSJ1 stability. The loss of the aromatic side chain may 
prevent the formation of the inter-helix interactions, destabilising the J domain structure and 
causing the unfolding and subsequent proteasomal degradation of HSJ1. The substitution to 
a cysteine may be particularly deleterious; its small side chain is unlikely to compensate for 
the large aromatic ring of the tyrosine residue. The increased turnover of HSJ1-Y5C results 
in a 37% and 48% decrease in HSJ1a-Y5C and HSJ1b-Y5C protein levels, respectively. As 
heterozygous carriers of the HSJ1 splice site mutations are healthy, with no observable 
phenotype, 50% of HSJ1 protein levels appear to be sufficient for function (Blumen et al. 
2012, Gess et al. 2014). As the reduction in HSJ1-Y5C levels is less than 50%, the reduced 
half-life of HSJ1-Y5C would not be expected to generate a loss of function phenotype. 
Considering the highly conserved nature of the residue and its proposed role in stabilising 
the J domain structure, it is somewhat surprising that the Y5C substitution does not have a 
more prominent effect on HSJ1 protein levels. However, it is possible that the reduction in 
HSJ1-Y5C is underestimated in this overexpression system. The high rate of HSJ1-Y5C 
protein synthesis may exceed the degradative capacity of the proteasome, leading to the 
accumulation of the protein. The observed HSJ1-Y5C protein levels may therefore not 
represent the true extent to which the substitution destabilises the protein. 
Chapter 4 
119 
 
Although the tyrosine residue is predicted to primarily adopt a structural role, it is possible 
that the residue has an indirect functional role, either by ensuring that the J domain is 
correctly orientated to interact with Hsp70 or by stabilising the binding of the two proteins. 
The functional impact of the Y5C substitution on J domain activity was assessed by 
examining the anti-aggregation function of HSJ1a-Y5C. HSJ1a-Y5C retained the ability to 
target misfolded proteins for degradation; however, compared to wild-type HSJ1a, HSJ1a-
Y5C was 39% and 30% less effective at reducing GFP-SOD1 G93A and GFP-Q103 
inclusion incidence, respectively. The 30-40% reduction in functionality correlates with the 
reduction in HSJ1a-Y5C expression levels. Considering that wild-type HSJ1a targets 
misfolded proteins for degradation in a concentration-dependent manner, the reduced ability 
to clear inclusions is likely due to the lower expression levels of HSJ1a-Y5C rather than an 
impairment in J domain activity. The retained functionality of HSJ1a-Y5C is consistent with 
previous mutagenesis studies. Nicoll et al. (2007) sought to examine the functional 
consequences of mutating some of the highly conserved J domain amino acids previously 
identified (Hennessy et al. 2000). The mutations were introduced into a range of chimeric 
proteins, generated by replacing the J domain of DnaJ with mammalian J domains, including 
that of HSJ1. Functionality was then assessed based on the ability to reverse the 
thermosensitivity of the mutant E. coli stain OD259, which lacks dnaJ and cpbA, a 
chaperone gene that can compensate for DnaJ. Tyrosine 5 of HSJ1 was mutated to alanine 
(referred to as Y7A based on the consensus sequence), generating a mutant HSJ1 chimeric 
protein. The mutant protein retained the ability to reverse the thermosensitivity of E. coli 
OD259, indicating that the chimeric HSJ1-Y5A protein was able to compensate for DnaJ 
and stimulate the ATPase activity of DnaK. The tyrosine residue does therefore not appear 
to play a critical role in J domain function, further supporting the hypothesis that the tyrosine 
residue adopts a structural role rather than a functional role.  
Neither the reduction in protein levels nor the accompanied reduction in activity would be 
sufficient to confer a full loss of function phenotype on HSJ1. An alternative mechanism by 
which the Y5C substitution may confer a loss of function phenotype is through the mis-
localisation of the protein, thereby preventing the interaction of HSJ1 with its clients. In SK-
N-SH cells, HSJ1a-Y5C and HSJ1b-Y5C exhibited normal staining patterns, with HSJ1a-
Y5C localised to the cytoplasm and the nucleus and HSJ1b-Y5C localised to the cytoplasmic 
face of the ER. In human retina, endogenous HSJ1a was found to localise to the axons of 
ganglia cells (Chapple and Cheetham 2003). It may therefore be worthwhile to examine the 
axonal localisation of HSJ1a-Y5C in cells that possess neuronal processes, such as NSC34, a 
motor neuron cell line. A loss of axonal localisation could account for the pathogenicity of 
the Y5C substitution. Interestingly, a loss of axonal localisation has been identified as an 
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underlying mechanism of disease pathogenesis in CMT2 caused by mutations in GARS. 
GARS, an essential enzyme that charges tRNA with cognate amino acids, localises to 
punctate structures within axons, enabling local translation (Antonellis et al. 2006). Patient 
mutations in GARS were found to prevent the axonal localisation of the protein when 
expressed in the motor neuron cell line MN-1 (Antonellis et al. 2006, Jordanova et al. 2006). 
The mis-localisation of the protein was proposed to prevent the local translation of axonal 
proteins, resulting in axonal dysfunction. An inability of HSJ1a-Y5C to interact with axonal 
client proteins could be a potential driving force behind axonal degeneration.  
Of course, it is possible that the Y5C substitution impairs an uncharacterised function of 
HSJ1. In Chapter 3, a potential interaction between HSJ1a and LC3 was identified. 
Interestingly, residue 5 of HSJ1 forms a predicted LIR sequence that may mediate the 
binding to LC3. The Y5C substitution was predicted to abolish the LIR, potentially 
preventing the interaction between the two proteins. Although the precise function of HSJ1a 
binding to LC3 is unknown, an inability of HSJ1a to interact with LC3 could impair the 
function of HSJ1. The ability of HSJ1a to co-immunopurify LC3 was therefore assessed. 
HSJ1a-Y5C retained the ability to co-immunopurify LC3. Similar levels of GFP-LC3 co-
immunopurified in the presence of wild-type myc-HSJ1a or myc-HSJ1a-Y5C, suggesting 
that the substitution does not impair the interaction with LC3. Of course, the level of wild-
type and mutant HSJ1 immunopurified would need to be similar in order to support this 
hypothesis; however, the preliminary data does suggest that residue 5 does not form a 
critical LIR that mediates the interaction between HSJ1a and LC3. 
Overall, the findings from this Chapter suggest that the Y5C substitution reduces the half-
life of HSJ1, leading to a reduction in protein levels. However, the reduction in protein 
levels was not sufficient in itself to characterise the Y5C substitution as a pathogenic 
mutation. To determine whether the heterologous expression of HSJ1-Y5C affected the 
protein levels observed, the levels of endogenous HSJ1-Y5C was examined in patient 
fibroblasts. The result of the experiment and further investigations into the pathogenicity of 
the Y5C substitution, using patient fibroblasts as a cell model, are presented in the following 
Chapter. 
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Chapter 5 – Investigating HSJ1-Y5C in patient fibroblasts 
5.1 Introduction 
In the previous Chapter, the heterologous expression of HSJ1-Y5C in SK-N-SH 
neuroblastoma cells demonstrated that the Y5C substitution reduces the half-life of HSJ1, 
leading to a reduction in protein levels. The reduction in protein levels was not sufficient to 
characterise the substitution as a pathogenic loss of function mutation; however, the 
overexpression of HSJ1-Y5C may have led to protein loss being underestimated. I therefore 
aimed to further investigate the potential pathogenicity of the Y5C substitution by 
examining the levels of endogenous HSJ1-Y5C in patient fibroblasts. 
Patient fibroblasts provide an advantage over the plasmid system in that they allow mutant 
proteins to be examined at their endogenous expression level, thereby avoiding artificial 
phenotypes caused by overexpression. Patient fibroblasts are therefore widely used to 
investigate the pathogenicity of novel mutations. They are particularly useful for examining 
mutations that are associated with an autosomal recessive pattern of inheritance, which 
typically confer a loss of function phenotype by significantly reducing the expression level 
of the mutant protein.  
All recessive cases of dHMN and CMT2 identified to date (caused by mutations in 
IGHMBP2, TRIM2, HINT1 and HSJ1) are associated with a loss of protein expression. 
Protein loss can be driven by nonsense-mediated decay (NMD) of the mRNA or post-
translational degradation of the protein, depending on the type of mutation. Patient 
fibroblasts have been successfully utilised to determine the extent of protein loss and the 
mechanism by which protein loss occurs. In the case of IGHMBP2, both mechanisms of 
protein loss have been reported. In one family with CMT2, a homozygous c.449+1G>T 
donor splice site mutation was identified (Schottmann et al. 2015). The loss of the donor 
splice site led to the activation of a downstream cryptic donor splice site at c.449+101, 
resulting in 100 bp of intron 3 being retained in the transcript. The retained sequence 
contained a premature stop codon and the transcript was predicted to undergo NMD as 
neither full length or truncated IGHMBP2 protein was detected in patient fibroblasts 
(Schottmann et al. 2015). In another family with CMT2, the patient was identified as a 
compound heterozygote, with a 5’ c.138T>A mutation and a 3’ frameshift in the last exon of 
the gene (Cottenie et al. 2014). Both wild-type and mutant IGHMBP2 mRNA levels were 
comparable in the patient fibroblasts, indicating that the transcripts were not subject to 
NMD. IGHMBP2 protein levels were reduced by around 70%, implying that the mutant 
protein was being targeted for degradation.  
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In the case of TRIM2, NMD and post-translational degradation were found to operate 
respectively on each allele of the TRIM2 gene. The CMT2 patient was a compound 
heterozygote, with a c.680A>T (E227V) missense mutation and a 1 bp deletion, leading to a 
frameshift with the introduction of a stop codon (c.1699delA, K567RfsX7) (Ylikalio et al. 
2013). Allele specific qPCR using cDNA from patient fibroblasts revealed that cDNA 
derived from the deletion allele was only 7% of total TRIM2 cDNA, suggesting degradation 
through NMD. The TRIM2 cDNA in the patient fibroblasts therefore originated almost 
completely from the c.680A>T allele. Western blot analysis revealed that the fibroblasts 
were almost completely devoid of TRIM2 protein, with protein levels around 10% of control 
cells, indicating post-translational degradation of TRIM2 E227V.  
In contrast to IGHMBP2 and TRIM2 mutations, all mutations identified in HINT1 to date are 
missense mutations that cause the post-translational degradation of the protein (Zimon et al. 
2012). qPCR using cDNA from 8 different patient lymphoblast cell lines revealed normal 
HINT1 mRNA levels, however negligible HINT1 proteins levels were detected. The 
treatment of patient lymphoblast cells with the proteasome inhibitor MG132 resulted in the 
accumulation of HINT1, confirming the degradation of the protein. 
With respect to the two HSJ1 splice site mutations, protein loss is likely to be driven by 
NMD, due to the inclusion of a premature stop codon in the transcript. Importantly, Blumen 
et al. (2012) and Gess et al. (2014) confirmed the presence of both HSJ1 isoforms in 
fibroblasts, enabling the pathogenicity of the two splice site mutations to be investigated. 
The expression of HSJ1 in fibroblasts and the previous cases whereby patient fibroblasts 
have been successfully utilised to examine recessively inherited mutations, suggests that 
patient fibroblasts could serve as a useful cellular model for investigating the pathogenicity 
of the Y5C substitution. The stability of endogenous HSJ1-Y5C was therefore examined in 
patient fibroblasts and the extent of protein loss was determined. Once altered HSJ1 
expression was confirmed, I utilised the fibroblasts as a cellular model to study how the loss 
of HSJ1 protein might cause cellular dysfunction. 
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5.2 Results 
5.2.1 HSJ1 levels are reduced in patient fibroblasts 
The level of endogenous HSJ1 was examined in control and patient fibroblasts by Western 
blot analysis (Figure 5.1A). In control fibroblasts, both HSJ1a and HSJ1b bands were 
detected, at the expected size of 36 kDa and 42 kDa, respectively. HSJ1b was expressed at a 
higher level than HSJ1a, as previously reported (Blumen et al. 2012, Gess et al. 2014). In 
contrast to the control fibroblasts, patient fibroblasts showed a 95% reduction in HSJ1b 
levels, with no detectable levels of HSJ1a (Figure 5.1B). A loss of HSJ1 protein was also 
confirmed by immunocytochemistry. Control fibroblasts showed a modest 
immunofluorescent staining intensity for HSJ1, whereas HSJ1 staining was barely detectable 
in the patient fibroblasts (Figure 5.1C).  
A loss of HSJ1 protein could be mediated at the mRNA or protein level. To distinguish 
between these possibilities, the effect of the c.14A>G Y5C substitution on the splicing and 
level of the HSJ1 transcript was investigated. RNA was extracted from both control and 
patient fibroblasts and was reverse transcribed to cDNA. PCR of the cDNA was performed 
using primers in exon 1 and 4 of the HSJ1 transcript, covering the c.14A>G substitution 
which lies in exon 2. Both control and patient samples showed a band at the expected size of 
400 bp (Figure 5.2A). No other bands were present, suggesting that the c.14A>G 
substitution does not lead to a mis-splicing event in exons 1-4. HSJ1 transcript levels were 
also compared by qPCR using control and patient cDNA. No significant difference was 
observed in the levels of HSJ1 transcript (Figure 5.2B); therefore the loss of HSJ1 is likely 
to be mediated post-translationally. 
To examine if HSJ1-Y5C is degraded by autophagy or the proteasome, control and patient 
fibroblasts were treated for 7 hours with 200 nM bafilomycin, to inhibit autophagy, or 50 
µM MG132, to inhibit the proteasome. In the control fibroblasts, both HSJ1a and HSJ1b 
showed no change in protein levels over the 7 hour period, establishing that both 
endogenous HSJ1 isoforms are stable proteins with long half-lives (Figure 5.3), as observed 
with the heterologous protein (Chapter 4). In the patient fibroblasts, the levels of HSJ1b-
Y5C increased 3 fold in the presence of MG132. HSJ1a-Y5C was not detectable in either 
untreated or treated samples. The data correlates with the observations made using the HSJ1-
Y5C plasmids and establishes that endogenous HSJ1-Y5C is degraded by the proteasome. 
The Y5C substitution therefore reduces the half-life of HSJ1 protein such that only 5% 
remains in patient fibroblasts. 
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Figure 5.1 Patient fibroblasts show reduced expression of HSJ1. A: Control and patient 
fibroblasts were lysed and 40 µg of total protein was resolved by SDS-PAGE. Western blot 
analysis was performed using a polyclonal sheep HSJ1 antibody (1:1000) and a monoclonal 
β-tubulin antibody (1:5000). B: Western blots of HSJ1 and β-tubulin were analysed using 
ImageJ. The level of HSJ1b was corrected for loading using β-tubulin and normalised to the 
control sample. Error bars represent ± SD. (*** P < 0.001, Student’s t-test, n=3). C: Control 
and patient fibroblasts were fixed in 4% PFA and permeabilised in 0.2% Triton-X. Cells 
were immunostained with sheep HSJ1 antibody (1:200), (Cy2 green) and DAPI. Cells were 
imaged using a Zeiss LSM 700 confocal microscope. Scale bar: 40 µm (n=3). 
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Figure 5.2 Patient fibroblasts show no defect in HSJ1 splicing and have similar levels of 
HSJ1 mRNA compared to control fibroblasts. A: RT-PCR of control and patient cDNA 
using primers in exons 1 and exons 4 of the HSJ1 gene. Both the control and patient show a 
band at the expected size of 400 bp. B: qPCR of control and patient cDNA using primers in 
exon 5 of the HSJ1 gene. The ribosomal housekeeping gene RPL19 was used as an internal 
reference. Error bars represent ± SD (N.S Student’s t-test, n=3). 
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Figure 5.3 HSJ1-Y5C is degraded via the proteasome. A: Control and patient fibroblasts 
were untreated or treated for 7 hours with 200 nM bafilomycin or 50 µM MG132. Cells were 
then harvested and 40 µg of total protein was resolved by SDS-PAGE. Western blot analysis 
was performed using a polyclonal sheep HSJ1 antibody (1:1000) and a monoclonal β-tubulin 
antibody (1:5000). B: Western blots were analysed by ImageJ. The level of HSJ1a and 
HSJ1b in the control fibroblasts was corrected for loading and normalised to the untreated 
HSJ1b sample. Error bars represent ± SD (N.S, Student’s t-test, n=3) C: The level of HSJ1b-
Y5C in the patient fibroblasts was corrected for loading and normalised to the untreated 
HSJ1b-Y5C sample. Error bars represent ± SD (*** P < 0.001, Student’s t-test, n=3). 
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5.2.2 Investigating the effect of the loss of HSJ1 on proteostasis in patient fibroblasts 
Having established the Y5C substitution as a pathogenic loss of function mutation, I next 
sought to investigate whether the loss of HSJ1 affected the cellular function of the 
fibroblasts. I initially examined whether the loss of HSJ1 had any effect on proteostasis. 
Impaired proteostasis typically leads to the accumulation of misfolded proteins. These 
proteins are often ubiquitylated; therefore the levels of ubiquitylated protein can be used as a 
measure of the amount of misfolded protein present in the fibroblasts. Control and patient 
fibroblasts were either untreated or treated for 4 hours with the proteasome inhibitor 
MG132. Cell lysates were then analysed by Western blot and probed for polyubiquitin 
(Figure 5.4A). In the untreated control fibroblasts, a smear of high molecular weight 
ubiquitin immunoreactive species was observed, ranging in size from 60 kDa to 250 kDa. In 
the presence of MG132, the relative expression of ubiquitylated protein increased 2.7 fold 
(Figure 5.4B). There was no significant difference in the levels of ubiquitylated proteins in 
the untreated patient fibroblast sample. However, in the presence of MG132, the patient 
fibroblasts only displayed a 1.8 fold increase in ubiquitylated protein levels compared to the 
2.7 fold increase observed for the control fibroblasts. 
The activity of the proteasome contributes to the levels of ubiquitylated protein present in 
the cell; therefore the proteasome activity of control and patient fibroblasts was examined. 
Proteasome activity was assessed using an AMC tagged peptide substrate. Upon cleavage by 
the chymotrypsin-like activity of the proteasome, free AMC fluoresces, providing a direct 
measure of activity. Control and patient fibroblast lysates were incubated for 1 hour with the 
fluorogenic substrate. Fluorescent intensity was measured using a spectrofluorometer and 
the results were normalised to the control fibroblasts (Figure 5.5). The patient fibroblasts 
showed a significant 50% lower proteasome activity compared to control fibroblasts. The 
lower proteasome activity is likely to account for the smaller increase observed in 
ubiquitylation levels in patient fibroblasts in the presence of MG132.  
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Figure 5.4 A comparison of the levels of ubiquitylated protein in control and patient 
fibroblasts. A: Control and patient fibroblasts were untreated or treated for 4 hours with 50 
µM MG132. Cells were then harvested and 30 µg of total protein was resolved by SDS-
PAGE. Membranes were boiled for 30 minutes after transfer then probed using a polyclonal 
rabbit ubiquitin antibody (1:1000) and a monoclonal β-tubulin antibody (1:5000). B: Blots 
were analysed using ImageJ. The level of ubiquitin species was corrected for loading using 
β-tubulin and normalised to the untreated control sample. Error bars represent ± SD. (* P < 
0.05, Student’s t-test, n=3). 
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Figure 5.5 Patient fibroblasts have a lower proteasome activity compared to control 
fibroblasts. 20 µg of cell lysate from control and patient fibroblasts was incubated for 1 
hour at 37 °C with 10 µM of the fluorogenic substrate AMC-LLVY. Fluorescence was then 
measured using a spectrofluorometer using an excitation of 380 nm and emission at 460 nm. 
Background readings were subtracted and the results were normalised to the activity of the 
control fibroblasts. Error bars represent ± SD. (* P < 0.05, Student’s t-test, n=3). 
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5.2.3 Optimising the knockdown of HSJ1 in control fibroblasts 
To establish if the reduced proteasome activity was due to the loss of HSJ1, I aimed to 
knockdown HSJ1 expression in the control fibroblasts to test if this could replicate the 
phenotype of the patient fibroblasts. To knockdown HSJ1, an adeno-associated virus (AAV) 
containing shRNA against HSJ1 was utilised (provided by Professor James Uney, University 
of Bristol). To determine the amount of virus particles required to sufficiently knockdown 
HSJ1, increasing amounts of virus particles per cell (the multiplicity of infection, MOI) were 
added to the control fibroblasts. 48 hours post infection, cells were harvested, lysed and 
proteins resolved by SDS-PAGE. The levels of HSJ1 were then determined by Western blot 
analysis, with protein levels normalised to the untreated sample (Figure 5.6A). MOIs of 5 
and 10 had no significant effect on the levels of HSJ1b. An MOI of 20 lead to a 21% 
reduction in HSJ1b levels, with an MOI of 50 resulting in a 43% reduction in protein levels 
(Figure 5.6B). Increasing the MOI further to 75 or 100 had no effect on HSJ1b levels. 
Endogenous HSJ1 levels were established to be stable over a 7 hour period, as demonstrated 
in Figure 5.3. HSJ1 exhibits a long half-life; therefore the cells may require a longer 
incubation time to turnover HSJ1 and increase the level of knockdown. The two most 
effective MOIs, 20 and 50, were used to infect control fibroblasts and this time the 
incubation period was increased from 48 to 72 hours. HSJ1 levels were then determined by 
Western blot analysis (Figure 5.6C). The levels of HSJ1b correlated with the levels observed 
after a 48 hour incubation. The MOI of 20 and 50 reduced HSJ1b levels by 11% and 48%, 
respectively (Figure 5.6D). Therefore, increasing the incubation period did not improve on 
the level of HSJ1 knockdown. 
5.2.4 Optimising the restoration of HSJ1 in patient fibroblasts 
The knockdown of HSJ1 in control fibroblasts was not sufficient to effectively model the 
effect of the Y5C mutation (43% vs 95%); therefore an alternative approach to confirming 
whether proteasome activity is affected by the loss of HSJ1 was adopted. Proteasome 
activity would be analysed upon restoration of HSJ1 levels in the patient fibroblasts. To 
restore HSJ1 to its endogenous level, AAV expressing either HSJ1a or HSJ1b were utilised 
(provided by Professor James Uney, University of Bristol). Patient fibroblasts were infected 
with either the HSJ1a or HSJ1b virus at MOIs of 2, 5, 10 and 20. 48 hours after transduction, 
HSJ1 protein levels were determined by Western blot analysis and the level of HSJ1 protein 
was compared to the control fibroblasts. All four MOIs used for the HSJ1a virus resulted in 
high expression levels of HSJ1a, with the levels of HSJ1a increasing with an increasing MOI 
(Figure 5.7A). An MOI lower than 2 was therefore required to reach the levels of HSJ1a 
observed in the control fibroblasts. Patient fibroblasts were therefore infected with HSJ1a 
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virus at the lower MOIs of 1, 0.8, 0.6, 0.4 or 0.2. 48 hours post infection, HSJ1a levels were 
analysed by Western blot (Figure 5.7B). An MOI of 0.4 appeared to generate comparable 
HSJ1a levels with the control fibroblasts. For HSJ1b, an MOI of 5 appeared to correspond 
with the levels of endogenous HSJ1b in the control fibroblasts. 
Although the required MOIs to match endogenous level had been determined, it was 
important to establish the transduction efficiencies at these MOIs to ascertain whether all 
cells were expressing similar levels of HSJ1. Patient fibroblasts transduced with HSJ1a at 
MOIs of 1, 0.8, 0.6, 0.4 and 0.2, or HSJ1b at MOIs of 20, 10, 5 and 2, were fixed in 4% PFA 
48 hours post infection. Cells were stained for HSJ1 and DAPI and the number of 
transduced cells was calculated and expressed as a percentage of the total number of cells 
(Figure 5.7C). The transduction efficiency for HSJ1b was above 80% for all four MOIs. In 
contrast, the transduction efficiency for HSJ1a dropped with decreasing MOI. An MOI of 1, 
0.8 and 0.6 displayed transduction efficiencies of 87%, 89% and 82% respectively. An MOI 
of 0.4 reduced the transduction efficiency to 51%, with an MOI of 0.2 reducing transduction 
efficiency even further, to 26%. Taking into account expression levels and transduction 
efficiency an MOI of 0.6 for HSJ1a and 5 for HSJ1b would be used in further experiments 
as this represented the best compromise for matching the level of HSJ1 in the majority of 
cells (Figure 5.8). 
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Figure 5.6 Optimising the knockdown of HSJ1 in control fibroblasts. A: Control 
fibroblasts were infected with an AAV containing shRNA against HSJ1 at increasing MOIs 
of 5, 10, 20, 50, 75 and 100. 48 hours post infection, 30 µg of total cell lysates were resolved 
by SDS-PAGE. Western blot analysis was performed using a polyclonal sheep HSJ1 
antibody (1:1000) and a monoclonal β-tubulin antibody (1:5000). B: Western blots were 
analysed using ImageJ. The level of HSJ1b was corrected for loading using β-tubulin and 
normalised to the untreated sample. The graph shows an n of 1. C: Control fibroblasts were 
infected with the virus at an MOI of 20 or 50 and incubated for 72 hours. 30 µg of total cell 
lysates were then resolved by SDS-PAGE and analysed by Western blot and as described 
above. D: Graph shows normalised HSJ1b levels (n=1). 
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Figure 5.7 Optimising the rescue of HSJ1 levels in patient fibroblasts. A: Patient 
fibroblasts were infected with a virus containing either HSJ1a or HSJ1b at MOIs of 2, 5, 10 
and 20. 48 hours post infection, 40 µg of total cell lysate was resolved by SDS-PAGE along 
with 40 µg of total cell lysate from untreated control fibroblasts (C). Membranes were 
probed for HSJ1 (1:1000) and β-tubulin (1:5000). B: Patient fibroblasts were infected with 
the HSJ1a virus at MOIs of 0.2, 0.4, 0.6, 0.8 and 1. 48 hours post infection, 40 µg of total 
cell lysate was resolved by SDS-PAGE along with 40 µg of total cell lysate from untreated 
control fibroblasts (C). Membranes were probed for HSJ1 (1:1000) and β-tubulin (1:5000). 
C: Patient fibroblasts were infected with the HSJ1b virus at MOIs of 20, 10, 5 and 2, or the 
HSJ1a virus at MOIs of 1, 0.8, 0.6, 0.4 and 0.2. 48 hours post transduction, cells were fixed 
in 4% PFA and stained for HSJ1 and DAPI. Transduction efficiency was calculated by 
counting the number of total cells and the number of transduced cells. The graph shows 
transduction efficiency ± SD (n=3). 
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Figure 5.8 Optimised restoration of endogenous levels of HSJ1 in patient fibroblasts. 
A: Patient fibroblasts were infected with HSJ1a virus at an MOI of 0.6, or HSJ1b virus at an 
MOI of 5. One sample was infected with both viruses. 48 hours post transfection, 40 µg of 
cell lysate was resolved by SDS-PAGE, alongside 40 µg of cell lysate from untreated control 
fibroblasts. Western blots were probed using a polyclonal sheep HSJ1 antibody (1:1000) and 
a monoclonal mouse β-tubulin antibody (1:5000). B: Patient fibroblasts were untreated or 
infected with HSJ1a virus at an MOI of 0.6, or HSJ1b virus at an MOI of 5. One sample was 
infected with both viruses. 48 hours post infection, cells were fixed in 4% PFA and stained 
for HSJ1 (1:200) (Cy2 green) and DAPI (blue). Representative images were captured on a 
Zeiss LSM 700 confocal microscope. Scale bar: 40 µm (n=3). 
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5.2.5 The lower proteasome activity observed in patient fibroblasts is independent of 
the loss of HSJ1 
To determine if the reduction in proteasome activity was due to a loss of HSJ1, the effect of 
restoring HSJ1 on proteasome activity was assessed. Patient fibroblasts were either 
untransduced, or transduced with HSJ1a, HSJ1b or both isoforms. 48 hours post 
transduction, cells were harvested and cell lysates were incubated for 1 hour with the 
flurogenic substrate AMC-LLVY. Fluorescent intensity was measured using a 
spectrofluorometer and the results were normalised to the untransduced patient fibroblast 
sample. The patient fibroblasts transduced with HSJ1 showed no significant difference in 
proteasome activity compared to the untransduced patient fibroblasts (Figure 5.9). 
Therefore, the loss of HSJ1 does not appear to account for the lower proteasome activity in 
the patient fibroblasts compared to the control fibroblasts.  
The difference in proteasome activity between the two fibroblast lines makes it difficult to 
meaningfully compare the levels of ubiquitylated protein. Therefore in this instance, the 
effect of the loss of HSJ1 on ubiquitylated protein levels cannot be simply determined by a 
comparison with the control fibroblasts. Instead, the effect of restoring HSJ1 on 
ubiquitylated protein levels was examined. Patient fibroblasts were untransduced or 
transduced with HSJ1a, HSJ1b or both. 48 hours post transfection, cells were harvested and 
protein lysates were analysed by Western blot. Restoring HSJ1a had no significant effect on 
the levels of ubiquitylated protein (Figure 5.10). However, restoring HSJ1b resulted in a 
significant 1.9 fold increase in protein ubiquitylation. A 1.5 fold increase in protein 
ubiquitylation was observed in the presence of both isoforms, although this increase did not 
reach significance. 
  
Chapter 5  
136 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.9 The restoration of HSJ1 in patient fibroblasts has no effect on proteasome 
activity. Patient fibroblasts were untransduced or transduced with the HSJ1a virus, HSJ1b 
virus or both. 48 hours post infection, 20 µg of cell lysate was incubated for 1 hour at 37 °C 
with 10 µM of the fluorogenic substrate AMC-LLVY. Fluorescence was then measured 
using a spectrofluorometer using an excitation of 380 nm and emission at 460 nm. 
Background readings were subtracted and the results were normalised to the activity of the 
untreated patient fibroblasts. Error bars represent ± SD (N.S, one-way ANOVA, n=3). 
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Figure 5.10 The restoration of HSJ1b in patient fibroblasts increases the level of 
ubiquitylated protein. A: Patient fibroblasts were untransduced or transduced with the 
HSJ1a or HSJ1b virus or both. 48 hours post infection, cells were harvested and 40 µg of 
total protein was resolved by SDS-PAGE. Membranes were boiled for 30 minutes after 
transfer then probed using a polyclonal rabbit ubiquitin antibody (1:1000) and a monoclonal 
β-tubulin antibody (1:5000). B: Blots were analysed by ImageJ. The level of ubiquitin 
species was corrected for β-tubulin and normalised to the untreated patient sample. Error 
bars represent ± SD. (* P < 0.05, one-way ANOVA with post hoc Tukey test, n=3). 
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5.2.6 The loss of HSJ1 does not activate the UPR in patient fibroblasts 
The impairment of ERAD has been established to cause ER stress, resulting in the activation 
of the UPR. I aimed to examine the levels of UPR markers in control and patient fibroblasts 
in order to determine whether the loss of HSJ1b has any effect on the ERAD process. Cell 
lysates from control and patient fibroblasts were resolved by SDS-PAGE. Western blot 
analysis was performed using markers from all three branches of the UPR. The expression 
levels of IRE1, ATF6 and BiP were used to examine the IRE1 and ATF6 branches. 
Phosphorylated eIF2α and total eIF2α levels were used to examine the activation of the 
PERK branch.  The control and patient fibroblasts showed no significant difference in the 
expression of UPR markers across all three branches (Figure 5.11). The UPR does therefore 
not appear to be activated in the HSJ1-Y5C patient fibroblasts. 
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Figure 5.11 Control and patient fibroblasts show no difference in the expression levels 
of UPR markers. A: 30 µg of total cell lysate from control and patient fibroblasts was 
resolved by SDS-PAGE. Western blot analysis was performed using BiP, IRE1, eIF2α, 
eIF2α-P and ATF6 antibodies. All were polyclonal rabbit antibodies and used at a dilution of 
1:1000. Mouse monoclonal β-tubulin was used as a loading control (1:5000). B: Western 
blots were analysed by ImageJ. The level of UPR marker was corrected for β-tubulin and 
normalised to the control fibroblasts. Error bars represent ± SD (N.S Student’s t-test, n=4). 
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5.3 Discussion 
The characterisation of heterologous HSJ1-Y5C expression described in Chapter 4 
suggested that the Y5C substitution reduces the half-life of HSJ1, leading to a reduction in 
protein levels. The reduction in protein levels was less than 50%, therefore the Y5C 
substitution could not be characterised as a disease-causing mutation based on the plasmid 
data alone. I aimed to further investigate the potential pathogenicity of the Y5C substitution 
by examining the levels of endogenous HSJ1 in fibroblasts from one of the affected siblings. 
When compared to healthy control fibroblasts, patient fibroblasts showed a 95% reduction in 
HSJ1b levels, with no detectable HSJ1a. The reduction in HSJ1 was mediated by the 
proteasomal degradation of the protein, implying that the Y5C substitution reduces the half-
life of HSJ1. This finding is consistent with the observations made in the previous chapter. 
Although both cell models identify the same mechanism underlying the reduction in protein 
levels, there is a disparity in the extent of the reduction. This disparity is likely due to 
differences in the rate of transcription. The overexpression of HSJ1-Y5C in SK-N-SH cells 
likely far exceeds the rate at which the protein can be degraded. The imbalance between 
protein synthesis and degradation is likely to cause HSJ1-Y5C to accumulate; the system 
would thereby underestimate the extent by which the Y5C substitution reduces the half-life 
of HSJ1.  
Utilising the patient fibroblasts as a cellular model suggests that the Y5C substitution is 
indeed a disease-causing loss of function mutation. However, considering that only one 
control line and one patient line were used in this study, the results can only strongly 
support, not confirm, the pathogenicity of the Y5C substitution. It will be important to 
examine HSJ1 levels in multiple control lines and in patient fibroblasts from the second 
sibling, in order to confirm that the loss of HSJ1 is a valid phenotype of the Y5C 
substitution. Having supported the pathogenicity of the Y5C substitution, the three mutations 
identified in HSJ1 to date can now be compared. It is interesting to note that the splice site 
mutations cause dHMN, whereas the missense mutation causes CMT2 (Blumen et al. 2012, 
Gess et al. 2014). It may be speculated that the difference in mutation accounts for the 
different clinical phenotypes, however; considering the small sample size this speculation 
may be somewhat premature. Also, in the case of HSPB1, HSPB8 and BSCL2, missense 
mutations have been identified to cause both dHMN and CMT2 (Irobi et al. 2004, Houlden 
et al. 2008, Ikeda et al. 2009, Evgrafov et al. 2012, Jerath et al. 2015). The identification of 
more mutations in HSJ1 will clarify whether there is indeed any link between the type of 
mutation and the clinical presentation of the disease. 
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It is interesting to compare the extent of HSJ1 protein loss in the three fibroblast cell lines. 
The low expression of HSJ1a in fibroblasts resulted in HSJ1a levels being below the limits 
of detection in all three patient fibroblasts lines, therefore any difference in the remaining 
HSJ1a levels cannot be ascertained. However, the remaining levels of HSJ1b can be 
compared, with reported HSJ1b levels varying between patient mutations. The c.229+1G>A 
splice site mutation resulted in no detectable levels of HSJ1b (Gess et al. 2014), whereas the 
c.352+1G>A splice site mutation lead to a partial loss of HSJ1b, although this reduction was 
not quantified (Blumen et al. 2012). The Y5C mutation resulted in a 95% reduction in 
HSJ1b levels. The extent of HSJ1 protein loss did not appear to affect the disease phenotype 
at the time of examination; patients from all three families presented with similar clinical 
features and ages of disease onset (Table 4.1). However, an important caveat that needs to be 
considered when comparing the levels of remaining HSJ1 protein is that different antibodies 
were used to detect HSJ1. The commercial antibody used by Blumen et al. and Gess et al. 
generated a signal in Hsj1
-/-
 spinal cords, suggesting that the antibody may detect another 
protein in addition to HSJ1 (Dr Sergey Novoselov, personal communications). It would 
therefore be interesting to examine the levels of HSJ1 in the two other patient fibroblast lines 
using the HSJ1 S653 antibody used in this study. If differences in the remaining HSJ1 
protein levels were detected between the three patient fibroblast lines, it would be interesting 
to investigate whether the different levels of remaining HSJ1 protein had any effect on the 
progression of the disease or indeed the severity of the disease. Detailed clinical follow up 
examinations of patients from all three families could provide important insights into the 
pathological consequences of varying HSJ1 levels.  
All three mutations are loss of function mutations; therefore HSJ1 function is clearly 
important for motor neuron survival. I aimed to investigate how the loss of HSJ1 leads to 
degeneration using the Y5C patient fibroblasts as a cellular model. I initially examined if the 
loss of HSJ1 chaperone activity had any effect on proteostasis by examining the levels of 
ubiquitylated protein. Control and patient fibroblasts exhibited similar levels of ubiquitylated 
protein under basal conditions. However, in the presence of MG132, patient fibroblasts 
showed a smaller accumulation of ubiquitylated protein. Proteasome activity was markedly 
reduced in patient fibroblasts, likely accounting for the lower accumulation of ubiquitylated 
protein upon proteasome inhibition. Unfortunately, the difference in proteasome activity in 
control and patient fibroblasts makes it difficult to compare the levels of ubiquitylated 
protein under basal conditions. The restoration of HSJ1 levels in the patient fibroblasts did 
not rescue proteasome activity, suggesting that the lower proteasome activity was 
independent of the loss of HSJ1. The activity of the proteasome is affected by aging. The 
comparison of fibroblasts from healthy individuals ranging in age from 20-82 years old 
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revealed a significant decrease in proteasome activity up to 50 years of age (Hwang et al. 
2007). The reduction in proteasome activity correlated with a decrease in the expression of 
proteasome subunits. The control fibroblasts were from an adult donor of unknown age, 
whereas the patient fibroblasts were from a 38 year old. A difference in age could therefore 
potentially account for the lower activity observed in the patient fibroblasts. Further 
investigations into how the loss of HSJ1 affects proteostasis in patient fibroblasts may 
therefore require the use of age-matched controls, in order to control for variability in 
proteasome activity.  
Factors such as age and gender could result in control and patient fibroblasts having 
substantially different phenotypes in addition to different genetic backgrounds. Such 
differences are likely to cause confounding effects and may lead to misleading phenotypic 
differences that are not associated with the disease-causing mutation. In order to avoid such 
confounding effects the generation of isogenic controls should be considered. Any observed 
phenotypic differences between the control and patient lines could then be fully attributed to 
the mutation. The generation of isogenic controls would require the correction of the 
c.14A>G substitution in patient fibroblasts. This could be achieved by targeted genome 
editing, a process that relies on the introduction of double-strand breaks at specific genomic 
loci and subsequent correction of the sequence. Double-strand breaks are generated using 
engineered nucleases such as zinc-finger nucleases (ZFN) and transcription activator-like 
effector nucleases (TALENs) (Bibikova et al. 2003, Christian et al. 2010). Both ZFN and 
TALENs consist of a DNA binding domain and a nuclease domain. The DNA binding 
domain can be designed specifically to bind to the required genomic sequence, targeting the 
action of the nuclease to the required location. ZFN and TALENs are usually delivered in 
AAVs along with single-strand DNA oligonucleotides that act as the correction template. 
Recently, clustered, regularly interspaced, short palindromic repeat system (CRISPR) 
technology has proved to be an easy and simple alternative to the use of ZFN and TALENs 
(Mali et al. 2013, Kim et al. 2014). Cells are transfected with vectors that encode the 
components required for CRISPR gene editing. The two components are Cas9, which cuts 
the DNA, and guide RNA, that directs Cas9 to the specific location where the break is to be 
made. Endogenous repair mechanisms then correct the sequence. The correction of the 
c.14A>G patient mutation using CRISPR technology would provide the most appropriate 
control to use in future investigations.  
The restoration of HSJ1b in patient fibroblasts led to an increase in ubiquitylated protein. 
This result was somewhat expected, considering that the overexpression of HSJ1 has been 
previously shown to increase ubiquitylated protein levels (Westhoff et al. 2005, Howarth et 
al. 2007). Considering the role of HSJ1b in ERAD, two explanations for a possible reduction 
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in protein ubiquitylation in the absence of the protein may be hypothesised. Firstly, the loss 
of HSJ1b may favour the deubiquitylation of ERAD substrates by deubiquitinases (DUBs). 
Secondly, the loss of HSJ1b may prevent the targeting of client substrates for ubiquitylation 
and subsequent degradation. During ERAD, the substrate is retrotranslocated across the ER 
membrane to the cytoplasm (Brodsky 2012). As the substrate emerges on the cytosolic side, 
the substrate is ubiquitylated by a membrane-associated E3 ubiquitin ligase. In addition to 
acting as a signal to target the substrate for degradation, the ubiquitin modification also 
enables the engagement of the AAA ATPase VCP (Ye et al. 2001, Flierman et al. 2003). 
The ATPase activity of VCP provides the driving force to extract the ubiquitylated protein 
from the membrane (Ye et al. 2003). It is possible that HSJ1b utilises its client binding 
domain and UIMs to hold the ubiquitylated substrate after its release from the membrane. 
The ubiquitylated substrate can then be transferred to chaperones that transport the substrate 
to the proteasome for degradation. The binding of the UIMs may protect the ubiquitin chains 
from promiscuous DUB activity, many of which reside at the cytoplasmic face of the ER 
(Westhoff et al. 2005, Reyes-Turcu et al. 2009). Although their role in ERAD remains to be 
fully characterised, it is hypothesised that the action of DUBs allows remodelling of the 
ubiquitin chains (Liu et al. 2012). The remodelling of the ubiquitin chains is proposed to 
enable the selective recognition of the ubiquitylated substrate by the appropriate chaperone 
or shuttle factor. A loss of HSJ1b protein may therefore result in an increase in 
deubiquitylation, possibly preventing the recognition of the substrate by its interacting 
protein. The targeting of the substrate to the proteasome may therefore become inefficient, 
leading to an accumulation of misfolded protein. The restoration of HSJ1b could combat the 
counterproductive deubiquitylation of substrates, leading to an increase in protein 
ubiquitylation.  
Alternatively, it may be speculated that an increase in ubiquitylation levels upon the 
restoration of HSJ1b suggests that the targeting of clients for ERAD may be impaired in the 
absence of the protein. HSJ1b can target CFTR and MC4R for proteasomal degradation 
(Westhoff et al. 2005, Meimaridou et al. 2011). Another DnaJ protein, DnaJB12, localises to 
the cytoplasmic face of the ER and was also shown to target CFTR for ERAD (Grove et al. 
2012). Importantly, the effect of DnaJB12 depletion on CFTR degradation was also 
investigated (Grove et al. 2012). The knockdown of DnaJB12 by siRNA increased the half-
life of CFTR, with an increase in the amount of plasma membrane localised CFTR. The 
depletion of DnaJB12 also increased the half-life of the mutant and permitted a small pool of 
CFTR∆F508 to escape from the ER. The data suggested that in the absence of DnaJB12, 
CFTR is partitioned into a folding pathway rather than a degradation pathway. A similar 
scenario may be occurring with HSJ1b. HSJ1b may target clients for ERAD. In the absence 
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of HSJ1b, the clients may be re-directed onto a folding pathway or could possibly be 
retained in the ER membrane. The restoration of HSJ1b would allow ERAD of the client to 
proceed, thereby promoting the ubiquitylation of the client and accounting for the increase in 
ubiquitylated protein levels. It would be interesting to determine whether the increase in 
ubiquitylation is driven by the ubiquitylation of a single substrate or group of proteins. The 
immunoprecipitation and subsequent mass spectrometry of ubiquitylated protein in the 
absence and presence of HSJ1b could enable HSJ1b ERAD clients to be identified. 
Overall, examining if the loss of HSJ1 had any effect on proteostasis in patient fibroblasts 
has provided limited findings. The increase in protein ubiquitylation upon the restoration of 
HSJ1b suggests a possible impairment in the ubiquitylation and degradation of HSJ1b 
clients. The restoration of HSJ1a had no effect on protein ubiquitylation levels. However, 
the possible accumulation of HSJ1a clients in the absence of the protein cannot be ruled out. 
Endogenous HSJ1a levels in fibroblasts were lower than HSJ1b levels, as seen previously in 
both human and mouse brain and spinal cord tissue (Chapple and Cheetham 2003, 
Novoselov et al. 2013). The lower expression may result in a longer time period being 
required to restore the ubiquitylation of HSJ1a clients. It will be important to establish 
whether a reduction in protein ubiquitylation is indeed a valid phenotype of patient 
fibroblasts or whether the observation is an artefact of restoring HSJ1. Although further 
investigations using patient fibroblasts may be useful for dissecting how the loss of HSJ1 
chaperone activity impacts proteostasis it is important to consider the possibility that 
fibroblasts may not express HSJ1 client proteins. The loss of HSJ1 leads to the selective 
degeneration of motor neurons; therefore HSJ1 clients may only be expressed in motor 
neurons, or alternatively, may be expressed at higher levels. For example, nerve biopsies 
from patients with TRIM2 mutations revealed the accumulation of NFL in axons (Ylikalio et 
al. 2013). NFL is a client of the TRIM2 E3 ubiquitin ligase, however NFL is not expressed 
in fibroblasts and mutant TRIM2 was found to have no effect on other intermediate 
filaments (Ylikalio et al. 2013). The fibroblasts therefore did not provide an accurate 
representation of the phenotype occurring in affected neurons. Differences in gene 
expression between skin fibroblasts and motor neurons is a caveat that may limit the 
successful modelling of disease in a fibroblast model. 
The validity of using fibroblasts as a cellular model to study neuronal diseases has indeed 
been questioned. Skin cells and neurons exhibit stark differences in architecture, function 
and gene expression. Cellular phenotypes observed in patient fibroblasts may therefore not 
represent the phenotype of the affected neurons. The ability to model disease in a relevant 
cell type has been revolutionised by the generation of induced pluripotent stem cells (iPSC) 
from patient fibroblasts (Takahashi et al. 2007). The transfection of patient fibroblasts with 
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the transcription factors Oct4, Sox2, c-Myc and Klf4 induces their reprogramming to a 
pluripotent state. The resulting iPSC have the capacity for self-renewal and can differentiate 
into all 3 embryonic germ layers. Motor neurons derived from iPSC have been established to 
possess many of the cellular and physiological characteristics of endogenous motor neurons, 
making them an excellent cellular model for studying motor neuron degeneration (Toma et 
al. 2015). iPSC-derived motor neurons have provided novel insights into disease 
pathogenesis, identifying abnormalities in electrophysiological properties as early events in 
both familial ALS and CMT2 (Devlin et al. 2015, Saporta et al. 2015). Motor neurons 
derived from patients with ALS and CMT2 both displayed hyperexcitability, followed by a 
progressive loss of action potential output and synaptic activity. A progressive decrease in 
voltage activated sodium and potassium currents was identified; implying that early 
dysfunction of ion channel activity may initiate the degenerative pathway. The generation of 
iPSC-derived motor neurons would provide a more physiologically relevant cellular model 
to probe how the loss of HSJ1 causes degeneration. Such a cell model would drastically 
increase the scope to investigate the underlying mechanism of disease, enabling the effect of 
the HSJ1 mutations on motor neuron size, shape, lifespan and electrophysiological 
properties to be examined in detail. These aspects could prove critical for establishing the 
timeframe of events and characterising early stages in the degeneration pathway. It would be 
interesting to generate motor neurons for all three HSJ1 patient mutations in order to 
compare whether the different mutations affect disease pathogenesis or whether they act via 
a universal mechanism. An iPSC disease model could be the key to unravelling the crucial 
role of HSJ1 in motor neurons and should be a priority for future studies. 
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Chapter 6 – Investigating motor neuron degeneration in Hsj1 knockout mice 
6.1 Introduction 
Although the HSJ1-Y5C patient fibroblasts provided a valuable opportunity to examine the 
loss of HSJ1 protein, skin cells do not replicate the cellular environment of motor neurons, 
potentially limiting the ability of fibroblasts to reliably model the mechanisms that underlie 
disease pathogenesis. Mouse models provide an advantage over patient fibroblasts in that 
they enable patient mutations to be examined in the context of a relevant cell type. Indeed, 
characterising the phenotype of motor neurons in dHMN and CMT2 mouse models has 
provided novel insights into the cellular mechanisms that drive motor neuron degeneration.  
A range of mouse models have been generated to study dHMN and CMT2. Patient 
mutations with autosomal dominant inheritance have been modelled through the knock-in or 
overexpression of the required gene, generating mice such as MFN2 R94W knock-in and 
Hsp27 S135F, Hsp22 K141N and GARS C201R transgenic overexpressors (Strickland et al. 
2015, d’Ydewalle et al. 2011, Zhang et al. 2014, Seo et al. 2014). Patient mutations with 
autosomal recessive inheritance, such as those in ATP7A, TRIM2 and KIF1B, have been 
modelled through the partial or complete knockout of the gene (Hodgkinson et al. 2015, 
Balastik et al. 2008, Zhao et al. 2000). The mouse models listed all exhibited progressive 
muscle weakness and atrophy, with reductions in grip strength, rotarod performance and 
muscle mass. Pathologically, the mice displayed a significant loss of motor neurons in the 
lumbar region of the spinal cord, along with the denervation of neuromuscular junctions. 
The mouse models generated therefore successfully recapitulate the clinical and pathological 
features of the human phenotype, making them an excellent tool for investigating disease 
pathogenesis.  
All three patient mutations reported in HSJ1 to date are loss of function mutations (Blumen 
et al. 2012, Gess et al. 2014, Chapter 5). As human HSJ1 shares 85% sequence identity with 
mouse Hsj1 (Figure 6), the Hsj1 knockout mouse provides an excellent model system for 
examining the underlying mechanisms that compromise motor neuron function and cause 
disease. Hsj1 knockout mice have previously been generated by the Cheetham laboratory 
(described in Wendy Mustill PhD Thesis, UCL), using the Cre/loxP system to delete exon 2 
and 3 of Hsj1 (Figure 6). The Hsj1 knockout mice were then utilised to investigate whether 
Hsj1 exerts a protective effect against motor neuron degeneration in a mouse model of ALS 
(Wendy Mustill PhD Thesis, UCL). The loss of Hsj1 exacerbated disease pathogenesis in 
SOD1 G93A mice, with a further reduction in motor unit number and motor neuron counts 
compared to single transgenic mice. Interestingly, prior to the identification of HSJ1 patient 
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mutation in dHMN and CMT2, our lab found that the loss of Hsj1 alone had detrimental 
effects on motor neuron survival. At 120 days, Hsj1 knockout mice displayed a reduction in 
motor unit number and a reduction in the number of motor neurons present in the lumbar 
region of the spinal cord. To determine if the degeneration of motor neurons was 
progressive, motor neuron survival was examined at the earlier time point of P20. A 
reduction in motor neuron counts was also observed at this time point (Anna Gray, personal 
communications). Although the Hsj1 knockout mice appear healthy, with no overt motor 
deficits, the degeneration of motor neurons is an encouraging sign that these mice can be 
used to successfully model the HSJ1 patient mutations and identify the underlying molecular 
mechanisms that drive the degeneration process.  
The aim of this study was to confirm the loss of motor neurons in Hsj1 knockout mice at 
P20 and establish whether the loss of motor neurons occurred during development or was 
due to post-natal degeneration. To assist the counting of motor neurons in Hsj1 wild-type 
and knockout spinal cords, Hb9:GFP mice would be utilised. These mice express GFP under 
the motor neuron specific promoter, Hb9, driving GFP expression in the dendrites, axons 
and somas of motor neurons (Wichterle et al. 2002). Hb9:GFP mice have been used to 
successfully visualise motor neurons, providing a marker to monitor the differentiation of 
mouse embryonic stem cells to motor neurons and enabling the study of embryonic motor 
axon development in SMA mice (Karumbayaram et al. 2009, McGovern et al. 2008). 
Generating Hb9:GFP-Hsj1
+/+
 and Hb9:GFP-Hsj1
-/-
 mice should simplify the identification 
of motor neurons and increase the reliability of motor neuron counts. If motor neurons were 
degenerating post-natally, the timeframe of the degeneration process would be established. 
The cellular phenotype of motor neurons would then be characterised prior to cell death 
through Western blot analysis of spinal cord lysates and immunostaining of spinal cord 
sections, to identify cellular changes that may be associated with motor neuron degeneration 
in dHMN and CMT2. 
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Figure 6 Sequence alignment of human and mouse HSJ1 and characterising the loss of 
Hsj1 in Hsj1
-/-
 mice. A: The alignment of human and mouse HSJ1b protein sequences. 
Human and mouse HSJ1b share 85% sequence identity. B: The sheep polyclonal HSJ1 S653 
antibody detects endogenous mouse Hsj1. Western blot analysis confirms the loss of both 
Hsj1 isoforms in Hsj1
-/-
 mice (Figure from Wendy Mustill PhD Thesis, UCL).  
B 
A 
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6.2 Results 
6.2.1 The generation of Hb9:GFP
+/-
 Hsj1
+/+
 and Hb9:GFP
+/-
 Hsj1
-/-
 mice 
Hb9:GFP
+/-
 mice were purchased from The Jackson Laboratory. They recommended that the 
strain should be maintained as hemizygotes, due to the high mortality of homozygous pups 
born to homozygous females. Hb9:GFP
+/-
 mice were therefore maintained in a hemizygote 
state through crossings with C57BL/6 mice. In order to examine the effect of Hsj1 knockout 
on motor neuron survival, both Hb9:GFP
+/-
 Hsj1
+/+
 and Hb9:GFP
+/-
 Hsj1
-/-
 double transgenic 
mice needed to be generated. Two rounds of breeding were therefore required. Firstly, 
Hb9:GFP
+/-
 mice were crossed with Hsj1
-/- 
mice to generate Hb9:GFP
+/- 
and Hb9:GFP
-/- 
mice heterozygous for Hsj1. Hb9:GFP
+/-
 Hsj1
+/-
 mice were then crossed with Hb9:GFP
-/-
 
Hsj1
+/-
 littermates, generating Hb9:GFP
+/-
 and Hb9:GFP
-/- 
mice that were either Hsj1 wild-
type, Hsj1 heterozygotes or Hsj1 knockout. To ensure experimental animals had comparable 
genetic backgrounds, Hb9:GFP
+/-
 Hsj1
+/+
 and Hb9:GFP
+/-
 Hsj1
-/-
 mice needed to be 
generated in the same litter. The colony was therefore maintained through the crossing of 
Hb9:GFP
+/-
 Hsj1
+/- 
and Hb9:GFP
-/-
 Hsj1
+/- 
mice. Offspring were born at the expected 
Mendelian frequency and appeared healthy, with Hb9:GFP
+/-
 Hsj1
-/- 
mice indistinguishable 
from Hb9:GFP
+/- 
Hsj1
+/+
 littermate controls. 
6.2.2 Characterising GFP expression in Hb9:GFP
+/-
 Hsj1
+/+
 mice 
The expression of GFP under the control of the Hb9 promoter has been reported to be 
detectable between embryonic day 9.5 and post-natal day 10 (Jackson Laboratories). To 
determine the latest time point at which GFP expression could still be detected, the level of 
GFP in spinal cord lysates from Hb9:GFP
+/-
 Hsj1
+/+ 
mice at P10, P15 and P20 was examined 
by Western blot analysis (Figure 6.1A). The levels of GFP were found to substantially 
decrease over time. GFP expression was reduced by 60% between P10 and P15. GFP levels 
were reduced by a further 32% between P15 and P20, resulting in P20 mice expressing 8% 
of the GFP levels observed at P10. To establish whether the reduction in GFP expression 
compromised the ability to visualise motor neurons, GFP fluorescence was examined at P10, 
P15 and P20. Hb9:GFP
+/- 
Hsj1
+/+
 mice of the required age were perfused and spinal sections 
were examined for GFP fluorescence on a Nikon Eclipse fluorescence light microscope. 
GFP positive motor neurons could be clearly visualised at both P10 and P15, although the 
fluorescent intensity was reduced at P15 (Figure 6.1B). In contrast, motor neurons could not 
be clearly distinguished at P20. The Hb9:GFP
+/- 
mice could therefore only be used to count 
motor neurons in mice at or below the age of P15. 
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Figure 6.1 Characterising GFP expression in GFP
+/-
 Hsj1
+/+
 mice at P10, P15 and P20. 
A: 30 µg of spinal cord lysate from Hb9:GFP
+/-
 Hsj1
+/+
 mice at P10, P15 and P20 was 
resolved by SDS-PAGE. Western blot analysis was performed using a monoclonal rabbit 
GFP antibody (1:1000) and a monoclonal mouse β-tubulin antibody (1:5000). B: 
Hb9:GFP
+/- 
Hsj1
+/+
 mice at P10, P15 and P20 were transcardially perfused with 4% PFA. 
Spinal cords were dissected, post-fixed in 4% PFA overnight then cryoprotected in 30% 
sucrose. The lumbar region of the spinal cord was then sectioned into 20 µm slices. GFP 
fluorescence was visualised on a Nikon Eclipse 80i fluorescence light microscope. Scale bar, 
(left panel) 500 µm (right panel) 50 µm. 
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6.2.3 Hb9:GFP
+/-
 Hsj1
+/+
 and Hb9:GFP
+/-
 Hsj1
-/-
 mice show no difference in the number 
of motor neurons at P10 and P15 
Motor neuron survival was examined in Hb9:GFP
+/- 
Hsj1
+/+
 and Hb9:GFP
+/- 
Hsj1
-/-
 mice at 
P10 and P15. Hb9:GFP
+/- 
Hsj1
+/+ 
and Hb9:GFP
+/- 
Hsj1
-/-
 mice were perfused with 4% PFA at 
both time points. Spinal cords were then dissected, post fixed, cryoprotected and the lumbar 
region was subsequently cut into 20 µm sections. The Hb9:GFP positive motor neurons were 
easily visualised on a Nikon Eclipse fluorescence light microscope at 40X magnification. 
There were no obvious differences in Hb9:GFP positive motor neuron localisation, shape or 
size between Hb9:GFP
+/- 
Hsj1
+/+ 
and Hb9:GFP
+/- 
Hsj1
-/-
 mice at P10 or P15 (Figure 6.2). 
GFP positive motor neurons located in the ventral horns were counted in every 4
th
 
consecutive spinal cord section, in order to avoid counting the same motor neuron twice. At 
least 30 sections were counted per animal and the average number of motor neurons per 
section was determined. At P10, Hb9:GFP
+/- 
Hsj1
+/+ 
mice had an average of 19.7 ± 1.2 motor 
neurons per spinal cord section, compared to 19.5 ± 0.8 motor neurons observed in 
Hb9:GFP
+/- 
Hsj1
-/-
 mice (Figure 6.3). Similar counts were observed at P15; Hb9:GFP
+/- 
Hsj1
+/+ 
mice had an average of 19.2 ± 0.6 motor neurons and Hb9:GFP
+/- 
Hsj1
-/-
 mice had an 
average of 19.1 ± 0.4 motor neurons per spinal cord section. Statistical analysis revealed no 
significant difference in the average number of motor neurons in Hb9:GFP
+/- 
Hsj1
+/+ 
and 
Hb9:GFP
+/- 
Hsj1
-/-
 mice at both P10 and P15. 
6.2.4 Hsj1
-/- 
mice show a loss of motor neurons between P15 and P20 
The loss of motor neurons in Hsj1
-/-
 mice had been previously observed at P20 (Anna Gray 
unpublished observations). The motor neuron counts at P10 and P15 in the Hb9:GFP
+/-
 mice 
therefore suggests that the loss may be occurring between P15 and P20. However, due to the 
reduction in GFP expression, the Hb9:GFP
+/-
 mice could not be used to examine this 
possibility. To confirm whether the loss of motor neurons in Hsj1
-/-
 mice is indeed occurring 
between P15 and P20, motor neurons were counted in the spinal cords of C57BL/6 wild-type 
mice and Hsj1
-/-
 mice (congenic on the C57BL/6 background) using the Nissl stain 
gallocyanine (Figure 6.4). Gallocyanine is a basic dye that binds to negatively charged 
nucleic acids. Motor neurons have a high rate of protein synthesis and their cytoplasm 
contains high levels of RNA, concentrated in rough endoplasmic reticulum (RER). 
Gallocyanine therefore strongly stains the cytoplasm of motor neurons in a blue/purple 
colour, enabling their distinction from other neurons in the spinal cord.  Hsj1
+/+
 and Hsj1
-/-
 
mice were perfused at P15 and P20. Spinal cords were dissected and the lumbar region was 
sectioned into 20 µm slices. Spinal cord sections were stained with gallocyanine, as 
described in Chapter 2, and were then visualised on a Nikon Eclipse light microscope. Motor 
Chapter 6 
152 
 
neurons were counted based on established criteria (Zhao et al. 2011, Guo et al. 2013, Iguchi 
et al. 2013). Only large, polygonal neurons with a darkly stained cytoplasm, a pale nucleus 
and a large, darkly stained nucleolus were included. Following these criteria, motor neurons 
in the sciatic pool of the ventral horns were counted in every 4
th
 consecutive spinal cord 
section. At least 30 sections were counted per animal and the average number of motor 
neurons per section was determined. At P15, Hsj1
+/+
 and Hsj1
-/-
 mice showed no significant 
difference in motor neuron counts (Figure 6.5). Hsj1
+/+
 mice had an average of 21.5 ± 0.3 
motor neurons per spinal cord section, with Hsj1
-/-
 mice displaying an average of 21.6 ± 0.4 
motor neurons. In contrast, at P20, Hsj1
-/-
 mice exhibited an 11.6% reduction in motor 
neuron counts compared to Hsj1
+/+
 mice. Hsj1
+/+
 mice had an average of 21.8 ± 0.4 motor 
neurons, whereas Hsj1
-/-
 mice had an average of 19.3 ± 0.2 motor neurons per spinal cord 
section. The 11.6% reduction was statistically significant (P <0.001). 
6.2.5 Motor neurons in Hsj1
-/-
 mice show a reduction in area at P15 and P20 
Large motor neurons are particularly vulnerable to degeneration (Saxena et al. 2009). To 
determine if large motor neurons are more susceptible to the loss of Hsj1, the average soma 
area of motor neurons in P15 and P20 Hsj1
+/+
 and Hsj1
-/-
 mice was analysed (Figure 6.6). 
Spinal sections were imaged on a Nikon Eclipse 80i light microscope. The area of motor 
neuron somas was then measured using ImageJ. Hsj1
+/+ 
motor neurons had an average soma 
area of 390 and 401 µm
2
, at P15 and P20, respectively. Hsj1
-/-
 mice displayed significantly 
smaller motor neurons at both time points, with an average soma area of 343 and 354 µm
2
 at 
P15 and P20, respectively. There was no significant difference in the average soma size of 
Hsj1
-/-
 motor neurons between P15 and P20.  
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Figure 6.2 GFP positive motor neurons in GFP
+/-
 Hsj1
+/+
 and GFP
+/-
 Hsj1
-/-
 spinal cord 
sections at P10 and P15. Hb9:GFP
+/-
 Hsj1
+/+
 and Hb9:GFP
+/-
 Hsj1
-/-
 mice were perfused 
with 4% PFA at P10 and P15. Spinal cords were dissected, post-fixed in 4% PFA overnight 
then transferred to 30% sucrose. The lumbar region of the spinal cord was sectioned into 20 
µm slices. Slides were mounted and imaged on a Zeiss LSM 700 confocal microscope. 
Arrows indicate GFP positive motor neurons. Scale bar, (left panel) 500 µm (right panel) 50 
µm. 
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Figure 6.3 The average number of GFP positive motor neurons per spinal cord section 
in GFP
+/-
 Hsj1
+/+
 and GFP
+/-
 Hsj1
-/-
 mice. GFP positive motor neurons located in the sciatic 
pool of the ventral horns were counted on a Nikon Eclipse 80i fluorescence light 
microscope. Motor neurons were counted in every 4
th
 consecutive section and at least 30 
sections were counted per animal. The average number of motor neurons per section was 
calculated. Error bars represent ± SD (N.S, Student’s t-test, n=4).  
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Figure 6.4 Staining of motor neurons with gallocyanine in Hsj1
+/+
 and Hsj1
-/-
 spinal 
cords at P15 and P20. Hsj1
+/+
 and Hsj1
-/-
 mice were perfused with 4% PFA at P15 and P20. 
Spinal cords were dissected, post-fixed in 4% PFA overnight, then cryoprotected in 30% 
sucrose. The lumbar region was sectioned into 20 µm sections. Slides were air-dried for 30 
minutes then immersed in gallocyanine for 1 hour. Slides were then washed in increasing 
concentrations of ethanol before being immersed in Histoclear for 10 minutes. Slides were 
then mounted using DPX. Spinal cord sections were then imaged on a Nikon Eclipse 80i 
light microscope. Arrows indicate motor neurons. Scale bar, (left panel) 500 µm (right 
panel) 50 µm. 
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Figure 6.5 The average number of motor neurons per spinal cord section in Hsj1
+/+
 and 
Hsj1
-/-
 mice. Gallocyanine-stained motor neurons in the sciatic pool of the ventral horns 
were counted on a Nikon Eclipse 80i light microscope. Only large, polygonal neurons with a 
darkly stained cytoplasm, a pale nucleus and a darkly stained nucleolus were included in the 
counts. Motor neurons in every 4
th
 consecutive spinal cord section were counted and at least 
30 sections were counted per animal. Counts were expressed as the average number of motor 
neurons per spinal cord section. Error bars represent ± SD (*** P <0.001, Student’s t-test, 
n=4). 
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Figure 6.6 The average soma area of Hsj1
+/+
 and Hsj1
-/-
 motor neurons at P15 and P20. 
Gallocyanine-stained spinal cord sections from P15 and P20 Hsj1
+/+
 and Hsj1
-/-
 mice were 
imaged on a Nikon Eclipse 80i light microscope. The area of motor neuron somas was 
measured using ImageJ. At least 300 motor neurons were analysed in total at each time 
point, for each genotype. Each point represents the area of one motor neuron, with the bar 
representing the average soma area (*** P <0.001, Student’s t-test, n=4). 
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 6.2.6 Hsj1
-/- 
spinal cords show increased levels of ubiquitylated protein 
Having established that a proportion of motor neurons are lost in Hsj1
-/-
 mice between P15 
and P20, I sought to characterise the phenotype of motor neurons at P15, prior to cell death, 
in order to provide insights into the underlying mechanisms driving motor neuron 
degeneration. Data from Chapter 5 suggested that the loss of HSJ1 in patient fibroblasts may 
impair proteostasis through an inability to target client proteins for ubiquitylation. To 
examine whether this was a phenotype that also occurred in vivo, protein ubiquitylation 
levels in spinal cord lysates from P15 Hsj1
+/+
 and Hsj1
-/-
 mice were analysed (Figure 6.7). 
Spinal cord lysates were resolved by SDS-PAGE then probed for polyubiquitin by Western 
blot. The level of ubiquitylated protein was corrected for loading using β-actin then 
normalised to the Hsj1
+/+
 sample. Hsj1
+/+
 spinal cord lysates showed a smear of high 
molecular weight ubiquitin species, ranging in size from over 250 kDa to around 100 kDa. 
Spinal cord lysates from Hsj1
-/-
 mice also showed a smear of high molecular weight 
ubiquitin species over the same size range. However, the expression level of ubiquitylated 
protein in Hsj1
-/-
 spinal cords was 1.9 fold higher than the levels observed in Hsj1
+/+
 spinal 
cords. This difference was statistically significant (P <0.001). 
6.2.7 The knockout of Hsj1 does not compromise the activity of the proteasome 
An increase in ubiquitylated protein in the Hsj1
-/- 
spinal cords may be due to defects in 
protein degradation. To determine whether the activity of the proteasome is compromised by 
the knockout of Hsj1, proteasome activity was assessed in spinal cord lysates from P15 
Hsj1
+/+
 and Hsj1
-/-
 mice. Spinal cord lysates were incubated for 1 hour with 10 µM of the 
fluorogenic substrate AMC-LLVY. Fluorescent intensity was measured using a 
spectrofluorometer. Background readings were subtracted and the activity of the proteasome 
was normalised to the Hsj1
+/+
 sample. The Hsj1
+/+
 and Hsj1
-/-
 spinal cord lysates showed no 
significant difference in proteasome activity (Figure 6.8). The increase in ubiquitylated 
protein therefore does not appear to be a result of impaired proteasome function. 
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Figure 6.7 Hsj1
-/-
 mice show an increase in ubiquitylated protein. A: 40 µg of spinal cord 
lysate from Hsj1
+/+
 and Hsj1
-/-
 mice at P15 was resolved by SDS-PAGE. Membranes were 
boiled for 30 minutes in Milli-Q water after transfer and then probed with a polyclonal poly-
ubiquitin antibody (1:1000) and a monoclonal mouse β-actin antibody (1:5000). B: Western 
blots were analysed using ImageJ. The level of ubiquitylated protein was corrected for 
loading using β-actin and normalised to the level of ubiquitylated protein in Hsj1+/+ spinal 
cords. Error bars represent ± SD (*** P <0.001, Student’s t-test, n=4). 
Chapter 6 
160 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8 Hsj1
+/+
 and Hsj1
-/-
 spinal cords show no difference in proteasome activity. 30 
µg of spinal cord lysate from Hsj1
+/+
 and Hsj1
-/-
 P15 mice was incubated with 10 µM AMC-
LLVY for 1 hour at 37 °C. Fluorescence was then measured using a spectrofluorometer 
using an excitation wavelength of 380 nm and an emission wavelength of 460 nm. 
Background readings were subtracted and the results were normalised to the proteasome 
activity in Hsj1
+/+
 spinal cords. Error bars represent ± SD (N.S, Student’s t-test, n=4). 
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6.2.8 Autophagy is activated in P15 Hsj1
-/-
 mice 
Alternatively, an increase in ubiquitylated protein may be caused by a block in protein 
degradation mediated by autophagy. To examine this possibility, the level of the 
autophagosome marker, LC3-II, in spinal cord lysates was determined. Spinal cord lysates 
from P15 Hsj1
+/+
 and Hsj1
-/-
 mice were resolved by SDS-PAGE then probed for LC3 by 
Western blot. LC3-I and LC3-II isoforms were detected in both spinal cord lysates, at 18 and 
16 kDa, respectively (Figure 6.9A). The level of each isoform was corrected for loading 
using β-actin then normalised to the level of LC3-I in Hsj1+/+ spinal cord lysates. Hsj1-/- 
spinal cords showed a small reduction in LC3-I levels compared to wild-type spinal cords, 
although this difference was not significant. In contrast, LC3-II levels were found to be 
significantly different between Hsj1
+/+
 and Hsj1
-/-
 spinal cords. LC3-II was 2.4 fold higher 
than LC3-I in Hsj1
+/+
 mice. In comparison, Hsj1
-/- 
spinal cords showed a 0.8 fold higher level 
of LC3-II, with a 3.2 fold higher expression than Hsj1
+/+
 LC3-I (Figure 6.9B). 
The higher levels of LC3-II in Hsj1
-/-
 mice may be due to an increase in autophagosome 
formation or a block in autophagosome degradation. The level of p62, a protein degraded by 
autophagy, was used to distinguish between these two possibilities. Hsj1
+/+
 and Hsj1
-/-
 spinal 
cord lysates were probed for p62 by Western blot analysis (Figure 6.10). Both wild-type and 
knockout spinal cords showed similar levels of p62, suggesting that the observed increase in 
LC3-II was due to an increase in autophagosome formation rather than a block in 
autophagosome degradation. To establish if the increase in autophagy was occurring in 
motor neurons, the number of autophagosomes present in the motor neurons of Hsj1
+/+
 and 
Hsj1
-/-
 spinal cord sections was compared using immunocytochemistry. The LC3 antibody 
used for Western blot was initially used to mark the autophagosomes; however, optimisation 
of the antibody for immunocytochemistry was unsuccessful. The p62 antibody used for 
Western blot was successfully optimised and was therefore used instead of the LC3 
antibody. Spinal cord sections from P15 Hsj1
+/+
 and Hsj1
-/-
 mice were permeabilised with 
0.2% Triton-X100, blocked for 1 hour, then immunostained for p62 and the neuronal marker 
β-III-tubulin. Z-stacks of the spinal cord sections were acquired using a Zeiss LSM 700 
confocal microscope. Only β-III-tubulin positive, large, polygonal cells, in a location 
consistent with motor neurons were imaged. p62 appeared both diffuse in the cytoplasm and 
in multiple puncta structures (Figure 6.11). The number and size of p62 puncta in at least 30 
motor neurons per animal were analysed using ImageJ, using maximum intensity 
projections. The number of p62 puncta per motor neuron were placed into 3 categories; <15, 
15-30 and >30 puncta per cell (Bandyopadhyay et al. 2014). The number in each category 
was then expressed as a percentage of the total number of motor neurons analysed (Figure 
6.12A). In Hsj1
+/+
 spinal cords, 68% of motor neurons contained <15 p62 puncta, with 20% 
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of motor neurons containing between 15-30 puncta. A slight shift in the number of p62 
puncta was observed in Hsj1
-/-
 motor neurons. 64% of motor neurons contained <15 p62 
puncta, with 25% of motor neurons containing 15-30 puncta. A 4% reduction in the 
percentage of motor neurons containing <15 p62 puncta is therefore accompanied by a 5% 
increase in the percentage of motor neurons containing between 15-30 puncta. The data 
suggests a possible increase in the number of p62 puncta in Hsj1
-/-
 motor neurons, although 
the trend did not reach statistical significance. There was no significant difference in the 
percentage of motor neurons containing >30 p62 puncta in both Hsj1
+/+
 and Hsj1
-/-
 spinal 
cords. The p62 puncta present in Hsj1
-/-
 motor neurons were found to be significantly 
smaller than p62 puncta observed in Hsj1
+/+
 motor neurons (Figure 6.12B). p62 puncta had 
an average area of 780 nm
2
 in Hsj1
+/+
  motor neurons, compared to an area of 726 nm
2
 in 
Hsj1
-/-
 motor neurons. Hsj1
-/-
 motor neurons therefore exhibit a subtle non-significant 
difference in the number of p62 puncta and a significant different in the size of the puncta. 
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Figure 6.9 LC3 levels in Hsj1
+/+
 and Hsj1
-/-
 spinal cords. A: 30 µg of spinal cord lysate 
from Hsj1
+/+
 and Hsj1
-/-
 P15 mice was resolved by SDS-PAGE. Western blot analysis was 
performed using a polyclonal rabbit LC3 antibody (1:750) and a monoclonal mouse β-actin 
antibody (1:5000). B: Western blots were analysed using ImageJ. The level of each LC3 
isoform was corrected for loading using β-actin before being normalised to the level of LC3-
I in Hsj1
+/+
 mice. Error bars represent ± SD (* P <0.05, Student’s t-test, n=4). 
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Figure 6.10 p62 levels in Hsj1
+/+
 and Hsj1
-/-
 spinal cords. A: 30 µg of spinal cord lysate 
from Hsj1
+/+
 and Hsj1
-/-
 P15 mice was resolved by SDS-PAGE. Western blot analysis was 
performed using a polyclonal rabbit p62 antibody (1:500) and a monoclonal mouse β-actin 
antibody (1:5000). B: Western blots were analysed using ImageJ. The level of p62 was 
corrected for loading using β-actin before being normalised to the level of p62 in Hsj1+/+ 
mice. Error bars represent ± SD (N.S, Student’s t-test, n=4). 
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Figure 6.11 p62 localisation in Hsj1
+/+
 and Hsj1
-/-
 spinal cords. Hsj1
+/+
 and Hsj1
-/-
 P15 
spinal cord sections were immunostained with a rabbit p62 antibody at a 1:200 dilution 
(Cy3, red) and a mouse β-III-tubulin antibody used at a 1:750 dilution (Cy2, green). Sections 
were imaged by Z-stack using a Zeiss LSM 700 confocal microscope. Only large, β-III-
tubulin positive cells in a location consistent with motor neurons were imaged. Arrows 
highlight p62 puncta. Maximum intensity projections were generated and the number and 
size of p62 puncta was analysed using ImageJ. At least 30 motor neurons were analysed for 
each animal. Scale bar, 10 µm. 
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Figure 6.12 The number and size of p62 puncta in Hsj1
+/+
 and Hsj1
-/-
 motor neurons. A: 
The number of p62 puncta were counted in Hsj1
+/+
 and Hsj1
-/-
 motor neurons using ImageJ. 
The number of motor neurons that contained <15, 15-30 or >30 puncta were expressed as a 
percentage of the total number of cells analysed. (N.S, Student’s t-test) B: The size of the 
p62 puncta was calculated using ImageJ. Each point represents the average area of p62 
puncta in one motor neuron. The bar represent the average area of p62 puncta (** P <0.01, 
Student’s t-test). 
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6.2.9 The presence of chromatolytic motor neurons in P15 Hsj1
-/-
 spinal cords 
Motor neuron counts at P15 and P20 established a timeframe during which motor neurons 
are lost in Hsj1
-/-
 mice. Interestingly, a proportion of motor neurons showed signs of 
degeneration at P15. The majority of motor neurons in P15 Hsj1
-/-
 spinal cords exhibited 
normal gallocyanine staining, with a darkly stained cytoplasm, a pale nucleus and a darkly 
stained nucleolus. However, some motor neurons showed abnormal staining; the dark 
gallocyanine stain only appeared at the periphery of the neuron, leaving a large unstained 
cytoplasm. In addition, the darkly stained nucleolus was displaced to the periphery of the 
neuron in these cells (Figure 6.13A). These observations are consistent with chromatolysis. 
Chromatolysis defines the dispersal and dissolution of Nissl bodies (RER) (Kusaka et al. 
1988, Martin et al. 1999). To determine the proportion of chromatolytic neurons, the number 
of normal and abnormal motor neurons was counted based on the criteria described above. 
At P15 only 0.6% of motor neurons were chromatolytic in Hsj1
+/+
 spinal cords. In contrast, 
10% of motor neurons were chromatolytic in Hsj1
-/-
 spinal cords (Figure 6.13B).  At P20, 
comparable levels of chromatolytic motor neurons were observed, with 0.5% in Hsj1
+/+
 and 
0.8% in Hsj1
-/-
 spinal cords. The increase in chromatolytic motor neurons in Hsj1
-/-
 mice at 
P15 was found to be statistically significant. The 10% of chromatolytic motor neurons 
correlates closely with the 11.6% loss of motor neurons at P20. Considering the percentage 
of chromatolytic neurons returns to the wild-type level at P20, the chromatolytic neurons 
observed at P15 could represent the motor neurons that undergo cell death between P15 and 
P20. 
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Figure 6.13 Chromatolytic motor neurons in Hsj1
-/-
 spinal cord sections at P15. A: 
Gallocyanine-stained spinal cord sections were imaged on a Nikon Eclipse 80i light 
microscope. Normal motor neuron (MN) staining, darkly stained cytoplasm, pale nucleus 
and darkly stained central nucleolus. Chromatolytic MNs appear with a large pale cytoplasm 
with the dispersal of Nissl bodies to the periphery of the neuron and the displacement of the 
nucleolus (highlighted by arrow). B: The number of chromatolytic motor neurons was 
counted based on the above criteria and expressed as a percentage of the total number of 
cells counted. Motor neurons were counted in every 4
th
 spinal cord section and at least 200 
neurons were counted per animal. Error bars represent ± SD (*** P <0.001, Student’s t-test, 
n=4). 
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6.2.10 The UPR is activated in Hsj1
-/-
 mice at P10  
The fragmentation and dissolution of RER has been reported to be a manifestation of 
chronic ER stress. To probe whether motor neurons in Hsj1
-/- 
mice exhibit an ER stress 
response, the levels of UPR markers in P15 Hsj1
+/+
 and Hsj1
-/-
 spinal cord lysates was 
investigated. Considering that chromatolysis has already occurred at P15, spinal cord lysates 
from an earlier time point, P10, were also examined for UPR markers. P10 and P15 Hsj1
+/+
 
and Hsj1
-/-
 spinal cord lysates were resolved by SDS-PAGE. Western blot analysis was 
performed using antibodies against components on the IRE1 branch (p-IRE1, IRE1 and 
BiP), the PERK branch (p-PERK, PERK, p-eIF2α, eIF2α and GADD34) and the ATF6 
branch (ATF6 and ATF6 (N)). The level of UPR marker was corrected for loading with β-
actin, then normalised to the level of UPR marker in Hsj1
+/+
 spinal cord. At P10, both the 
IRE1 and PERK branches of the UPR appeared to be activated. The level of phosphorylated 
IRE1 was 3 fold higher in Hsj1
-/-
 spinal cords, with total IRE1 levels also increased 1.6 fold. 
Phosphorylated PERK was 0.5 fold higher in the Hsj1
-/-
 spinal cords, with total PERK, p-
eIF2α and GADD34 showing a 1.8, 1.6 and 2 fold increase in expression levels, respectively 
(Figure 6.14). The total levels of eIF2α were unchanged in Hsj1-/- mice, as were the levels of 
full length ATF6, cleaved ATF6 and BiP. The increase in p-IRE1, IRE1, p-PERK, PERK, p-
eIF2α and GADD34 were statistically significant. At P15, no signs of UPR activation were 
observed in Hsj1
-/-
 spinal cords (Figure 6.15). The levels of UPR markers were comparable 
between both Hsj1
+/+
 and Hsj1
-/- 
mice.  
To determine if the UPR was activated in motor neurons, I tried to examine the expression 
levels of UPR markers in the motor neurons of spinal cord sections by 
immunocytochemistry. Unfortunately, p-IRE1, p-PERK, p-eIF2α, eIF2α and ATF6 
antibodies could not be optimised for immunocytochemistry. The BiP antibody did however 
produce a specific signal. P15 Hsj1
+/+
 and Hsj1
-/-
 spinal cord sections were therefore 
immunostained for BiP and the neuronal marker β-III-tubulin. Motor neurons were imaged 
on a Zeiss LSM 700 confocal microscope and the same settings were maintained when 
imaging both Hsj1
+/+
 and Hsj1
-/-
 sections. The fluorescent intensity of BiP staining appeared 
similar in both Hsj1
+/+
 and Hsj1
-/-
 motor neurons at P15 (Figure 6.15). The data therefore 
supports the Western blot data, suggesting that BiP is not upregulated in Hsj1
-/-
 motor 
neurons. 
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Figure 6.14 UPR markers in Hsj1
+/+
 and Hsj1
-/-
 spinal cords at P10. A: 30 µg of spinal 
cord lysate from Hsj1
+/+
 and Hsj1
-/-
 P10 mice was resolved by SDS-PAGE. Western blot 
analysis was performed using rabbit antibodies against p-IRE1, IRE1, p-PERK, PERK, p-
eIF2α, eIF2α, GADD34, ATF6 and BiP, all used at a dilution of 1:1000, and a monoclonal 
mouse antibody against β-actin (1:5000). B: Western blots were analysed using ImageJ. The 
level of each UPR marker was corrected for loading using β-actin before being normalised 
to the level of the UPR marker in Hsj1
+/+
 mice. Error bars represent ± SD (*** P <0.001, ** 
P <0.01, Student’s t-test, n=4).  
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Figure 6.15 UPR markers in Hsj1
+/+
 and Hsj1
-/-
 spinal cords at P15. A: 30 µg of spinal 
cord lysate from Hsj1
+/+
 and Hsj1
-/-
 P15 mice was resolved by SDS-PAGE. Western blot 
analysis was performed using rabbit antibodies against p-IRE1, IRE1, p-PERK, PERK, p-
eIF2α, eIF2α, GADD34, ATF6 and BiP, all used at a dilution of 1:1000, and a monoclonal 
mouse antibody against β-actin (1:5000). B: Western blots were analysed using ImageJ. The 
level of each UPR marker was corrected for loading using β-actin before being normalised 
to the level of the UPR marker in Hsj1
+/+
 mice. Error bars represent ± SD (N.S, Student’s t-
test, n=4).  
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Figure 6.16 BiP staining in Hsj1
+/+
 and Hsj1
-/-
 motor neurons at P15. Spinal cord sections 
from Hsj1
+/+
 and Hsj1
-/-
 P15 mice were immunostained with a rabbit BiP antibody at a 1:750 
dilution (Cy3 red) and a mouse β-III-tubulin antibody at a 1:750 dilution (Cy2 green). 
Sections were imaged on a Zeiss LSM 700 confocal microscope. Only large, β-III-tubulin 
positive cells in a location consistent with motor neurons were imaged. Settings were 
maintained during the imaging of the Hsj1
+/+
 and Hsj1
-/-
 motor neurons. Scale bar, 10 µm. 
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6.3 Discussion 
Previous data from our lab identified a reduction in motor neuron counts in the spinal cords 
of both 120 day old and 20 day old Hsj1
-/-
 mice (Wendy Mustill and Anna Gray). To confirm 
the loss of motor neurons at P20 and to establish whether motor neuron loss was occurring 
during development or postnatally, mice expressing GFP specifically in motor neurons were 
utilised to assist the counting process in Hsj1
+/+
 and Hsj1
-/-
 mice at P10, P15 and P20. 
Hb9:GFP
+/-
 Hsj1
+/+
 and Hb9:GFP
+/-
 Hsj1
-/- 
mice showed no difference in motor neuron 
counts at P10 and P15. The data therefore suggested that the loss of motor neurons occurs 
postnatally, between P15 and P20. Unfortunately, due to the loss of GFP expression between 
P15 and P20, Hb9:GFP
+/-
 mice could not be used to quantify the number of motor neurons 
present at P20. Instead, the Nissl stain, gallocyanine, was used to count the motor neurons in 
the spinal cord sections of P15 and P20 Hsj1
+/+
 and Hsj1
-/-
 mice. Hsj1
-/-
 mice revealed a 
significant 11.6% loss of motor neurons at P20. The loss of motor neurons therefore occurs 
after P15, as suggested by the data from the Hb9:GFP
+/-
 mice.  
The two methods of counting motor neurons yielded comparable results. Hb9:GFP
+/-
 Hsj1
+/+
 
mice had an average of 19.5 motor neurons per spinal cord section at P15. At the same time 
point, Hsj1
+/+
 spinal cords stained with gallocyanine displayed a slightly higher average, 
with 21.5 motor neurons per spinal cord section. The comparison of the two values suggests 
that, on average, two gallocyanine-stained cells per section may have been incorrectly 
identified as motor neurons. However, the error between the two values is subtle, and both 
values are consistent with published motor neuron counts from wild-type mice (Zhao et al. 
2011, Guo et al. 2013, Iguchi et al. 2013). The concordance with published data suggests 
that the counts obtained from both Hb9:GFP
+/-
 mice and through gallocyanine staining are 
reliable.  
Motor neurons are classified into subtypes according to the contractile properties of the 
motor units they form. Motor neurons are classed as fast fatigable (FF), fast fatigue-resistant 
(FR) or slow fatigue-resistant (S). FF motor neurons are the largest, with more dendritic and 
axonal branches than the other two subtypes. FF motor neurons were identified as the first 
motor neurons to undergo degeneration in SOD1 G93A mice, followed by FR motor 
neurons (Frey et al. 2000). S motor neurons were relatively resistant to degeneration, 
remaining preserved until late stages of the disease. To examine whether FF motor neurons 
were particularly vulnerable to the loss of Hsj1, the average soma area of motor neurons in 
P15 and P20 Hsj1
+/+
 and Hsj1
-/-
 mice was measured. Hsj1
-/-
 motor neurons were significantly 
smaller than Hsj1
+/+
 motor neurons at both P15 and P20. Hsj1
-/-
 motor neurons were reduced 
from an average size of 390 to 343 µm
2
 at P15, with a reduction from 401 to 354 µm
2
 at 
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P20. There was no significant difference in the area of Hsj1
-/-
 motor neurons at P15 and P20. 
Cell shrinkage is a classical feature of degeneration and it is possible that the large motor 
neurons shrink prior to P15, before undergoing cell death. Alternatively, the smaller area 
may indicate a developmental failure (d’Errico et al. 2013). To clarify whether FF motor 
neurons are indeed susceptible to degeneration in this model, the number of FF motor 
neurons at P15 and P20 could be compared using a marker protein. Recently, the 
examination of gene expression profiles in vulnerable and resistant motor neurons revealed 
that matrix metalloproteinase-9 (MMP-9) was solely expressed in FF motor neurons (Kaplan 
et al. 2014). The immunostaining of MMP-9 could therefore be used to distinguish FF motor 
neurons from the other two subtypes. 
Alternatively, the selective vulnerability of FF motor neurons could be investigated by 
assessing the number of FF motor units in leg muscles, such as the extensor digitorum 
longus (EDL) or tibialis anterior (TA) muscle. A reduction in motor unit number would 
indicate the loss of FF motor neurons. It would be interesting to assess FF motor unit 
number at P15, prior to the cell death. A reduction in motor unit number at P15 would 
support a ‘dying-back’ phenomenon, whereby denervation of the NMJ is the first 
pathological event to occur and is followed by the gradual degeneration of the neuron 
towards the cell body. Increasing experimental evidence suggests that motor neuron 
degeneration in ALS may proceed through a dying-back mechanism. Several studies in 
SOD1 G93A mice found that NMJ denervation occurs at an early stage of the disease, long 
before the loss of motor neuron cell bodies (Fischer et al. 2004, Rocha et al. 2014). 
Assessing motor unit number in Hsj1
-/-
 mice could greatly enhance our understanding of the 
degeneration process and may pinpoint whether NMJ denervation is an early pathological 
event in disease progression.  
At P15, 10% of Hsj1
-/-
 motor neurons appeared chromatolytic, with the loss of Nissl bodies 
from the cytoplasm and the eccentric positioning of the nucleus and nucleolus. 
Chromatolysis has been reported to be induced by axonal injury, ischemia and neurotoxicity, 
and is a prominent pathological feature of neurodegenerative diseases such as ALS, SMA 
and AD (Wakayama et al. 1992, Sasaki et al. 2011, Tapia et al. 2012, Palanca et al. 2014). 
Chromatolysis is regarded as a sign of degeneration and is often followed by apoptosis 
(Martin et al. 1999). The 10% of chromatolytic motor neurons at P15 may therefore 
represent the motor neurons that are lost by P20.  
The loss of Nissl bodies in the cytoplasm of chromatolytic neurons is caused by structural 
changes in the RER network. Electron microscopy of chromatolytic motor neurons in SOD1 
G93A mice revealed extensive morphological alterations, with RER appearing collapsed, 
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fragmented and with the detachment of membrane-associated polyribosomes (Riancho et al. 
2014). These structural changes compromise the ability of the ER to participate in active 
translation, thereby suppressing protein synthesis. The disruption of the RER network is 
proposed to be a manifestation of chronic ER stress. Chronic ER stress is an early 
pathological event observed in SOD1 G93A mice and precedes the appearance of 
chromatolytic motor neurons (Saxena et al. 2009, Riancho et al. 2014). The appearance of 
chromatolytic motor neurons in Hsj1
-/-
 mice suggests that the loss of Hsj1 may result in ER 
stress. To probe this possibility, UPR markers were examined in spinal cord lysates from 
P10 and P15 mice. At P10, expression levels of phosphorylated PERK, total PERK, 
phosphorylated eIF2α and GADD34 were increased in Hsj1-/- spinal cords, indicating that 
the PERK branch of the UPR had been activated. The activation of the PERK branch can 
mediate a pro-survival or pro-apoptotic response. To determine which response is generated 
in Hsj1
-/-
 spinal cords, the expression of ATF4 target genes should be examined. The 
upregulation of ER chaperones or ERAD components would indicate a protective response, 
whereas the upregulation of the transcription factor CHOP could indicate a pro-apoptotic 
response (Walter et al. 2011). In SOD1 G85R and G93A mouse models, the activation of the 
PERK branch appears to drive a protective response, promoting motor neuron survival. The 
hemizygous deletion of PERK in SOD1 G85R mice accelerated disease onset and shortened 
life span (Wang et al. 2011). The acceleration in disease was proposed to be caused by the 
loss of PERK-mediated inhibition of general translation, preventing the downregulation of 
SOD1 G85R synthesis. Indeed, sustaining eIF2α phosphorylation in mutant SOD1 mice 
delayed disease onset and prolonged lifespan (Wang et al. 2014). It is possible that the 
activation of the PERK branch is part of a protective adaptive response in Hsj1
-/-
 mice. 
It is interesting to note that in addition to phosphorylated PERK, total PERK, 
phosphorylated eIF2α and GADD34, expression levels of phosphorylated IRE1 and total 
IRE1 were also increased at P10. It will be important to clarify whether the IRE1 signalling 
pathway is active in future studies. To examine this possibility, the levels of spliced XBP-1 
could be examined in Hsj1
-/-
 spinal cords. The upregulation of both PERK and IRE1 
themselves could indicate that UPR signalling is active prior to P10. Considering that 
chromatolysis is linked with chronic ER stress it would be important to establish the full 
time frame of UPR activation and determine whether UPR activation precedes the 
appearance of chromatolytic motor neurons.  
Both the PERK and IRE1 branches of the UPR are capable of inducing ER stress-mediated 
cell death. How the two signalling pathways shift from a pro-survival to a pro-apoptotic 
response remains unclear. However, a recent study suggests that the temporal activation 
pattern of the two branches may contribute to cell fate decisions (Walter et al. 2015). Using 
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fluorescent cell reporters, XBP-1 splicing and ATF4 translation were monitored over time 
following tunicamycin treatment. The relative timing of IRE1 and PERK signalling differed 
between dying cells and those resistant to ER stress-induced death. In the IRE1 reporter 
cells, early onset and early attenuation in XBP-1 splicing was observed in cells resistant to 
death. In the PERK reporter cells, resistant cells showed a slow translation of ATF4 and a 
late re-initiation of general translation. Temporal differences in the relative dynamics of the 
signalling pathways therefore appear to dictate either a pro-survival or pro-apoptotic 
response.  
Further investigations are required to elucidate whether UPR signalling drives motor neuron 
degeneration in Hsj1
-/-
 mice. Although the UPR appears to be activated in spinal cords 
lysates, its occurrence in motor neurons needs to be confirmed. If the UPR is indeed 
activated in motor neurons it would be interesting to determine the proportion of motor 
neurons that show such activation. The global activation of the UPR could possibly suggest 
differential responses in vulnerable and resistant motor neurons. In resistant motor neurons 
the UPR may mediate a pro-survival response, whereas a pro-apoptotic response may occur 
in the vulnerable motor neurons. This selective vulnerability may be driven by differences in 
the temporal dynamics of IRE1 and PERK signalling pathways in different motor neurons 
(Walter et al. 2015). Alternatively, the UPR may be selectively activated in the 11.6% of 
motor neurons that degenerate. This is seen in SOD1 G93A mice (Saxena et al. 2009). 
Essentially all subtypes of motor neurons showed an increase in ubiquitin signal 25-30 days 
before the earliest denervation event occurs; however, an unfolded protein response was 
only initiated in the vulnerable FF motor neurons. A recent study sought to build on these 
findings and investigate the mechanism underlying motor neuron subtype-selective ER 
stress (Filézac de L’Etang et al. 2015). Using qPCR, gene expression profiles of ER resident 
proteins were examined in vulnerable and resistant motor neurons in wild-type mice, with 
the aim of characterising the molecular environment of the ER in the two motor neuron 
subtypes. ER resident proteins were found to be differentially expressed in FF and S motor 
neurons. Vulnerable FF motor neurons displayed 2-3 fold higher levels of transcripts 
belonging to the ERAD machinery and the ER stress sensors PERK, IRE1 and eIF2α. In 
contrast, resistant S motor neurons were enriched for transcripts encoding protein folding 
chaperones. An enhanced protein folding capacity of the ER therefore appears to confer S 
motor neurons resistant to the activation of the UPR. 
It is interesting to contemplate whether the distinct molecular environment of the ER in FF 
motor neurons renders them particularly vulnerable to the loss of the ER-associated isoform, 
HSJ1b. High expression levels of ERAD machinery and ER stress sensors implies that FF 
motor neurons may be particularly prone or vulnerable to protein misfolding in the ER 
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(Filézac de L’Etang et al. 2015). FF motor neurons may therefore place high demands on the 
ERAD system to efficiently remove misfolded protein and maintain proteostasis in the ER. 
If the ERAD system is basally under considerable strain, the ER may be unable to tolerate 
impairments in the pathway. As discussed in previous chapters, HSJ1b functions to target 
misfolded clients for ERAD. Considering the apparent high rate of protein misfolding in FF 
motor neurons, HSJ1b may be required to target a larger number of proteins for degradation. 
If this were the case, the loss of HSJ1b could substantially increase the load of misfolded 
proteins in the ER of FF motor neurons, activating the unfolded protein response. The high 
level of misfolded protein could potentially overwhelm the protective capabilities of the 
UPR in 10% of FF motor neurons, triggering a pro-apoptotic response (Figure 6.17). To 
investigate the selective vulnerability of FF motor neurons further, it would be interesting to 
examine HSJ1 expression levels in motor neuron subtypes. The upregulation of HSJ1b in FF 
motor neurons, in addition to other ERAD components, would support the hypothesis that 
HSJ1b targets a larger number of proteins for degradation in FF motor neurons and therefore 
plays a more critical role in maintaining ER homeostasis. The differential demands on the 
ERAD machinery, and possible on HSJ1b itself, could account for the potential vulnerability 
of FF motor neurons to the loss of HSJ1b.  
The activation of the UPR can most likely be attributed to the loss of the ER-associated 
isoform, HSJ1b, as discussed above. However, it cannot be ruled out that UPR activation 
lies downstream of the loss of the cytosolic isoform, HSJ1a. In SBMA mice, activation of 
the UPR was found to be downstream of protein misfolding in the cytosol (Montague et al. 
2014). SBMA is caused by a polyglutamine expansion in the androgen receptor gene. The 
mutant androgen receptor aggregates into inclusions, preventing the binding of androgen 
ligand to the receptor and the subsequent translocation of the protein to the nucleus where it 
activates target genes. One of the target genes regulated by androgen receptor is the 2b 
isoform of sarco/endoplasmic reticulum calcium ATPase (SERCA2b) (Foradori et al. 2008). 
SERCA2b expression levels were reduced in cultured embryonic motor neurons from 
SBMA mice, resulting in the depletion of ER Ca
2+
 levels (Montague et al. 2014). The 
reduction in Ca
2+
 levels lead to ER stress, with UPR markers observed in cell culture and in 
the spinal cords of SBMA mice. The loss of both Hsj1 isoforms could therefore, in theory, 
contribute to UPR activation, through the accumulation of misfolded proteins in the ER or in 
the cytosol.  
At P15, Hsj1
-/-
 spinal cord lysates exhibited a 1.9 fold increase in the level of ubiquitylated 
protein. In addition, Hsj1
-/-
 mice also displayed a significant increase in LC3-II levels. The 
levels of p62 remained unchanged, suggesting that the increase in LC3-II was caused by an 
increase in autophagosome formation rather than a block in autophagosome degradation. 
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Figure 6.17 A potential model for how the loss of HSJ1 activates the UPR. HSJ1b binds 
to misfolded ER transmembrane proteins and targets them for ERAD. In the absence of 
HSJ1b, misfolded proteins fail to be targeted for ERAD, leading to their accumulation. In FF 
motor neurons, the load of misfolded proteins may be sufficient to activate the UPR. The 
high level of misfolded protein may overwhelm the protective capabilities of the UPR, 
resulting in a pro-apoptotic response being mediated. 
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The number of p62 puncta in Hsj1
+/+
 motor neurons correlated with published p62 counts 
performed on the motor neurons of three month old wild-type mice (Bandyopadhyay et al. 
2014). Interestingly, there was a subtle shift in the number of p62 puncta in the motor 
neurons of Hsj1
-/-
 mice, with a 4% decrease in the percentage of motor neurons containing 
less than 15 puncta, and a 5% increase in the percentage of motor neurons containing 15-30 
puncta. The shift did not reach statistical significance; however, considering the small 
change in percentage it may be worthwhile to increase the number of motor neurons 
analysed. Considering that both HSJ1a and HSJ1b target misfolded proteins for degradation, 
an increase in ubiquitylated protein and a rise in LC3-II levels could be attributed to the loss 
of either Hsj1 isoform. The ubiquitylated protein could represent misfolded and potentially 
aggregated Hsj1 client proteins, or alternatively, misfolded proteins retrotranslocated from 
the ER following an ER stress-induced UPR-mediated upregulation of ERAD. In both 
scenarios the increase in autophagy is likely to represent a protective response in an attempt 
to clear the misfolded proteins. It will be important to dissect the order in which the 
responses are observed in future studies. The activation of the UPR followed by an increase 
in ubiquitylated protein would support the hypothesis the accumulation of misfolded 
proteins in the ER caused by the loss of HSJ1b is the initiator of motor neuron degeneration. 
The accumulation of ubiquitylated protein followed by the activation of the UPR would 
establish HSJ1a as the critical isoform. Of course, the two mechanisms may not be mutually 
exclusive; the loss of both HSJ1 isoforms could contribute to disease pathogenesis. The use 
of mice expressing HSJ1a only (hHSJ1a
+/-
 : Hsj1
-/-
) or HSJ1b only (hHSJ1b
+/-
 : Hsj1
-/-
) 
generated by our lab will prove to be a particularly valuable tool for defining the role of each 
isoform in motor neurons and their respective importance in motor neuron survival. 
Preliminary data from the HSJ1a only and HSJ1b only mice suggests that the loss of the 
HSJ1b isoform drives motor neuron degeneration (Bernadett Kalmar unpublished 
observations). At 120 days, HSJ1a only mice exhibited a significant reduction in EDL motor 
units. No significant reduction in motor unit number was observed in the HSJ1b only mice. 
It would be interesting to build on these findings in the future and establish whether a loss of 
motor units in HSJ1a only mice is accompanied by a loss of motor neurons. A 10% loss of 
motor neurons in HSJ1a only mice would place ER stress at the centre of disease 
pathogenesis and would potentially help to identify critical client proteins. 
Mouse models of dHMN and CMT2 have increased the scope to investigate the underlying 
mechanisms of motor neuron degeneration. Many of the models recapitulate the phenotype 
of the disease and have identified dysfunctions in a wide range of cellular processes. 
However, not all mouse models of dHMN and CMT2 display motor neuron deficits, as seen 
with the Hsj1
-/-
 mice. LRSAM1 mutations are typically associated with autosomal dominant 
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CMT2; however, a mutation in LRSAM1 was identified in one family with autosomal 
recessive CMT2, with the mutation causing a loss of function phenotype (Guernsey et al. 
2010). Lrsam1 knockout mice appear healthy and demonstrate largely normal 
neuromuscular performance (Bogdanik et al. 2013). Even though the mice did not show a 
motor deficit, the axons of Lrsam1
-/-
 motor neurons were found to be more sensitive when 
challenged with the neurotoxic agent, acrylamide. Greater axonal degeneration was observed 
after acrylamide treatment, indicating that the loss of Lrsam1 compromised axonal 
homeostasis, making them more vulnerable to degeneration upon exposure to cell stress. It 
would be interesting to examine whether the exposure of Hsj1
-/-
 mice to cell stress could 
exacerbate motor neuron degeneration. This could be achieved by examining axonal 
regeneration after sciatic nerve lesion. Impaired or delayed NMJ re-innervation could 
indicate that the loss of HSJ1 compromises the ability of motor neurons to restore 
homeostasis after exposure to cell stress. Conferring a vulnerability to cell stress could 
account for the lack of apparent motor deficits observed in both Lrsam1
-/-
 and Hsj1
-/-
 mice. 
Mouse motor neurons are unlikely to experience the same type, magnitude and frequency of 
stress compared to human motor neurons. However, there are other possible explanations for 
the disparity between the mouse and human phenotype. Differences in gene expression 
between mouse and human motor neurons could mask the deficiencies caused by the loss of 
Hsj1 in the mouse model. For example, mice may only express Hsj1 client proteins in 10% 
of motor neurons. Alternatively, mice may express a compensatory protein that is able to 
orchestrate the required functions normally mediated by Hsj1. Examining motor neuron 
degeneration on different genetic backgrounds could reveal a more pronounced phenotype. 
For example, GARS C201R mice exhibited a relative mild motor phenotype on a C3H 
genetic background; a more severe phenotype was observed on a C57BL/6 background 
(Achilli et al. 2009).  
Overall, the results described in this Chapter identify UPR activation, an accumulation of 
ubiquitylated protein, an increase in autophagy and chromatolysis as key cellular events that 
occur prior to motor neuron cell death in Hsj1
-/-
 mice. It will be important to expand on these 
findings in the future and characterise the degeneration process in detail. Identifying the 
cellular event that acts as the initial trigger for motor neuron dysfunction could enhance our 
outstanding of HSJ1 function and characterising motor neuron degeneration in HSJ1a only 
and HSJ1b only mice may establish whether one of the HSJ1 isoforms plays a more 
dominant role in motor neuron survival.   
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Chapter 7 – Discussion 
Unravelling the genetic etiology of dHMN and CMT2 has provided fundamental insights 
into the cellular mechanisms that underlie motor neuron degeneration. Recently, mutations 
in the DnaJ protein, HSJ1, were reported in autosomal recessive cases of the disease 
(Blumen et al. 2012, Gess et al. 2014). The identification of HSJ1 as a novel causative gene 
extends the number of causative genes with protein products that function in protein quality 
control, strengthening the concept that motor neurons are particularly vulnerable to 
impairments in proteostasis. 
The protective role of HSJ1 in motor neurons is highlighted by the ability of the HSJ1a 
isoform to combat the aggregation of ALS-associated proteins in cell and mouse models of 
the disease (Novoselov et al. 2013, Jack Miller, MSc project, UCL). In Chapter 3, I propose 
that HSJ1a may also mediate a protective effect against mutant ubiquilin-2 aggregation. The 
data presented in Chapter 3 identifies ubiquilin-2, a protein recently implicated in ALS, as a 
novel binding partner of HSJ1a. The ability of HSJ1a to bind to ALS-linked ubiquilin-2 
mutants suggests that HSJ1a overexpression could potentially modulate mutant ubiquilin-2 
aggregation in cells. It will be important to build on these findings in future studies and 
determine whether HSJ1a represents a therapeutic target that could be used to delay motor 
neuron degeneration in ubiquilin-2 linked cases of ALS.  
The protective role of HSJ1 in motor neurons is further highlighted by the loss of function 
phenotype underlying dHMN and CMT2. The data presented in Chapter 4 and Chapter 5 of 
this thesis extends the spectrum of HSJ1 patient mutations, characterising the recently 
identified HSJ1-Y5C substitution as a disease-causing loss of function mutation. All three 
patient mutations identified to date are therefore loss of function mutations. HSJ1 therefore 
appears critical for motor neuron survival. 
Investigations using a Hsj1 knockout mouse model place impairments in proteostasis at the 
centre of disease pathogenesis. Prior to motor neuron degeneration, Hsj1
-/-
 mice exhibited an 
increase in ubiquitylated protein, an increase in autophagosome formation and activation of 
the IRE1 and PERK branches of the UPR. The activation of these cellular stress responses 
supports the hypothesis that the loss of HSJ1 leads to an increase in the levels of misfolded 
protein, potentially due to impairments in the targeting of proteins for degradation. It 
remains to be determined whether the accumulation of HSJ1a or HSJ1b client proteins is 
more detrimental to motor neurons. However, a number of observations suggest that the 
accumulation of HSJ1b client proteins may be more deleterious. Firstly, the higher 
expression levels of HSJ1b compared to HSJ1a in human fibroblasts and mouse brain and 
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spinal cord tissue implies that HSJ1b may play a more prominent role in protein clearance 
(Chapple and Cheetham 2003, Blumen et al. 2012). As such, the loss of HSJ1b would be 
expected to have a greater impact on proteostasis compared to the loss of HSJ1a. Secondly, 
only HSJ1a only mice displayed a reduction in EDL motor units; no reduction in EDL motor 
units was observed in HSJ1b only mice (Bernadett Kalmar, personal communications). 
Taking these observations into consideration, I propose a model that places the loss of the 
HSJ1b isoform at the centre of disease pathogenesis. Based on the increase in protein 
ubiquitylation upon the restoration of HSJ1b in patient fibroblasts, I propose a model 
whereby UPR activation in Hsj1
-/-
 mice is driven by the inability to target HSJ1b misfolded 
clients for ubiquitylation, impairing the ERAD process and subsequently resulting in the 
accumulation of misfolded proteins in the ER. I hypothesise that the demand for HSJ1b-
mediated ERAD in motor neurons overwhelms the ER with misfolded protein, leading to a 
vicious cycle that results in the collapse of ER proteostasis. I propose that the UPR is unable 
to compensate for the loss of HSJ1b and ultimately triggers UPR-induced cell death. 
Of course, they are many aspects of the disease mechanism that require further investigation. 
The identification of endogenous HSJ1 client proteins could prove to be particularly 
informative; examining the levels of HSJ1 client proteins in the motor neurons of Hsj1
-/-
 
mice could help to ascertain whether the targeting of proteins for degradation is indeed 
impaired in the absence of HSJ1. Interestingly, the copper transporter ATP7A has recently 
been identified to interact with HSJ1 in a high-throughput proteomic study (Huttin et al. 
2015, BioGRID, pre-publication). Mutations in ATP7A have been identified in patients with 
X-linked dHMN, highlighting its important role in motor neuron survival (Kennerson et al. 
2010). As a membrane protein, ATP7A will be folded in the ER, potentially interacting with 
HSJ1b; therefore, ATP7A could represent a HSJ1b client protein. It will be interesting to 
determine whether the loss of HSJ1 has any effect on the folding or degradation of ATP7A. 
Such investigations could potentially implicate impaired copper homeostasis as a cause of 
motor neuron degeneration in this model.  
Future investigations should also aim to identify and characterise motor neuron-specific 
HSJ1 clients or indeed HSJ1 client proteins that are expressed at high levels in motor 
neurons. Such investigations could provide important insights into why motor neurons are 
selectively vulnerable to the loss of HSJ1. 
It is hoped that the generation of iPSC-derived motor neurons from patient fibroblasts will 
help to address the outstanding questions. Importantly, iPSC-derived motor neurons will 
mimic the human disease in relation to the fact that, unlike Hsj1
-/-
 mice, motor neurons in 
this cell model will need to continually degrade HSJ1-Y5C protein. It will be interesting to 
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determine whether this additional demand on the UPS enables the cell model to more closely 
reflect the human disease and the extent of motor neuron degeneration. iPSC-derived motor 
neurons from the HSJ1-Y5C patients have now been generated by the lab and are currently 
being characterised. 
Overall, the data presented in this Thesis builds on our understanding of the function of 
HSJ1 in motor neurons, highlighting its protective role and suitability as a therapeutic target 
in cases where motor neuron degeneration is driven by impairments in proteostasis. 
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